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ABSTRACT
A large body of neuroscientific research has focused on reactive gliosis and glial
scar formation because these are among the most prominent features of the cellular
response to central nervous system (CNS) injury. Despite much progress in our
understanding, controversy remains regarding the relative balance between the protective
nature of the astroglial scar and its anti-regenerative features. Recent work suggests that
astrocytes are heterogeneous in their resting state and in their reactivity. In traumatic
injuries such as stroke and spinal cord injury, proliferative reactive astrocytes protect
CNS tissue. By contrast, under neuroinflammatory and/or neurodegenerative conditions,
neurotoxic astrocyte phenotypes may contribute to disease progression.
Our previously published work showed that endothelin receptor type-B (ETBR)
signaling was required for reactive astrocyte proliferation in a distal middle cerebral
artery occlusion (dMCAO) model of stroke. In the studies for this dissertation, we
utilized stem cells derived from the peri-infarct area after stroke to model astroglial ETBR
signaling and identified the array of paracrine factors released in response to endothelin
signaling. The secreted factor with gene expression most decreased by astroglial ETBRknockout was Angiopoietin-2 (Ang-2), a pro-angiogenic paracrine factor that affects
stroke recovery. We found that astrocytes expressed significantly more Ang-2 after
stroke. Ang-2 expression was specifically regulated by ETBR and downstream NFB and
MEK/ERK signaling. After stroke, we discovered that adult microglia, the sentinel
immune cells of the brain, increased their expression of Tie-2, the receptor for Ang-2. To
evaluate whether paracrine activity controlled by ETBR functioned in neuroinflammation,
we performed astrocyte-specific conditional knockout of ETBR using GFAP-CreERTMEDRNB-fl/fl mice. Notably, peri-infarct CD11b+ cells, corresponding to
microglia/macrophages/monocytes, proliferated significantly less after dMCAO in
astrocyte-specific ETBR-knockout mice as compared with controls. Taken together, our
results indicated that astroglial ETBR signaling may promote Ang-2 release to regulate
the proliferation, survival, and/or the inflammatory status of microglia after stroke.
In addition to Ang-2, we demonstrated that astroglial ETBR regulates the
expression of CD109, a TGF co-receptor and C3 alpha-2-macroglubulin family
member. CD109 is the target of multiple proteases such as furin, and retains many of its
functions as a released, soluble protein. In reactive astrocytes, increased expression of
CD109 mRNA was reported to indicate a “neuroprotective” phenotype. We show that
ETBR signaling increased astroglial expression of several forms of CD109. Astroglial
CD109 expression increased following stroke, and ETBR-knockout prevented strokeinduced increases in CD109 expression. Consistent with a function for CD109 in altering
astroglial neuroinflammatory status, in the presence of TNFα and an ETBR specific
agonist, CD109-knockdown blocked ETBR-dependent effects on C3d expression. To test
the disease modifying potential of soluble (free) CD109, we injected mice with
recombinant human CD109 after stroke. At 7 days after dMCAO, CD109 treatment
tended to increase the size of cortical infarcts and areas of secondary reactive astrocyte
thalamic reactivity. Further research will be required to determine potential differences
between the membrane-bound and protease- cleaved forms of CD109 and their effects on
neuroinflammation, injury progression and resolution. Improved understanding of
paracrine, juxtacrine, and/or autocrine cell signals regulated by astroglial ETBR may
provide valuable targets to treat CNS injury and disease.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW
1.1 Glial cell types of the central nervous system
Astrocytes
Astrocytes are macroglial cells of the central nervous system, originally named neuro-glia
(nerve-cement), then named more specifically for their star-like appearance when stained
for glial fibrillary acidic protein (GFAP) (Golgi, 1873; Virchow, 1858; von Lenhossek,
1893). During development, radial glial cells first give rise to neurons and then take on a
glial restricted fate, producing fibrous astrocytes, protoplasmic astrocytes, and
oligodendrocytes (Clavreul et al., 2019; Wang and Bordey, 2008). Numerous cellautonomous factors and cell-cell signaling events balance the proliferation of radial glial
cells, the relative numbers of neurons and glia they produce, and the relative proportion
of astrocytes and oligodendrocytes they generate (Beattie et al., 2017; Hippenmeyer and
Luo, 2010; Hirabayashi et al., 2009). For example, Achaete-scute homolog-1 (Ascl1) is
thought of as a canonically pro-neuronal transcription factor, but it also regulates the
balance between astrocytes and oligodendrocytes generated in the gray and white matter
of the spinal cord (Vue et al., 2014). The transcription factor lethal giant larvae homolog1 (Lgl1) regulates the production of both radial glia and astroglial cells, but its effects on
astroglial specification are highly dependent on interactions with epidermal growth factor
receptor (EGFR) signaling (Beattie et al., 2017).
Once generated by radial glial cells, astrocytes undergo clonal expansion to tile
the brain. Each cell forms its own territory, overlapping the processes of neighboring
astrocytes minimally (Clavreul et al., 2019; Beattie et al., 2017; Oberheim et al., 2009;
Wilhelmsson et al., 2006). The sequential development of radial glia and corresponding
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cascade of signaling events is necessary to establish the correct balance of neuronal and
glial cell numbers. Differentiated neurons require astrocytes to support them trophically,
metabolically, and to maintain ionic balance. Additionally, astrocyte endfeet form one
part of the tripartite synapse, maintaining the extracellular environment at axonal myelin
internodes (Araque et al., 1999; Arizono et al., 2020; Ventura and Harris, 1999). Defined
neuronal communication is altered without astroglial transport to remove glutamate from
the synapse (Arnth-Jensen et al., 2002; Marcaggi et al., 2003; Takatsuru et al., 2013).
There are two primary categories of astrocytes that reside in the healthy brain.
Astrocytes responsible for maintaining the axonal environment at myelin internodes are
fibrous and reside within the white matter of the brain, supporting axons and the
oligodendrocytes that myelinate them (Butt et al., 1994; Gadea et al., 2009; Raff et al.,
1988; Simons and Trajkovic, 2006). Protoplasmic astrocytes exist in the gray matter and
have more extensive ramifications which interact with neurons to regulate their
extracellular environment as well as synaptic transmission. Both fibrous and
protoplasmic astrocytes extend processes that cover the vasculature and contribute to
blood-brain barrier (BBB) regulation and function (Boulay et al., 2017; Simard et al.,
2003). There is further heterogeneity beyond these two astrocyte subpopulations.
Astrocytes are often characterized by expression of the intermediate filament protein glial
fibrillary acidic protein (GFAP), but even GFAP is differentially expressed by astrocytes
depending on brain region and astroglial subtype (Emsley and Macklis 2006; Meng et al.,
2015; Nolte et al., 2001). Additional astroglial diversity has been characterized based on
anterior-posterior, dorsal-ventral, and cortical layer-specific astroglial gene expression
profiles (Bayraktar et al., 2020; Lanjakornsipan et al., 2018; Miller et al., 2019).
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In response to central nervous system pathologies astrocytes become reactive,
altering morphology, paracrine signaling, and cellular transporters to limit neuronal
injury (Wilhelmsson et al., 2004; Zamanian et al., 2012). Reactive astroglia are not a
single homogenous population but have a variety of functions within and between disease
states. In diseases such as Alzheimer’s and Parkinson’s, astrocytes alter gene expression
and paracrine signaling in ways that can be toxic to neurons (Liddelow et al., 2017; Yun
et al., 2018). In brain injuries such as stroke and stab wound models, astrocytes increase
proliferation and trophic factor expression to protect neurons (Anderson et al., 2016 and
2018; Shimada et al., 2012). These two distinct types of reactive astrocytes have been
characterized as “neurotoxic” (A1) and “neuroprotective” (A2). It is unlikely that reactive
astrocytes fall exclusively into two simple states, but these categories may represent
general roles for astrocytes depending on the type of injury, just as pro-proliferative
reactive gliosis may have distinct features from non-proliferative (Sirko et al., 2013). It
remains to be determined if this reactivity is a spectrum, or if there are numerous discrete
reactive states that are generated, depending on the mixture of paracrine signals and the
injury type present.
Proliferative reactive astrocytes likely represent a type of neuroprotective
astrocyte state. Proliferation of reactive astrocytes has been tied to astroglial vascular
contacts and blood-cell infiltration (Bardehle et al., 2013). Specific removal of
proliferating reactive astrocytes leads to increased lesion sizes after brain-stab, spinal
cord injury, and stroke (Buffo et al., 2008; Bush et al., 1999; LeComte et al., 2015;
Shimada et al., 2012; Wanner et al., 2013). Work from our lab and others indicates that
Notch1, signal transducer and activator of transcription-3 (STAT3), and endothelin
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receptor type-B (ETBR) regulate astroglial proliferation after stroke (Anderson et al.,
2016; LeComte et al., 2015; Shimada et al., 2012). Notch1 is a membrane-bound receptor
that interacts with membrane-bound ligands (e.g. Jagged, Delta-Like) in a juxtacrine
fashion. This interaction leads to intracellular cleavage of the Notch intracellular domain,
which translocates to the nucleus and acts as a transcription factor (Bray, 2016). The
transcription factor STAT3 is part of the JAK-STAT pathway downstream from
cytokines and paracrine factors such as EGF, leukemia inhibitory factor (LIF), and
interleukin-6 (IL-6). Phosphorylation of STAT3 promotes its translocation to the nucleus
and STAT3 activation is a characteristic of astrocyte reactivity. Endothelin receptor typeB is a potent regulator of vascular tone in response to endothelin ligands (Lucas et al.,
1996; Verhaar et al., 1998). The removal of any one of these signals (Notch1, STAT3,
ETBR) decreases astroglial proliferation in response to traumatic central nervous system
injury, and therefore removes the tissue protection derived from proliferative reactive
astrocytes. Interestingly, genetic removal of astroglial STAT3 improves aspects of the
cellular response in a mouse model of Alzheimer’s disease (Reichenbach et al., 2019).
Astrocytes are generally not proliferative in Alzheimer’s disease. If astroglial STAT3
signaling is detrimental in Alzheimer’s but beneficial in traumatic injuries, it indicates
that regulators of reactive gliosis are performing disease-specific functions. These
functions are detrimental or beneficial depending on the inflammatory context, possibly
independent of their promotion of glial proliferation. Importantly, the paracrine activity
of proliferating reactive astrocytes and how that activity is regulated by pro-proliferative
signaling pathways has not been determined. Aspects of neuroprotection are mediated by
the release of paracrine factors such as glial derived neurotrophic factor (GDNF) and
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brain derived neurotrophic factor (BDNF), but the full neuroprotective paracrine profile
of proliferative reactive astrocytes, and how this profile is regulated, has not been
characterized (Koyama et al, 2003a, 2003b, 2005; Rocha et al., 2012; Toyomoto et al.,
2005). Determining the paracrine profile downstream of each astroglial pro-proliferative
pathway, and the disease-specific impacts of each, may lead to new treatments for CNS
injury.
Microglia
Microglia are derived from hypoblast/yolk sac erythromyeloid precursors, an important
cellular source of blood cells during development (Ginhoux et al., 2010; Kierdorf et al.,
2013). Primitive macrophages enter the central nervous system through the vasculature
and leptomeninges prior to neurogenesis (Monier et al., 2007). The transition from
erythromyeloid progenitor (c-Kit+ cells) to mature microglial cell is dependent on
signaling through the colony stimulating factor-1 receptor (CSF1R). Microglial
maturation is characterized by subsequent upregulation of the transcription factors Pu.1
and Irf8 (Ginhoux et al. 2010; Kierdorf et al. 2013). The CSF1R ligands are CSF1 and
interleukin-34 (IL-34), cytokines which are thought to have interchangeable trophic
functions. There is some evidence that the CSF1 and IL-34 have slightly different
mechanisms of action, in part because IL-34 is able to interact with receptor type proteintyrosine phosphatase zeta (PTP) in addition to CSF1R (Nandi et al., 2013). Furthermore,
IL-34 is expressed at high levels during microglial cell development as compared with
CSF1 expression, indicating that development of the mature microglial phenotype is
likely IL-34 dependent and less dependent on CSF1 (Ginhoux et al. 2010). IL-34 and
CSF1 are differentially expressed between adult white matter and gray matter, which
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drives a corresponding differential dependence of microglia on IL-34 and CSF1 between
white and gray matter (Easley-Neal et al., 2019). Microglial progenitors induced by these
signals upregulate MMPs, possibly as a mechanism of entry into the brain. Progenitors
also express increased TGF1, an essential factor that regulates microglial activity,
survival, and identity (Kierdorf et al. 2013).
Once in the brain, microglia are maintained locally, renewed by other microglial
cells, with blood-cell contribution limited or non-existent in the uninjured brain due the
presence of the blood-brain barrier (Ajami et al., 2007). This sets microglial cells apart
from many other neural cells within the brain, in that they are not ectodermally-derived
like macroglial cells and neurons. In the adult brain, long after CSF1R signaling has
induced microglial specification, microglia remain dependent on CSF1R signaling to
survive and maintain their identity (Elmore et al., 2014). CSF1R inhibition eliminates
microglial cells from the adult brain. Transforming growth factor- (TGF) signaling
plays a similar role in maintaining microglial identity and limiting de-differentiation and
reactivity (Bohlen et al., 2017; Butovsky et al. 2014; Qin et al. 2018; Zoller et al. 2018).
Removal of TGF paracrine signals can cause microglia to lose aspects of their unique
signature that set them apart from other macrophages and monocytes. They dedifferentiate, taking on a pro-neurodegenerative phenotype, leading to lethal
demyelination. It is unclear if TGF microglial maintenance occurs through microglial
expressed TGF receptors or TGF signaling in other cell types (Hickman et al., 2013).
Of interest, TGF signaling also induces infiltrating blood-cells to take on microglial-like
mRNA signatures in a time-dependent manner after a BBB compromising injury (Qin et
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al., 2018). Promotion of a microglial-like phenotype by TGF signaling reigns in some of
the neurotoxic effects of blood-cell entry into the brain (Cekanaviciute et al., 2014).
Certain aspects of microglial identity are highly specified to neuronal functions.
For example, in developing neural pathways of the visual system, there is a surplus of
synapses that undergo significant pruning to refine the pathways to support coherent
conveyance of visual information. Microglial cells are involved in pruning of these
excess synapses. TGF3 signaling induces superfluous synapses to express complement
C1 components that promote synaptic engulfment by microglia (Bialas and Stevens,
2013). Neuronal synapse pruning during development lends further evidence to the tight
regulatory role of TGF signaling in microglial functions. TGF, along with other
paracrine regulators, often have parallel roles in regulating cellular dynamics in both
neural development and adult injury/diseases states.
While microglial engulfment of complement-tagged synapses occurs during
development and CSF1 regulates the microglial development, similar mechanisms also
play a significant role in adult CNS injury and disease. In Alzheimer’s Disease, synapses
near amyloid beta plaques are tagged by complement for microglial engulfment (Hong et
al., 2016). Complement is also a microglial-derived signal which leads to the formation
of neurotoxic astrocytes in diseases such as Alzheimer’s and Parkinson’s (Liddelow et
al., 2017; Shi et al., 2017). In models of peripheral nerve injury, sensory neurons release
CSF1 which activates microglia and leads to chronic neuropathic pain (Guan et al.,
2016). This is in contrast with evidence that IL-34 promotes microglial neuroprotection
and improved BBB integrity (Jin et al., 2014; Mizuno et al., 2011). CSF1-receptor
inhibitors have been used to reduce microglial inflammatory activity and prevent memory
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deficits in Alzheimer’s disease mouse models (Dagher et al., 2015); these same inhibitors
eliminate microglia from the brain altogether (Elmore et al., 2014). Therefore, as seen
with reactive astroctyes, many aspects of developmental signaling (CSF1, TGF, and
complement) are recapitulated or repurposed in microglial responses to injury and/or
disease in adults.
During development, embryonic day 7.5-8.5 (E7.5-8.5) microglial cells briefly
express the Tie-2 receptor before expression disappears by E10.5 (Gomez Perdiguero et
al., 2015). The function of Tie-2 receptor signaling in regulating microglial development
and/or inflammation has not been determined. Macrophages express Tie-2 in certain
injury situations, particularly in angiogenic contexts and tumor angiogenesis (Chen et al.,
2016; Patel et al., 2013). The timeline of Tie-2 expression in microglia closely
corresponds to their initial entry into the brain around E9.0 (Kierdorf et al., 2013). This
entry is prior to neurogenesis and angiogenesis, so it is possible that Tie-2 is expressed to
induce a pro-angiogenic microglial state in development, similar to pro-angiogenic Tie-2
expressing macrophages (TEMs) (Arnold and Betsholtz, 2013; Dudiki et al., 2020). It is
also possible that angiopoietins in the CNS promote entry of microglial precursors, just as
angiopoietins are pro-migratory to TEMs. Many injuries and diseases in the brain have
vascular involvement and traumatic injuries such as stroke are particularly dependent on
angiogenesis for optimal recovery. Given that TEMs appear in a variety of situations
requiring angiogenesis, such as dermal wound healing and as pro-angiogenic cells in
tumor angiogenesis, it is reasonable to predict that Tie-2 expressing microglia could play
similar pro-angiogenic roles (Chen et al., 2016; Patel et al., 2013). If microglia behave
similarly to their macrophage counterparts, it is likely that pro-angiogenic microglia
8

increase Tie-2 expression in conjunction with post-stroke angiogenesis. After stroke, Tie2 activity in both microglia and the vasculature may function to synchronize proangiogenic signaling and inflammatory state in the stroke penumbra.
Oligodendrocytes
Oligodendrocytes are macroglial cells of the central nervous system that generate dense
protein and lipid-rich structures called myelin. Oligodendrocytes have multiple processes
with myelin at the distal end. The processes wrap and insulate neuronal axons of the CNS
to facilitate fast conduction and prevent action potentials from spreading between axons.
The myelin covered portion of the axon is referred to as the internode, and each internode
is separated by small unmyelinated axon segments called nodes of Ranvier (Bergles and
Richardson, 2015). Oligodendrocytes and myelin also support axons through trophic and
cell-cell signaling mechanisms that are distinct from the effects of myelin on axonal
electrophysiology (Byravan et al., 1994; Du and Dreyfus, 2002; Lappe-Siefke et al.,
2003; Wilkins et al., 2003).
In multiple sclerosis (MS) relapses and secondary progressive MS, demyelination
and oligodendrocyte cell-death lead to symptoms such as motor dysfunction and visual
deficits. Oligodendrocyte progenitors (a.k.a. OPC, NG2+ glial cell, polydendrocyte)
remyelinate axons and may improve symptoms after therapy or during disease remission
(Baxi et al., 2017). OPCs exhibit plasticity in the healthy adult brain, generating new
myelin internodes and contributing to certain types of learning (Hughes et al., 2018;
McKenzie et al., 2014). Similar to other glial cells, OPCs proliferate after many CNS
injuries including stroke (Bonfanti et al., 2017; McTigue et al., 2001). OPCs are some of
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the first cells to respond to LPS injection, and change morphology prior to microglial
cells (Rhodes et al., 2006).
Schwann Cells
Schwann cells are the glia of the peripheral nervous system (PNS) that myelinate single
axons, but also ensheath single or multiple axons to support neurons and/or facilitate fast
saltatory conduction. In contrast with CNS oligodendrocytes which myelinate multiple
axons, Schwann cells generate compacted myelin to wrap a single axon and only the
largest caliber axons are myelinated. Schwann cell myelin is similar in nature to CNS
oligodendrocyte myelin in its facilitation of faster axonal conduction speeds (Salzer,
2015). Smaller caliber axons are ensheathed by a subset of Schwann cells called Remak
cells. Remak cells can have a single or multiple troughs that contain the small axon(s)
(Jessen and Mirsky, 2019). Similar to CNS astrocytes, Remak cells also secrete trophic
factors to promote growth and maintenance of peripheral axons, but do not facilitate
faster axonal conduction.
After peripheral nerve injury, Schwann cells withdraw their myelin, phagocytose
debris, and secrete factors that promote axon growth (Jessen and Mirsky, 2019). If the
connective tissue of the nerve is still aligned after the injury, axons regrow down the
nerve and re-innervate their destination sites. Axonal regeneration after an injury is
dependent on Schwann cell c-Jun signaling and expression of the trophic factors artemin
(Artn), brain derived neurotrophic factor-1 (BDNF1), glial derived neurotrophic factor
(GDNF), leukemia inhibitory factor (LIF), and nerve growth factor (NGF) (Fontana et al.,
2012). Notably, this repair process contrasts with that of CNS injuries in which axons do
not significantly regenerate.
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Muller Cells
Muller cells are glia that provide specialized support to the diverse neural cell types of
the retina. Both Muller cells and neurons of the retina arise from a common progenitor in
development (Turner and Cepko, 1987). Astrocytes and Muller cells are the neuroglia of
the retina that, along with microglial cells, maintain retinal homeostasis. Astrocytes are
more prevalent in the nerve fiber and inner nuclear layers of the retina. Muller cells are
radially oriented such that they interact with all retinal cell layers. Many functions such
as BBB maintenance and regulation of the neural cell environment are shared between
Muller glia and astrocytes (Vecino et al., 2016).
Injury to the retina causes glial reactivity in a manner similar to glial responses in
the rest of the CNS. Microglial cells respond to retinal high-intensity light-injuries by
upregulating trophic factors such as GDNF, NGF, neurotrophin-3 (NT-3), and ciliary
neurotrophic factor (CNTF). Additionally, microglial cells induce Muller glia to express
increased levels of bFGF, GDNF, and BDNF, that serve to protect retinal neurons after
injury (Harada et al., 2002). Muller glial GDNF and BDNF also confer neuronal
protection in diabetic retinopathy (Fu et al., 2015). Similar to astrocytes, Muller glia
regulate innate immune complement cascades, which affect neurotoxicity and retinal
degeneration (Guttenplan et al., 2020; Pauly et al., 2019). Due to the therapeutic
accessibility of the retina, many studies manipulate retinal neuroinflammatory responses
to model nervous system injury. However, it will be important to understand the
distinctions between glial cells of the retina and the CNS in order to translate these
therapeutic approaches to CNS injuries and disease.

11

1.2 Background on stroke
Basics
Stroke is a cerebro-vascular event in which blood flow is blocked to regions of the central
nervous system. In most clinical cases this is induced by a thrombus or embolus that
occludes an artery. If the blockage leads to rupture of the blood vessel, a hemorrhagic
stroke develops. The most common type of stroke is an ischemic stroke, in which the
occluded artery does not rupture (Campbell et al., 2019). In ischemic stroke, the flow of
nutrients and oxygen to parts of the brain is impaired, but there is not an acute influx of
blood into the brain parenchyma. Due to the lack of blood flow and oxygen, oxidative
phosphorylation in the affected area drops. Without adenosine tri-phosphate (ATP),
neurons cannot pump ions against their concentration gradients and neuronal activity
ceases (Lipton and Wittingham, 1979; Santos et al., 1996). Additionally, ATP and
adenosine levels increase in the extracellular environment, triggering microglial
adenosine receptor signaling (Lu et al., 2012; Monif et al., 2009). The lack of oxygen also
triggers hypoxia inducible factor (HIF) activation. Endothelins and HIF are known to
induce each other’s expression and activity, possibly indicating a positive feedback loop.
Under hypoxic and injurious conditions, endothelins are released by endothelial cells,
microglial cells, and astrocytes (Hammond et al., 2014; Khamaisi et al., 2015; Tsang et
al., 2001; Wang et al., 2018; Wu et al., 2006). Endothelins induce blood vessel
vasoconstriction, which could exacerbate stroke, but may also function to protect the area
from blood flow that might infiltrate through the leaky vasculature. The longer that
cerebral tissue is deprived of nutrients and oxygen, the greater the level of neuronal death
and tissue necrosis.
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Types of stroke
Ischemic stroke resulting from thrombus involves a blood clot that occludes a cerebral
artery. The blockage leads to impaired blood flow and a decrease of nutrient and oxygen
delivery within the downstream vascular distribution of the impacted artery. Some
redistribution of blood flow can mitigate the damage, such as rerouting of blood at the
Circle of Willis, or through anastomosis of anterior, middle, and posterior cerebral
arteries.
Hemorrhagic stroke, or stroke with hemorrhagic transformation, is a significant
clinical complication because of the limited supportive interventions available. This type
of stroke includes intracerebral hemorrhage in which the bleeding occurs within the brain
parenchyma, and subarachnoid hemorrhage in which the bleeding occurs outside the
parenchyma but underneath the dural and arachnoid meningeal layers (outside of the pial
layer). In ischemic stroke, there can also be hemorrhagic transformation, with bleeding
developing within the infarcted area. A common clinical consideration in treating
ischemic stroke is ensuring that the patient is not at risk of hemorrhaging in response to
tPA administration (Yaghi et al., 2017).
A frequent precursor to a major stroke is a transient ischemic attack (TIA), in
which blood flow is only temporarily impeded to an area of the brain. Since the transient
ischemia often occurs for less than an hour, the tissue is rarely permanently damaged, and
an infarct is generally not formed. Clinically diagnosing the source of the clot is essential
to determining if the TIA patient is at high risk of a subsequent cerebrovascular event that
will result in significant tissue with infarction (Amarenco et al., 2018; Perry et al., 2011).
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Similar to TIA, silent cerebral infarcts (SCIs) can be precursors to a major stroke.
In contrast to TIAs, SCIs are detected only by MRI. As the name indicates, these small
infarcts do not impact enough brain tissue or behaviorally-essential brain area to cause
noticeable symptoms and are therefore termed “silent” (DeBaun et al., 2012).
Border zone infarcts (watershed infarcts) are strokes that occur at the edges of the
vascular distribution of the major arterial blood flow to the brain. A decrease in cerebral
blood flow leads to inadequate perfusion of small blood vessels that anastomose between
vascular territories of the three major cerebral arteries: the middle, anterior, and posterior
cerebral arteries; this leads to unique stroke patterns following the edges of each major
vessels’ vascular territories. Infarcts of this type result from haemodynamic compromise,
reduced blood flow due to other clinical conditions, or from emboli (Mangla et al., 2011).
Ischemic Stroke Treatment
To date, the only FDA-approved treatment for ischemic stroke is recombinant
tissue plasminogen activator (rtPA, also known as Alteplase) and supportive care. Tissue
plasminogen factor, expressed by endothelial cells, is a serine protease that induces
fibrinolysis (breakdown of blood clots) by converting plasminogen into plasmin (Suzuki
et al., 2011). The recombinant form of tPA was developed to break down an arterial
thrombus that causes a stroke. Unfortunately, there is a strict time window during which
rtPA is therapeutically effective (~4.5 hours) (Barber et al., 2001; O’Rourke et al., 2009).
Outside of this time window rtPA can actually increase the risk of hemorrhaging and
worsen stroke outcomes (Yaghi et al., 2017). The inability of many people to recognize
the symptoms of a stroke and quickly get to a hospital means that the majority of
ischemic stroke patients do not receive rtPA treatment (only ~7% treated). Attempts to
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expand beyond the limits of the ~4.5 hour effective time window of rtPA have led to only
minor improvements in patient outcomes. Minimal added effectiveness, and increased
risk of intracerebral hemorrhage mean that expanded time windows are generally not
indicated for most patients.
A second treatment option is endovascular and mechanical, in which a catheter is
used to access the vasculature and remove the thrombus from major arteries. This
approach includes a more flexible treatment timeline than does rtPA, but because of the
intervention mechanism, thrombectomy is limited to large arteries. Estimates of the
percent of ischemic stroke patients treatable by thrombectomy vary widely from 3% to
22% (Mokin et al., 2019). Notably, with the majority of ischemic stroke patients not
receiving a reperfusion treatment, more therapies are needed to treat stroke patients that
are not reperfused.
1.3 Cell signaling background
Endothelins
Endothelins are evolutionarily conserved signaling peptides involved in the maintenance
of vascular tone. There are three endothelin ligands: ET-1, ET-2, and ET-3. All
endothelins start out as precursor proteins termed “big-endothelin” and are converted to
their active form by endothelin converting enzyme (ECE) (Davenport et al., 2016;
Khamaisi et al., 2015). The peptide ligands are then secreted into the extracellular space
by secretory vesicles or are processed to their active form to reside within Weibel-Palade
Bodies (WPBs) (Ozaka et al.,1997; Russell et al., 1998). The receptors for endothelin
ligands are endothelin receptor type-A (ETBR) and endothelin receptor type-B (ETBR).
Both receptors are expressed in vascular cells, where endothelin signaling regulates
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vascular tone (Bacon and Davenport, 1996; Brain et al., 1998). High densities of
endothelin receptor type-A and type-B expressed on smooth muscle cells trigger
intracellular Ca2+ release, leading to vasoconstriction (Bacon and Davenport, 1996;
Merlen et al., 2013; Roubert et al., 1991). By contrast, endothelin receptor type-B
expressed on endothelial cells triggers Nitric Oxide release and vasodilation (Dupuis,
2001; Schneider et al., 2007; Verhaar et al., 1998). ETBR signaling simulates downstream
RAC-alpha Serine/Threonine-protein kinase (AKT) and extracellular signal-regulated
kinase (ERK) activity, which may account for some of the indirect vasodilatory effects of
endothelins. WPBs contain von Willebrand factor (VWF), P-selectin, and endothelins.
WPB exocytosis is one of the first responses to vascular injury, triggering blood clotting,
inflammatory cell recruitment, and vasoconstriction. Hypoxic/ischemic tissue injuries
such as stroke induce the exocytosis of WPBs include hypoxia injuries (Pinsky et al.,
1996; Rondaij et al., 2006).
In addition to endothelial cells, microglial cells also express endothelin. Like
endothelial cells, microglia express ET-1 and ETBR in response to ischemia (Li et al.,
2010; Rogers et al., 1997). There is also evidence that microglia increase ET-1 expression
in response to inflammatory stimuli such as lipopolysaccharide (Wu et al., 2006). This
indicates that endothelin ligands may not be exclusively coupled to endothelial cell
function and vascular tone but may also act as important regulators of inflammatory
responses.
Astrocytes do not express endothelins under normal conditions but upregulate
endothelin secretion under pathological conditions such as stroke, accumulation of
amyloid beta peptide, and in proximity to multiple sclerosis plaques (Ehrenreich et al.,
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1993; Hama et al., 1997; Ho et al., 2001; Jiang et al., 1993; Zhang et al., 1994). ET-1
blocks remyelination in multiple sclerosis lesions by promoting increased Jagged-1
expression in astrocytes, which is associated with a putative protective/proliferative
reactive astrocyte phenotype. Astrocyte Jagged-1 signals to oligodendrocyte Notch
receptors to inhibit remyelination (Hammond et al., 2014). JaggedHi astrocytes are
associated with neuroprotection in stroke, but inhibit myelination in multiple sclerosis,
again illustrating the context-dependence of reactive astrocyte phenotypes (LeComte et
al., 2015). Furthermore, endothelin signaling can stimulate the migration of
subventricular zone progenitors which have similarities to reactive astrocytes (Gadea et
al., 2009).
In multiple CNS diseases and disorders, astroglial endothelin signaling serves as a
pro-growth trophic factor, inflammatory regulator, and mediator of vascular tone (Jo et
al., 2014). In the brain, astrocytes express some of the highest levels of ETBR relative to
other cells, while expressing low levels of ETAR (Guo et al., 2014; Hammond et al.,
2015; John Lin et al., 2017; Zhang et al., 2014). Strong ETBR expression localizes to
reactive astrocytes within the peri-infarct area after ischemic stroke (Lecomte et al.,
2015). After stroke, it is likely that astrocytes need an array of receptors to detect BBB
compromise and respond to the injury. ETBR expression may provide a multifaceted
response mechanism to detect injury signals and induce both growth and inflammatory
responses in reactive astrocytes.
Angiopoietins
Angiopoietins are a family of secreted paracrine factors made up of angiopoietins 1-4
(Ang1-4) and Angiopoietin-like proteins 1-8 (Angptl1-8). Angiopoietin family members
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regulate the sprouting of new blood vessels from existing vessels (angiogenesis) and
vascular stability. This is notably a separate process from de novo development of
vasculature from precursor cells (vasculogenesis) which can also be regulated by Tie-2,
vascular endothelial growth factor (VEGF), and Angptl2 (Dumont et al., 1994;
Richardson et al., 2014; Shalaby et al., 1995). Ang-1 is the primary agonist of the Tie-2
receptor. Ang-1/Tie-2 signaling promotes endothelial cell survival, tight junction
integrity, and vascular stability. Ang-2 was originally described as an antagonist of the
Tie-2 receptor that promoted destabilization of the vasculature (Maisonpierre et al.,
1997). Increasing evidence suggests that Ang-2 acts as an agonist or antagonist
depending on context; this includes the presence or absence of inflammation (Akwii et
al., 2019; Hegen et al., 2004; Kim et al., 2016). One aspect of this context dependence is
expression levels of the Tie-1 receptor, which can be altered by infection and tumor
necrosis factor (TNF) signaling. Tie-1 and Tie-2 are differentially expressed within the
endothelial cells of growing vasculature to promote tip-cell proliferation, as compared
with stable, non-growing blood vessels (Kim et al., 2016; Savant et al., 2015; Yuan et al.,
2007). Tie-2 can form homodimers or heterodimerize with the Tie-1 receptor. There is
evidence that heterodimerization blocks Ang-2 signaling, but Ang-1 treatment dissociates
heterodimer and Tie-2 homodimer formation and signaling (Seegar et al., 2010). An
additional important factor in the function of Ang-2 is the presence or absence of VEGF.
In the absence of VEGF, Ang-2 promotes vascular collapse and endothelial cell death. In
the presence of VEGF, Ang-2 promotes angiogenesis (Zhu et al., 2005).
These different signaling environments might explain why the effects of Ang-2 in
the context of stroke are controversial. In the acute phase of stroke, when delivered prior
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to ischemic injury, Ang-2 is reported to be protective (Marteau et al., 2013).
Alternatively, the canonical role of Ang-2 in downregulating vascular tight junctions and
increasing vascular permeability is thought to exacerbate stroke injury (Gurnik et al.,
2016). These differences in Ang-2 function could be important to effectively use it in
stroke therapies. Translational studies designed to modify post-stroke recovery and tissue
regeneration using VEGF hydrogels have injected them 5 days post-infarct (Nih et al.,
2018). Both timing of the administration and the contents of the hydrogels is critical
because they will interact with endogenous signals. Therefore, it is important to
understand related signaling pathways in necrosing tissue as ischemia progresses.
Defining how VEGF interacts with endogenous Ang-2 may be critical for mechanistic
understanding of the observed treatment effects of the VEGF hydrogels. Other
inflammatory signals such as tumor necrosis factor (TNF), which is thought of as proinflammatory and cell-death promoting, are similarly context dependent. TNF is an
essential factor in developmental and post-stroke angiogenesis (Huang et al., 2016). It
promotes angiogenesis, in part, by inducing the expression of Ang-2. The contrasting
pro-angiogenic and pro-apoptotic functions of TNF signaling illustrates how a variety of
post-stroke signal transducers are highly context-specific and timing-dependent. This also
highlights the manner in which the inflammatory and angiogenic paracrine environments
after stroke are intricately linked. To better design and properly time the administration of
disease-modifying therapies, it will be critical to better understand the full array of cell
signals and their spatial and temporal specificity.
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TGF signaling
The transforming growth factor- (TGF) superfamily consists of cytokine signaling
molecules that includes TGFs (1-3), bone morphogenic proteins (BMPs 1-20), activins
(A and B), inhibins (A and B), myostatin, nodal, leftys (1 and 2), Mullerian inhibiting
substance (MIS), and glial derived neurotrophic factor (GDNF) family members (Gordon
and Blobe, 2008; Eigenbrot and Gerber, 1997). The superfamily is named for the
originally discovered cytokine TGF1.
TGFs are characterized by expression in a dimerized form with a large
prodomain. The prodomain maintains the factors in a latent (non-signaling form,
although latent forms may have some activity). Latent TGFs associate with the
extracellular matrix through latent TGF binding proteins (LTBPs). Importantly latent
TGFs are in a “ready-to-activate state”, and able to respond to changes in the cellular
environment or to injury (Schachtrup et al., 2010). Integrins, thrombospondins,
fibrinogen, and environmental changes such as temperature and pH, all promote
transformation of latent TGF into its active form.
There are three major TGF ligands: TGF1, TGF2, and TGF3 (Derynck and
Budi, 2019; Massague, 2012). TGFs bind to and induce heterodimeric complexes of
Type I and Type II TGF receptors. There are seven type I receptors, five type II
receptors, and a small number of type III co-receptors that modulate the signaling of
ligands through the type I and II receptors. TGF signals through type I receptors,
phosphorylating and activating downstream SMAD2 (SMA, small worm phenotype;
MAD, Mothers against Decapentaplegic) and SMAD3 signaling. BMPs activate their
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type I receptors to signal through downstream SMAD1, SMAD5, and SMAD8 (Akhurst
and Hata, 2012). These SMADs cooperate with SMAD4 to translocate to the nucleus,
interact with transcription factors, and alter gene expression. The mechanism that inhibits
SMAD transcriptional activity is the expression of inhibitory SMADs (6 and 7), which
are essential to CNS development (Casellas and Brivanlou, 1998; Imamura et al., 1997;
Nakao et al. 1997). The list of signaling pathways that can be activated by TGF family
members is extensive, and includes: tumor necrosis factor receptor-associated factors
(TRAFs), P38/MAPK, RHO, PI3K, AKT, ERK, JNK, and NFB (Zhang, 2009).
TGF has essential roles in the regulation of development and inflammatory
responses. The induction of ectoderm and the primitive nervous system requires the
inhibition of TGF/BMP signaling, and this effect has been shown to cause embryonic
stem cells and induced pluripotent stem cells to take on a neural cell fate (Chambers et
al., 2009). Increased TGF signaling suppresses some aspects of stroke injury (Doyle et
al., 2010; Gross et al., 1993; McNeill et al., 1994; Pang et al., 2001). TGF promotes a
mature microglial state and reigns in certain aspects of microglial activity such as
microglial-driven demyelination (Hollander et al., 2017; Qin et al., 2018; Stoll et al.,
2004). In other settings, TGF promotes astroglial and immune cell reactivity and
inflammation (Diniz et al., 2017; Schachtrup et al., 2010; Veldhoen et al., 2008). These
effects contrast with the role of TGF in limiting reactivity and dampening down
inflammation in astrocytes and microglia.
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CD109
CD109 is an alpha-2 macroglobulin C3, C4, C5 family member and a TGF co-receptor
(Finnson et al., 2006; Lin et al., 2002). As a membrane-bound thioester-containing
protein, CD109 can be released from the cell membrane through furin cleavage (Janssen
et al., 2005). The solubility of CD109, and its role in controlling cellular growth has
made it a marker of more aggressive cancers and a target for early cancer diagnosis
(Dong et al., 2015; Emori et al., 2013). Studies on the function of CD109 have been
limited to determining how it regulates fibroblast proliferation and extracellular matrix
production in injuries and diseases of the skin. Two primary models for the actions of
CD109 have arisen from these studies. The first is that CD109 binds to TGF receptors,
localizes the receptors to caveolae, and induces receptor degradation and desensitization
of cells to TGF signaling (Bizet et al., 2011). The other model proposes that CD109
binds TGF and TGF receptors, shunting TGF signaling away from ALK5 class
receptors toward ALK1 receptors (Vorstenbosch et al., 2017). ALK1 signals through
SMAD1/5, decreasing extracellular matrix production and increasing cellular
proliferation. Notably, many functions of membrane bound CD109 are retained by furin
cleaved, soluble CD109 (Li et al., 2016; Litvinov et al., 2011). Thus, soluble CD109 may
have widespread or local effects on the injury environment.
In mouse models of rheumatoid arthritis, neutralization of CD109 decreased
inflammation, improved symptoms, and led to better outcomes (Song et al., 2019). This
illustrates that CD109 is likely to alter the inflammatory activities regulated by TGF.
Adding complexity to this picture, CD109 was shown to affect EGF signaling (Zhang et
al., 2015). Notably, it is closely related to complement C3, a key element in complement
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activation, inflammation, and a marker of neurotoxic astrocytes (Janssen et al., 2005;
Liddelow et al., 2017).
The role of CD109 in other systems is just being elucidated. In the brain, studies
have found expression of CD109 mRNA in neuroprotective astrocytes. To our knowledge
no mechanistic studies of the function of CD109 in astrocytes have been reported
(Liddelow et al., 2017). CD109 expression causes increased glioma-cell proliferation and
decreased survival times in glioma mouse models (Shiraki et al., 2017). Increased CD109
expression in glioblastoma was also associated with radioresistance and poor prognosis
(Minata et al., 2019). Gene expression studies indicate that CD109 is primarily highly
expressed by endothelial cells in the healthy brain. During brain injury and
neuroinflammation, CD109 is one of the most upregulated genes in reactive astrocytes
(Zamanian et al., 2012). Additionally, an analysis of the astrocyte glio-vascular endfoot
found CD109 mRNA undergoing active translation (Boulay et al., 2017). As vascularcontacting astrocytes are uniquely proliferative and scar forming, and this process is
partially regulated by TGF, the location of CD109 at the astrocyte vascular enfoot may
be significant. Given the location of CD109 in astrocytes, and changes to CD109 after
injury, the function of astroglial CD109 in the brain during homeostasis and after injury
warrants further investigation.
1.4 Proliferative reactive astrocyte response to injury
Opinions pertaining to reactive astrogliosis and proliferative reactive astrocytes,
are, in many ways, tied to the history of the glial scar. This is exemplified by studies that
eliminated proliferative reactive astrocytes and prevented the formation of the glial scar
(Bush et al. 1999, Wanner et al. 2013). Glial scars usually form in response to traumatic
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injuries such as stroke and spinal cord injury and are often the most striking feature of
CNS injury. It’s commonly thought that the glial scar is inhibitory to mammalian central
nervous system regeneration after an injury (Hu et al., 2010; Wang et al., 2018; Yiu and
He, 2006). This hypothesis derives from an observed lack of regeneration in the central
nervous system after injury, in contrast to notable nerve regeneration seen after peripheral
nerve injuries. Historically, mammalian glial scarring was shown to prevent axonal
regeneration, while there is clearly axon regeneration through glial scars in multiple other
species, including amphibians. In the rat central nervous system axons grow into grafts or
“bridges” of peripheral nervous system tissue after spinal cord transection (David et al.
1981; Richardson et al. 1980). Also, the glial scar contains astrocytes that express
chondroitin sulfate proteoglycans, which dramatically inhibit axon growth (Fry et al.
2010; Monnier et al. 2003; Snow et al. 2002). Myelin within the central nervous system is
generated by oligodendrocytes, whereas peripheral nervous system axons are myelinated
by Schwann cells. Oligodendrocytes express multiple factors inhibitory to axonal growth,
including the aptly named protein “nogo” (GrandPre et al. 2002; Stephany et al., 2014).
These studies highlight differences between the mammalian CNS and PNS tissue, and the
CNS tissue of other species.
Recent work, particularly from the Sofroniew lab, is helping to change the
negative view of the glial scar. Prior attempts at a therapy for spinal cord injury attempted
to eliminate the scar or scar components, in order to promote regeneration (Janzadeh et
al., 2017; Rosenzweig et al., 2019). Advances in mouse genetics have allowed for the
selective removal of proliferative reactive astrocytes and therefore inhibition of scar
formation in response to spinal cord injury (Faulkner et al., 2004; Herrmann et al., 2008).
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As expected, wild-type axons grow into the scar but are unable to pass through the scar
after spinal cord injury. Surprisingly, genetic removal of proliferative reactive astrocytes
and glial scar actually led to decreased axon regeneration as compared to that observed in
wild-type mice (Anderson et al., 2016). Multiple strategies were applied to significantly
regenerate axons through the scar in wild-type mice, including hydrogel-based delivery
of trophic factors and viral delivery of pro-regenerative signals to neurons. While these
strategies promoted axon regeneration through the scar and lesion after SCI, they
universally failed in mice with inhibited scar formation (Anderson et al., 2018).
Importantly, there is some question as to whether delivering such therapies 2 days postspinal cord injury leads to regeneration prior to full maturation of the glial scar. Some
aspects of the scar are not fully mature at this time point, but many of the inhibitory
molecules are present within the scar at the time of the reported treatments. Regardless,
these studies demonstrate the importance of proliferative reactive astrocytes in spinal
cord injury recovery and add to our understanding of the role of the glial scar in
regeneration.
Reactive astrocytes proliferate in response to catastrophic injuries of the central
nervous system such as stroke, spinal cord injury, and penetrating traumatic brain injury
(Frik et al., 2018; Lecomte et al., 2015; Shimada et al., 2012; Wanner et al., 2013). This
is in contrast with inflammatory neural disfunction such as Alzheimer’s disease, multiple
sclerosis, and Parkinson’s disease, in which astrocytes become reactive but proliferate
minimally (Liddelow and Barres, 2017). This difference has been mirrored in recent work
that shows that astrocytes become “neuroprotective” in response to stroke but become
largely “neurotoxic” during inflammatory diseases of the brain (Liddelow et al., 2017).
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When proliferative reactive astrocytes are eliminated and scar formation is
inhibited, injuries to the CNS expand, axon regeneration decreases, and blood-cell
infiltration increases. Interestingly, blood-cell infiltration is a primary stimulus of
astroglial proliferation in the first place (Frik et al., 2018). After injury, vascular
contacting astrocytes proliferate disproportionately as compared to non-vascular
contacting astrocytes (Bardehle et al., 2013). Despite potentially neuroprotective features
of proliferative reactive astrocytes and changes in the cellular environment upon their
removal, research has largely focused on scar formation and ignored paracrine factors
released by these cells. With the recent discovery of multiple regulators of astroglial
proliferation in stroke, tools are now available to determine how proliferative astrocyte
regulators alter astroglial derived paracrine signals. Endothelins regulate vascular tone
and our laboratory recently showed that endothelin signaling controls astroglial
proliferation through a Notch1-STAT3-ETBR signaling axis. With the ties between the
vasculature and reactive astrogliosis, it is of great interest to determine how endothelins
alter astroglial paracrine signaling.
1.5 Progression of blood brain barrier permeability and inflammation after stroke
In the healthy adult brain, the BBB keeps blood components out and participates in the
selective trafficking of fluid and molecules into and out of the CNS (Wimmer et al.,
2019). The maintenance of this barrier is dependent on tight junctions between
endothelial cells and the active transport of selected molecules and cells (i.e. diapedesis)
into the brain by endothelial cells. Astrocyte endfeet completely encase the vascular
compartment, which includes endothelial cells, extracellular matrix, and pericytes. These
barrier functions also act to limit the entry of immune-cells, such as leukocytes, into the
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brain. The limited exposure of the brain to the immune system contributes to the
perception of the brain’s status as an immune-privileged organ (Forrester et al., 2018).
When the BBB of the CNS is intact, most immune functions are maintained and
performed by microglial cells (Ajami et al., 2007).
After ischemic stroke without hemorrhage, there is still dysregulation of
endothelial cell tight junctions; this leads to increased blood cell infiltration and
contributes to neuroinflammation after stroke (Gelderblom et al., 2009; Reijerkerk et al.,
2011). The compromise of the BBB is a significant event that must be detected, and
responded to, by a variety of CNS cell types. Microglial cells in particular have evolved a
sensitive system wherein blood components act as damage associated molecular patterns
(DAMPs) that they detect and that control their biology (Hickman et al., 2013). The array
of receptors that microglia express to detect DAMPs has been referred to as “pattern
recognition receptors” (PRRs). The array of PRRs prime microglia to detect the earliest
signs of damage such as metabolic dysfunction and BBB permeability early in ischemia.
One of the most studied groups of PRRs include the Toll-like receptors (TLRs). TLRs
detect pathogen-associated lipopolysaccharide (LPS), specific blood components such as
fibrinogen and fibronectin, and necrotic cells (Gulke et al., 2018; Kigerl et al., 2014).
Toll-like receptor signaling triggers a variety of downstream paracrine and inflammatory
effectors, including those that mediate neuroprotection (Kamigaki et al., 2016). Another
notable wing of the PRR system is the P2Y receptors. These receptors detect nucleotides
such as ADP and ATP in the extracellular space, as these are often signatures of tissue
damage or disease. Microglia express P2Y receptors, and one of these (P2Y12) has been
characterized as a microglial-specific marker within the CNS. Another characteristic
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receptor of microglia is CD11b, which acts as a receptor for complement proteins and
also triggers microglial activation after binding fibrinogen (Adams et al., 2007).
BBB breakdown contributes to the reactive astroglial response to injury and
disease. Several studies have shown that blood-cell infiltration directly stimulates
reactive astrocyte proliferation after CNS injury (Frik et al., 2018). Along with bloodcells, blood-specific components such as thrombin and fibrinogen enter the brain after
stroke. Fibrinogen and other blood-borne factors activate latent TGF in the brain, and
the activation of TGF by fibrinogen stimulates astrocyte scar formation in response to
injury (Schachtrup et al., 2010; Zhang et al., 2018).
Due to the immune-privileged nature of the brain and the interplay of blood cell
infiltration with neuroinflammation, it is important to understand how BBB dysfunction
and neuroinflammation progress after ischemic stroke. An early step in barrier
dysfunction after stroke is the shutdown of ionic transporters and the loss of ionic
gradients (Yang et al., 1992). Changes in ionic balance lead to increased entry of fluid
from the blood into the perivascular space (Chen et al., 2015). Additionally, oxidative
stress and metabolic dysfunction promote downregulation of endothelial cell tight
junction components, causing further edema (Lochhead et al., 2010; McCaffrey et al.,
2009; Witt et al., 2003). Cell signaling changes such as fibrinogen activation of TGF,
and the presence of other DAMPs (e.g. HSPs, HMGB1, nucleotides), induce microglial
inflammatory reactions. Microglial cell numbers peak from 1-3 days after stroke,
generally preceding peak blood cell infiltration (Gelderblom et al., 2009). Many of the
inflammatory signals released by microglia in response to CNS damage also act to recruit
blood-borne immune cells into the brain parenchyma. Endothelins, which are released by
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microglia and numerous other CNS cells, including astrocytes, control the diapedesis of
monocytes into the brain (Reijerkerk et al., 2012). The infiltration of blood cells into the
brain is greatest around 3-days post-stroke (Gelderblom et al., 2009). Blood-cell
infiltration into the CNS is toxic to neurons by direct cell-cell contact and release of
proteases (Dimitrijevic et al., 2007; Dinkel et al., 2003; Soriano et al., 1999).
An important consideration in developing drugs to protect and regenerate neural
tissue after stroke is the propensity of pharmacological agents to increase vascular leak.
The most obvious example of this problem is rtPA treatment, which can cause increased
blood infiltration, particularly when delivered outside of its specified time window or in
patients with other complications such as hypertension, diabetes, or metabolic disease
(Dong et al., 2016; Suzuki et al., 2015). Problematically, pro-angiogenic therapies such as
VEGF treatment can lead to vascular leakage. Thus, there is great interest in developing
drugs that can promote rescue and/or repair without compromising the vasculature or
BBB (Rust et al., 2019).
1.6 Adult neural stem cells
Since their discovery, adult neural stem cells (NSCs) have been the focus of intense
research. This is in part because of their perceived regenerative potential and the
possibility that these cells or their downstream functions could contribute to adult CNS
regeneration. These cells have many similarities to adult reactive astrocytes and may
offer clues to inducing adult reactive astrocytes to promote regeneration after injury.
During development, most NSCs exhaust their self-renewal potential and differentiate.
However, a select number of NSCs persist into the adult brain (Reynolds and Weiss,
1992; Spalding et al., 2013). In the adult brain, NSC/NPCs reside in two main niches.
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One niche is the walls of the lateral ventricles (the subventricular zone, SVZ), and the
other niche is in the subgranular zone (SGZ) of the dentate gyrus (Bond et al., 2015;
Fuentealba et al., 2012). SVZ neural stem cells self-renew and give rise to neuroblasts
which migrate to the olfactory bulb by way of the rostral migratory stream. Within the
olfactory bulb, these neural progenitors differentiate into interneurons that control
olfactory processing (Merkle et al., 2014). SGZ stem cells self-renew and generate
neuroblasts, but their progeny differentiate into neurons that incorporate into the granule
cell layer of the hippocampus, later participating in hippocampal mechanisms associated
with learning and memory (Kirschen et al., 2017; Zhuo et al., 2016).
A major question that persisted in the field after the discovery of adult
neurogenesis was: where do adult neural stem cells come from? SVZ neural stem cells
were recently shown to derive from a select number of cortical radial glial cells during
development. Through signals such as vascular cell adhesion molecule-1 (VCAM1),
neurotropin-3 (NT-3), Notch2, and -catenin, selected radial glial cells are triggered
during developmental neurogenesis to downregulate proliferation and become slowproliferating (quiescent) adult neural stem cells. In contrast to other radial glial cells,
which lose self-renewal potential and differentiate, these VCAM1+ cells lower their
division rate to avoid prematurely reaching their hayflick limit, thus allowing them to
persist as stem cells into adulthood (Hu et al., 2017). Radial glial cells become the adult
NSC, also known as the B-cell or the quiescent NSC of the adult SVZ stem cell niche
(Codega et al., 2014). One current model indicates that there are two stem-cell types that
self-renew at different rates and maintain the neurogenic potential of the SVZ. One is the
quiescent NSC, characterized by a protein profile including expression of CD133, GFAP,
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VCAM1, and FGFR, and a lack of EGFR expression (Codega et al., 2014). When the
quiescent cell becomes an activated NSC, it loses VCAM1 expression and gains
expression of EGFR (Codega et al., 2014). Along with these changes, there is a
corresponding increase in cellular proliferation and expression of proliferative markers
such as PCNA. The NSCs maintain EGFR expression and become transit amplifying
progenitor cells (NPCs), which contribute to the pool of migratory neuroblasts, in part
characterized at these later stages by doublecortin (DCX) expression.
In addition to VCAM1, which contributes to the specification of NSCs during
development, there are a variety of other factors that maintain the unique state of adult
NSCs. These signals are important to balance quiescence, proliferation, and
differentiation. If this balance is not maintained, the stem cell pool could be exhausted or
proliferate until reaching their Hayflick limit, thereby becoming senescent. Notch
signaling is required for NSC self-renewal (Aguirre et al., 2010; Hatakeyama et al., 2014;
Shen et al., 2002). Notch2 signaling maintains quiescent neural stem cells, while Notch1
functions to promote a more proliferative, activated stem cell phenotype (Basak et al.,
2012; Engler et al., 2018; Wilhelmsson et al., 2012). Notch and VCAM1 illustrate the
necessity of cell-cell juxtacrine signaling for stem-cell self-renewal, but a variety of other
secreted signals are also essential to stem-cell maintenance. VCAM1 expression is
promoted by IL-1 and promotes the maintenance of adult quiescent NSCs (Hu et al.,
2017; Kokovay et al., 2012). Endothelial and cerebral spinal fluid-derived neurotrophin-3
(NT-3) also contribute to stem cell quiescence (Delgado et al., 2014). Leucine rich
repeats and immunoglobulin like domain proteins (Lrigs), Tenascins, FGF-receptors, and
EGF-receptors, each function in pathways known to regulate stem cell dynamics and are
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differentially-expressed across the lineages of quiescent NSCs, activated NSCs, and
NPCs. Multiple FGF-receptors (e.g. Fgfr1, 2, 3) show greater than 5-fold enrichment in
qNSCs relative to aNSCs, whereas EGFR is more highly-expressed in the aNSCs.
EDNRB (the gene for ETBR) is ~3-fold more expressed in qNSCs than in aNSCs,
whereas EDNRA is ~15-fold more expressed in qNSCs than aNSCs (Codega et al., 2014).
Recent data show that endothelin signaling helps to maintain neural stem cells in the SVZ
of early postnatal animals (Adams et al., 2020). This evidence suggests that endothelin
receptors expressed by neural stem cells may allow these stem cells to persist into
adulthood. It remains to be determined if ETBR and/or ETAR regulate neural stem-cell
proliferation dynamics in the adult SVZ.
Context and framework of Dissertation
Heterogeneity of reactive astrocytes is increasingly a focus of research to improve disease
outcomes. Dissecting the molecular mechanisms regulating particular astroglial
phenotypes could lead to therapies that alter astroglial reactivity and therefore change the
inflammatory environment in CNS diseases and injuries. To accurately model most
reactive astrocyte contexts which occur in adulthood/aging, we utilized Reactive
astrocyte-derived Neural Stem Cells (Rad-NSCs) to generate adult reactive astrocytes in
vitro, then model reactive astroglial signaling. This contrasts with a large portion of the
reactive astrocyte research using immature in vitro cellular models, which are known to
exhibit different reactive phenotypes.
In chapter 2 of this dissertation we begin characterizing the paracrine profile of
proliferative reactive astrocytes promoted by ETBR-signaling. Our microarray analysis of
ETBR-knockout astrocytes reveals an extensive profile of downstream paracrine factors
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and suggests that ETBR may promote certain features of neuroprotection and/or represses
astroglial neurotoxicity. We particularly focus on Ang-2 secretion by astroctyes, as this
factor could be released in response to stroke to promote vascular protection and to
regulate the neuroinflammatory environment. We found that microglia respond to Ang2/Tie-2 signaling with altered cellular survival and inflammatory state (Figure 1.1). These
findings indicate that astroglial neuroprotective states may not depend solely on paracrine
trophic factors released to neurons, but also on paracrine regulation of microglial
activation and paracrine protection of the vasculature.
In chapter 3 we more closely focus on how ETBR-signaling, and downstream
CD109 expression, alter astroglial neuroprotection/neurotoxicity. We show that the
expression of multiple forms of CD109 is downstream of ETBR signaling, including
enzymatically released forms. CD109 mRNA is reported to be a marker of
neuroprotective astrocytes, so we began characterizing how astroglial CD109 influences
astroglial phenotypes (Figure 1.2). CD109 regulated both astroglial Ang-2 and
complement C3, consistent with altering astroglial phenotypes. Injection of a soluble
form of CD109 tended to increase stroke sizes, though it is unclear if this is through
direct interactions with astrocytes or other CNS cell types. Further work is needed to
determine how CD109 alters astrocytes directly and the cellular environment through
astroglial released CD109. It will also be important to establish if ETBR and/or CD109
are necessary for neuroprotective astrocytes to perform their functions in traumatic CNS
injuries, and, whether signaling through either protein is sufficient to convert neurotoxic
astrocytes to neuroprotective.
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Figure 1. 1.
A model illustrating the main findings of chapter 2 of this dissertation. Endothelin ligands
released in the extracellular mileau, or ETBR-specific drugs such as IRL-1620, interact
with astroglial ETBR receptors. ETBR signaling activates downstream NFB and
MEK/ERK signaling. This increases transcription and secretion of Ang-2, which then
signals through microglial Tie-2 receptors. Tie-2 signaling promotes the
survival/proliferation of microglial cells under hypoxic conditions and also alters
microglial inflammatory state.
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Figure 1. 2.
A model illustrating the main findings of chapter 3 of this dissertation. Endothelin ligands
released in response to stroke, or ETBR-specific drugs such as IRL-1620, stimulate
astroglial ETBR receptors. ETBR signaling increases astroglial CD109 expression. CD109
acts to alter TGF signaling, thereby regulating astroglial neurotoxic/neuroprotective
phenotypes in response to injuries and/or inflammatory factors.

37

Chapter 1 References
Adams KL, Riparini G, Banerjee P, Breur M, Bugiani M, Gallo V (2020) Endothelin-1
signaling maintains glial progenitor proliferation in the postnatal subventricular zone. Nat
Commun 11:2138.
Adams RA, Bauer J, Flick MJ, Sikorski SL, Nuriel T, Lassmann H, Degen JL,
Akassoglou K (2007) The fibrin-derived gamma377-395 peptide inhibits microglia
activation and suppresses relapsing paralysis in central nervous system autoimmune
disease. J Exp Med 204:571-582.
Aguirre A, Rubio ME, Gallo V (2010) Notch and EGFR pathway interaction regulates
neural stem cell number and self-renewal. Nature 467:323-327.
Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM (2007) Local self-renewal can
sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci
10:1538-1543.
Akhurst RJ, Hata A (2012) Targeting the TGFβ signalling pathway in disease. Nat Rev
Drug Discov 11:790-811.
Akwii RG, Sajib MS, Zahra FT, Mikelis CM (2019) Role of Angiopoietin-2 in Vascular
Physiology and Pathophysiology. Cells 8:471.
Amarenco P, Lavallée PC, Monteiro Tavares L, et al. (2018) Five-Year Risk of Stroke
after TIA or Minor Ischemic Stroke. N Engl J Med 378:2182-2190.
Anderson MA, Burda JE, Ren Y, et al. (2016) Astrocyte scar formation aids central
nervous system axon regeneration. Nature 532:195-200.

38

Anderson MA, O'Shea TM, Burda JE, et al. (2018) Required growth facilitators propel
axon regeneration across complete spinal cord injury. Nature 561:396-400.
Araque A, Parpura V, Sanzgiri RP, Haydon PG (1999) Tripartite synapses: glia, the
unacknowledged partner. Trends Neurosci 22:208-215.
Arizono M, Inavalli VVGK, Panatier A, et al. (2020) Structural basis of astrocytic Ca2+
signals at tripartite synapses. Nat Commun 11:1906.
Arnold T, Betsholtz C. (2013) The importance of microglia in the development of the
vasculature in the central nervous system. Vasc Cell 5:4.
Arnth-Jensen N, Jabaudon D, Scanziani M. (2002) Cooperation between independent
hippocampal synapses is controlled by glutamate uptake. Nat Neurosci 5:325-331.
Bacon CR, Davenport AP (1996) Endothelin receptors in human coronary artery and
aorta. Br J Pharmacol 117:986-992.
Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM (2001) Why are stroke
patients excluded from TPA therapy? An analysis of patient eligibility. Neurology
56:1015-1020.
Bardehle S, Krüger M, Buggenthin F, et al. (2013) Live imaging of astrocyte responses to
acute injury reveals selective juxtavascular proliferation. Nat Neurosci 16:580-586.
Basak O, Giachino C, Fiorini E, Macdonald HR, Taylor V (2012) Neurogenic
subventricular zone stem/progenitor cells are Notch1-dependent in their active but not
quiescent state. J Neurosci 32:5654-5666.

39

Baxi EG, DeBruin J, Jin J, et al. (2017) Lineage tracing reveals dynamic changes in
oligodendrocyte precursor cells following cuprizone-induced demyelination. Glia
65:2087-2098.
Bayraktar OA, Bartels T, Holmqvist S, et al. (2020) Astrocyte layers in the mammalian
cerebral cortex revealed by a single-cell in situ transcriptomic map. Nat Neurosci 23:500509.
Beattie R, Postiglione MP, Burnett LE, et al. (2017) Mosaic Analysis with Double
Markers Reveals Distinct Sequential Functions of Lgl1 in Neural Stem Cells. Neuron
94:517-533.e3.
Bergles DE, Richardson WD (2015) Oligodendrocyte Development and Plasticity. Cold
Spring Harb Perspect Biol 8:a020453.
Bialas AR, Stevens B. (2013) TGF-β signaling regulates neuronal C1q expression and
developmental synaptic refinement. Nat Neurosci 16:1773-1782.
Bizet AA, Liu K, Tran-Khanh N, et al. (2011) The TGF-β co-receptor, CD109, promotes
internalization and degradation of TGF-β receptors. Biochim Biophys Acta 1813:742-753.
Bohlen CJ, Bennett FC, Tucker AF, Collins HY, Mulinyawe SB, Barres BA (2017)
Diverse Requirements for Microglial Survival, Specification, and Function Revealed by
Defined-Medium Cultures. Neuron 94:759-773.e8.
Bond AM, Ming GL, Song H (2015) Adult Mammalian Neural Stem Cells and
Neurogenesis: Five Decades Later. Cell Stem Cell 17:385-395.

40

Bonfanti E, Gelosa P, Fumagalli M, et al. (2017) The role of oligodendrocyte precursor
cells expressing the GPR17 receptor in brain remodeling after stroke. Cell Death Dis
8:e2871.
Boulay AC, Saubaméa B, Adam N, et al. (2017) Translation in astrocyte distal processes
sets molecular heterogeneity at the gliovascular interface. Cell Discov 3:17005.
Bray SJ (2016) Notch signalling in context. Nat Rev Mol Cell Biol 17:722-735.
Brain SD, Tippins JR, Williams TJ (1998) Endothelin induces potent microvascular
constriction. Br J Pharmacol 95:1005-1007.
Buffo A, Rite I, Tripathi P, et al. (2008) Origin and progeny of reactive gliosis: A source
of multipotent cells in the injured brain. Proc Natl Acad Sci U S A 105:3581-3586.
Bush TG, Puvanachandra N, Horner CH, et al. (1999) Leukocyte infiltration, neuronal
degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in
adult transgenic mice. Neuron 23:297-308.
Butovsky O, Jedrychowski MP, Moore CS, et al. (2014) Identification of a unique TGFβ-dependent molecular and functional signature in microglia. Nat Neurosci 17:131-143.
Butt AM, Colquhoun K, Berry M. (1994) Confocal imaging of glial cells in the intact rat
optic nerve. Glia 10:315-322.
Byravan S, Foster LM, Phan T, Verity AN, Campagnoni AT (1994) Murine
oligodendroglial cells express nerve growth factor. Proc Natl Acad Sci U S A. 91:88128816.

41

Campbell BCV, De Silva DA, Macleod MR, et al. (2019) Ischaemic stroke. Nat Rev Dis
Primers 5:70.
Casellas R, Brivanlou AH (1998) Xenopus Smad7 inhibits both the activin and BMP
pathways and acts as a neural inducer. Dev Biol 198:1-12.
Cekanaviciute E, Fathali N, Doyle KP, Williams AM, Han J, Buckwalter MS (2014)
Astrocytic transforming growth factor-beta signaling reduces subacute
neuroinflammation after stroke in mice. Glia 62:1227-1240.
Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L (2009)
Highly efficient neural conversion of human ES and iPS cells by dual inhibition of
SMAD signaling. Nat Biotechnol 27:275-280.
Chen L, Li J, Wang F, et al. (2016) TIE2 Expression on Macrophages Is Required for
Blood Vessel Reconstruction and Tumor Relapse after Chemotherapy. Cancer Res
76:6828-6838.
Chen YJ, Wallace BK, Yuen N, Jenkins DP, Wulff H, O'Donnell ME (2015) Blood-brain
barrier KCa3.1 channels: evidence for a role in brain Na uptake and edema in ischemic
stroke. Stroke 46:237-244.
Clavreul S, Abdeladim L, Hernández-Garzón E, et al. (2019) Cortical astrocytes develop
in a plastic manner at both clonal and cellular levels. Nat Commun 10:4884.
Codega P, Silva-Vargas V, Paul A, et al. (2014) Prospective identification and
purification of quiescent adult neural stem cells from their in vivo niche. Neuron 82:545559.

42

Dagher NN, Najafi AR, Kayala KM, et al. (2015) Colony-stimulating factor 1 receptor
inhibition prevents microglial plaque association and improves cognition in 3xTg-AD
mice. J Neuroinflammation 12:139.
Davenport AP, Hyndman KA, Dhaun N, et al. (2016) Endothelin. Pharmacol Rev
68:357-418.
David S, Aguayo AJ (1981) Axonal elongation into peripheral nervous system "bridges"
after central nervous system injury in adult rats. Science 214:931-933.
DeBaun MR, Armstrong FD, McKinstry RC, Ware RE, Vichinsky E, Kirkham FJ (2012)
Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic
injury in sickle cell anemia. Blood 119:4587-4596.
Delgado AC, Ferrón SR, Vicente D, et al. (2014) Endothelial NT-3 delivered by
vasculature and CSF promotes quiescence of subependymal neural stem cells through
nitric oxide induction. Neuron 83:572-585.
Derynck R, Budi EH (2019) Specificity, versatility, and control of TGF-β family
signaling. Sci Signal 12:eaav5183.
Dimitrijevic OB, Stamatovic SM, Keep RF, Andjelkovic AV (2007) Absence of the
chemokine receptor CCR2 protects against cerebral ischemia/reperfusion injury in mice.
Stroke 38:1345-1353.
Diniz LP, Tortelli V, Matias I, et al. (2017) Astrocyte Transforming Growth Factor Beta
1 Protects Synapses against Aβ Oligomers in Alzheimer's Disease Model. J Neurosci
37:6797-6809.

43

Dinkel K, Dhabhar FS, Sapolsky RM (2004) Neurotoxic effects of polymorphonuclear
granulocytes on hippocampal primary cultures. Proc Natl Acad Sci U S A 101:331-336.
Dong F, Lu C, Chen X, Guo Y, Liu J (2015) CD109 is a novel marker for squamous
cell/adenosquamous carcinomas of the gallbladder. Diagn Pathol 10:137.
Dong MX, Hu QC, Shen P, et al. (2016) Recombinant Tissue Plasminogen Activator
Induces Neurological Side Effects Independent on Thrombolysis in Mechanical Animal
Models of Focal Cerebral Infarction: A Systematic Review and Meta-Analysis. PLoS
One 11:e0158848.
Doyle KP, Cekanaviciute E, Mamer LE, Buckwalter MS (2010) TGFβ signaling in the
brain increases with aging and signals to astrocytes and innate immune cells in the weeks
after stroke. J Neuroinflammation 7:62.
Dudiki T, Meller J, Mahajan G, et al. (2020) Microglia control vascular architecture via a
TGFβ1 dependent paracrine mechanism linked to tissue mechanics. Nat Commun 11:986.
Dumont DJ, Gradwohl G, Fong GH, et al. (1994) Dominant-negative and targeted null
mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in
vasculogenesis of the embryo. Genes Dev 8:1897-1909.
Dupuis J (2001) Endothelin-receptor antagonists in pulmonary hypertension. Lancet
358:1113-1114.
Du Y, Dreyfus CF (2002) Oligodendrocytes as providers of growth factors. J Neurosci
Res 68:647-654.

44

Easley-Neal C, Foreman O, Sharma N, Zarrin AA, Weimer RM (2019) CSF1R Ligands
IL-34 and CSF1 Are Differentially Required for Microglia Development and
Maintenance in White and Gray Matter Brain Regions. Front Immunol 10:2199.
Ehrenreich H, Costa T, Clouse KA, et al. (1993) Thrombin is a regulator of astrocytic
endothelin-1. Brain Res 600:201-207.
Eigenbrot C, Gerber N. (1997) X-ray structure of glial cell-derived neurotrophic factor at
1.9 A resolution and implications for receptor binding. Nat Struct Biol 4:435-438.
Elmore MR, Najafi AR, Koike MA, et al. (2014) Colony-stimulating factor 1 receptor
signaling is necessary for microglia viability, unmasking a microglia progenitor cell in
the adult brain. Neuron 82:380-397.
Emori M, Tsukahara T, Murase M, et al. (2013) High expression of CD109 antigen
regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel
epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma.
PLoS One 8:e84187.
Emsley JG, Macklis JD. (2006) Astroglial heterogeneity closely reflects the neuronaldefined anatomy of the adult murine CNS. Neuron Glia Biol 2:175-186.
Engler A, Rolando C, Giachino C, et al. (2018) Notch2 Signaling Maintains NSC
Quiescence in the Murine Ventricular-Subventricular Zone. Cell Rep 22:992-1002.
Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV (2004)
Reactive astrocytes protect tissue and preserve function after spinal cord injury. J
Neurosci 24:2143-2155.

45

Finnson KW, Tam BY, Liu K, et al. (2006) Identification of CD109 as part of the TGFbeta receptor system in human keratinocytes. FASEB J 20:1525-1527.
Fontana X, Hristova M, Da Costa C, et al. (2012) c-Jun in Schwann cells promotes
axonal regeneration and motoneuron survival via paracrine signaling. J Cell Biol
198:127-141.
Forrester JV, McMenamin PG, Dando SJ (2018) CNS infection and immune privilege.
Nat Rev Neurosci 19:655-671.
Frik J, Merl-Pham J, Plesnila N, et al. (2018) Cross-talk between monocyte invasion and
astrocyte proliferation regulates scarring in brain injury. EMBO Rep 19:e45294.
Fry EJ, Chagnon MJ, López-Vales R, Tremblay ML, David S. (2010) Corticospinal tract
regeneration after spinal cord injury in receptor protein tyrosine phosphatase sigma
deficient mice. Glia 58:423-433.
Fu S, Dong S, Zhu M, et al. (2015) Müller Glia Are a Major Cellular Source of Survival
Signals for Retinal Neurons in Diabetes. Diabetes 64:3554-3563.
Fuentealba LC, Obernier K, Alvarez-Buylla A (2012) Adult neural stem cells bridge their
niche. Cell Stem Cell 10:698-708.
Gadea A, Aguirre A, Haydar TF, Gallo V (2009) Endothelin-1 regulates oligodendrocyte
development. J Neurosci 29:10047-10062.
Gelderblom M, Leypoldt F, Steinbach K, et al. (2009) Temporal and spatial dynamics of
cerebral immune cell accumulation in stroke. Stroke 40:1849-1857.

46

Ginhoux F, Greter M, Leboeuf M, et al. (2010) Fate mapping analysis reveals that adult
microglia derive from primitive macrophages. Science 330:841-845.
Golgi C (1873) On structure of the gray matter of the brain. Gazzetta Medica Italiana
Lombardia.
Gomez Perdiguero E, Klapproth K, Schulz C, et al. (2015) Tissue-resident macrophages
originate from yolk-sac-derived erythro-myeloid progenitors. Nature 518:547-551.
Gordon KJ, Blobe GC (2008) Role of transforming growth factor-beta superfamily
signaling pathways in human disease. Biochim Biophys Acta 1782:197-228.
GrandPré T, Li S, Strittmatter SM (2002) Nogo-66 receptor antagonist peptide promotes
axonal regeneration. Nature 417:547-551.
Gross CE, Bednar MM, Howard DB, Sporn MB (1993) Transforming growth factor-beta
1 reduces infarct size after experimental cerebral ischemia in a rabbit model. Stroke
24:558-562.
Guan Z, Kuhn JA, Wang X, et al. (2016) Injured sensory neuron-derived CSF1 induces
microglial proliferation and DAP12-dependent pain. Nat Neurosci 19:94-101.
Gülke E, Gelderblom M, Magnus T (2018) Danger signals in stroke and their role on
microglia activation after ischemia. Ther Adv Neurol Disord 11:1756286418774254.
Guttenplan KA, Stafford BK, El-Danaf RN, et al. (2020) Neurotoxic Reactive Astrocytes
Drive Neuronal Death after Retinal Injury. Cell Rep 31:107776.
Hama H, Kasuya Y, Sakurai T, et al. (1997) Role of endothelin-1 in astrocyte responses
after acute brain damage. J Neurosci Res 47:590-602.
47

Hammond TR, Gadea A, Dupree J, et al. (2014) Astrocyte-derived endothelin-1 inhibits
remyelination through notch activation. Neuron 81:588-602.
Harada T, Harada C, Kohsaka S, et al. (2002) Microglia-Müller glia cell interactions
control neurotrophic factor production during light-induced retinal degeneration. J
Neurosci 22:9228-9236.
Hatakeyama J, Wakamatsu Y, Nagafuchi A, Kageyama R, Shigemoto R, Shimamura K
(2014) Cadherin-based adhesions in the apical endfoot are required for active Notch
signaling to control neurogenesis in vertebrates. Development 141:1671-1682.
Hegen A, Koidl S, Weindel K, Marmé D, Augustin HG, Fiedler U (2004) Expression of
angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory
promoter elements. Arterioscler Thromb Vasc Biol 24:1803-1809.
Herrmann JE, Imura T, Song B, et al. (2008) STAT3 is a critical regulator of astrogliosis
and scar formation after spinal cord injury. J Neurosci 28:7231-7243.
Hickman SE, Kingery ND, Ohsumi TK, et al. (2013) The microglial sensome revealed by
direct RNA sequencing. Nat Neurosci 16:1896-1905.
Hippenmeyer S, Luo L (2010) Genetic Mosaic Dissection of Lis1 and Ndel1 in neuronal
migration. Neuron 68:695-709.
Hirabayashi Y, Suzki N, Tsuboi M, et al. (2009) Polycomb limits the neurogenic
competence of neural precursor cells to promote astrogenic fate transition. Neuron
63:600-613.

48

Hollander MC, Latour LL, Yang D, et al. (2017) Attenuation of Myeloid-Specific TGFβ
Signaling Induces Inflammatory Cerebrovascular Disease and Stroke. Circ Res 121:13601369.
Ho MC, Lo AC, Kurihara H, Yu AC, Chung SS, Chung SK (2001) Endothelin-1 protects
astrocytes from hypoxic/ischemic injury. FASEB J 15:618-626.
Hong S, Beja-Glasser VF, Nfonoyim BM, et al. (2016) Complement and microglia
mediate early synapse loss in Alzheimer mouse models. Science 352:712-716.
Huang H, Huang Q, Wang F, Milner R, Li L (2016) Cerebral ischemia-induced
angiogenesis is dependent on tumor necrosis factor receptor 1-mediated upregulation of
α5β1 and αVβ3 integrins. J Neuroinflammation 13:227.
Hughes EG, Kang SH, Fukaya M, Bergles DE (2013) Oligodendrocyte progenitors
balance growth with self-repulsion to achieve homeostasis in the adult brain. Nat
Neurosci 16:668-676.
Hu R, Zhou J, Luo C, et al. (2010) Glial scar and neuroregeneration: histological,
functional, and magnetic resonance imaging analysis in chronic spinal cord injury. J
Neurosurg Spine 13:169-180.
Hu XL, Chen G, Zhang S, et al. (2017) Persistent Expression of VCAM1 in Radial Glial
Cells Is Required for the Embryonic Origin of Postnatal Neural Stem Cells. Neuron
95:309-325.e6.
Imamura T, Takase M, Nishihara A, et al. (1997) Smad6 inhibits signalling by the TGFbeta superfamily. Nature 389:622-626.

49

Janssen BJ, Huizinga EG, Raaijmakers HC, et al. (2005) Structures of complement
component C3 provide insights into the function and evolution of immunity. Nature
437:505-511.
Janzadeh A, Sarveazad A, Yousefifard M, et al. (2017) Combine effect of Chondroitinase
ABC and low level laser (660nm) on spinal cord injury model in adult male rats.
Neuropeptides 65:90-99.
Jessen KR, Mirsky R (2019) The Success and Failure of the Schwann Cell Response to
Nerve Injury. Front Cell Neurosci 13:33.
Jiang MH, Höög A, Ma KC, Nie XJ, Olsson Y, Zhang WW (1993) Endothelin-1-like
immunoreactivity is expressed in human reactive astrocytes. Neuroreport 4:935-937.
Jin S, Sonobe Y, Kawanokuchi J, et al. (2014) Interleukin-34 restores blood-brain barrier
integrity by upregulating tight junction proteins in endothelial cells. PLoS One
9:e115981.
Jo WK, Law AC, Chung SK. (2014) The neglected co-star in the dementia drama: the
putative roles of astrocytes in the pathogeneses of major neurocognitive disorders. Mol
Psychiatry 19:159-167.
Kamigaki M, Hide I, Yanase Y, et al. (2016) The Toll-like receptor 4-activated
neuroprotective microglia subpopulation survives via granulocyte macrophage colonystimulating factor and JAK2/STAT5 signaling. Neurochem Int 93:82-94.
Khamaisi M, Toukan H, Axelrod JH, et al. (2015) Endothelin-converting enzyme is a
plausible target gene for hypoxia-inducible factor. Kidney Int 87:761-770.

50

Kierdorf K, Erny D, Goldmann T, et al. (2013) Microglia emerge from erythromyeloid
precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci 16:273-280.
Kigerl KA, de Rivero Vaccari JP, Dietrich WD, Popovich PG, Keane RW (2014) Pattern
recognition receptors and central nervous system repair. Exp Neurol 258:5-16.
Kirschen GW, Shen J, Tian M, et al. (2017) Active Dentate Granule Cells Encode
Experience to Promote the Addition of Adult-Born Hippocampal Neurons. J Neurosci
37:4661-4678.
Kim M, Allen B, Korhonen EA, et al. (2016) Opposing actions of angiopoietin-2 on TIE2
signaling and FOXO1 activation. J Clin Invest 126:3511-3525.
Kokovay E, Wang Y, Kusek G, et al. (2012) VCAM1 is essential to maintain the
structure of the SVZ niche and acts as an environmental sensor to regulate SVZ lineage
progression. Cell Stem Cell 11:220-230.
Koyama Y, Baba A, Matsuda T (2005) Endothelins stimulate the expression of
neurotrophin-3 in rat brain and rat cultured astrocytes. Neuroscience 136:425-433.
Koyama Y, Tsujikawa K, Matsuda T, Baba A (2003) Endothelin-1 stimulates glial cell
line-derived neurotrophic factor expression in cultured rat astrocytes. Biochem Biophys
Res Commun 303:1101-1105.
Koyama Y, Tsujikawa K, Matsuda T, Baba A (2003) Intracerebroventricular
administration of an endothelin ETB receptor agonist increases expressions of GDNF and
BDNF in rat brain. Eur J Neurosci 18:887-894.

51

Lanjakornsiripan D, Pior BJ, Kawaguchi D, et al. (2018) Layer-specific morphological
and molecular differences in neocortical astrocytes and their dependence on neuronal
layers. Nat Commun 9:1623.
Lappe-Siefke C, Goebbels S, Gravel M, et al. (2003) Disruption of Cnp1 uncouples
oligodendroglial functions in axonal support and myelination. Nat Genet 33:366-374.
LeComte MD, Shimada IS, Sherwin C, Spees JL. (2015) Notch1-STAT3-ETBR
signaling axis controls reactive astrocyte proliferation after brain injury. Proc Natl Acad
Sci U S A 112:8726-8731.
Lenhossek MV (1893) Der feinere Bau des Nervensystems im Lichte neuester.
Liddelow SA, Barres BA (2017) Reactive Astrocytes: Production, Function, and
Therapeutic Potential. Immunity 46:957-967.
Liddelow SA, Guttenplan KA, Clarke LE, et al. (2017) Neurotoxic reactive astrocytes are
induced by activated microglia. Nature 541:481-487.
Li C, Hancock MA, Sehgal P, Zhou S, Reinhardt DP, Philip A (2016) Soluble CD109
binds TGF-β and antagonizes TGF-β signaling and responses. Biochem J 473:537-547.
Li JJ, Wu LH, Cao Q, et al. (2010) Endothelins-1/3 and endothelin-A/B receptors
expressing glial cells with special reference to activated microglia in experimentally
induced cerebral ischemia in the adult rats. Neuroscience 167:665-677.
Lin M, Sutherland DR, Horsfall W, et al. (2002) Cell surface antigen CD109 is a novel
member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing
proteins. Blood 99:1683-1691.
52

Lipton P, Whittingham TS (1979) The effect of hypoxia on evoked potentials in the in
vitro hippocampus. J Physiol 287:427-438.
Litvinov IV, Bizet AA, Binamer Y, Jones DA, Sasseville D, Philip A (2011) CD109
release from the cell surface in human keratinocytes regulates TGF-β receptor expression,
TGF-β signalling and STAT3 activation: relevance to psoriasis. Exp Dermatol 20:627632.
Lochhead JJ, McCaffrey G, Quigley CE, et al. (2010) Oxidative stress increases bloodbrain barrier permeability and induces alterations in occludin during hypoxiareoxygenation. J Cereb Blood Flow Metab 30:1625-1636.
Lucas GA, White LR, Juul R, Cappelen J, Aasly J, Edvinsson L (1996) Relaxation of
human temporal artery by endothelin ETB receptors. Peptides 17:1139-1144.
Lu YM, Tao RR, Huang JY, et al. (2012) P2X7 signaling promotes microsphere
embolism-triggered microglia activation by maintaining elevation of Fas ligand. J
Neuroinflammation 9:172.
Mangla R, Kolar B, Almast J, Ekholm SE (2011) Border zone infarcts: pathophysiologic
and imaging characteristics. Radiographics 31:1201-1214.
Marcaggi P, Billups D, Attwell D (2003) The role of glial glutamate transporters in
maintaining the independent operation of juvenile mouse cerebellar parallel fibre
synapses. J Physiol 552:89-107.
Massagué J (2012) TGFβ signalling in context. Nat Rev Mol Cell Biol 13:616-630.

53

Marteau L, Valable S, Divoux D, et al. (2013) Angiopoietin-2 is vasoprotective in the
acute phase of cerebral ischemia. J Cereb Blood Flow Metab 33:389-395.
Maisonpierre PC, Suri C, Jones PF, et al. (1997) Angiopoietin-2, a natural antagonist for
TIE2 that disrupts in vivo angiogenesis. Science 277:55-60.
McCaffrey G, Willis CL, Staatz WD, et al. (2009) Occludin oligomeric assemblies at
tight junctions of the blood-brain barrier are altered by hypoxia and reoxygenation stress.
J Neurochem 110:58-71.
McKenzie IA, Ohayon D, Li H, et al. (2014) Motor skill learning requires active central
myelination. Science 346:318-322.
McNeill H, Williams C, Guan J, et al. (1994) Neuronal rescue with transforming growth
factor-beta 1 after hypoxic-ischaemic brain injury. Neuroreport 5:901-904.
McTigue DM, Wei P, Stokes BT. (2001) Proliferation of NG2-positive cells and altered
oligodendrocyte numbers in the contused rat spinal cord. J Neurosci 21:3392-3400.
Meng X, Yang F, Ouyang T, Liu B, Wu C, Jiang W (2015) Specific gene expression in
mouse cortical astrocytes is mediated by a 1740bp-GFAP promoter-driven combined
adeno-associated virus 2/5/7/8/9. Neurosci Lett 593:45-50.
Merkle FT, Fuentealba LC, Sanders TA, Magno L, Kessaris N, Alvarez-Buylla A (2014)
Adult neural stem cells in distinct microdomains generate previously unknown
interneuron types. Nat Neurosci 17:207-214.

54

Merlen C, Farhat N, Luo X, et al. (2013) Intracrine endothelin signaling evokes IP3dependent increases in nucleoplasmic Ca²⁺ in adult cardiac myocytes. J Mol Cell Cardiol
62:189-202.
Miller SJ, Philips T, Kim N, et al. (2019) Molecularly defined cortical astroglia
subpopulation modulates neurons via secretion of Norrin. Nat Neurosci 22(5):741-752.
Minata M, Audia A, Shi J, et al. (2019) Phenotypic Plasticity of Invasive Edge Glioma
Stem-like Cells in Response to Ionizing Radiation. Cell Rep 26:1893-1905.e7.
Mizuno T, Doi Y, Mizoguchi H, et al. (2011) Interleukin-34 selectively enhances the
neuroprotective effects of microglia to attenuate oligomeric amyloid-β neurotoxicity. Am
J Pathol 179:2016-2027.
Mokin M, Ansari SA, McTaggart RA, et al. (2019) Indications for thrombectomy in
acute ischemic stroke from emergent large vessel occlusion (ELVO): report of the SNIS
Standards and Guidelines Committee. J Neurointerv Surg 11:215-220.
Monier A, Adle-Biassette H, Delezoide AL, Evrard P, Gressens P, Verney C (2007)
Entry and distribution of microglial cells in human embryonic and fetal cerebral cortex. J
Neuropathol Exp Neurol 66:372-382.
Monif M, Reid CA, Powell KL, Smart ML, Williams DA (2009) The P2X7 receptor
drives microglial activation and proliferation: a trophic role for P2X7R pore. J Neurosci
29:3781-3791.

55

Monnier PP, Sierra A, Schwab JM, Henke-Fahle S, Mueller BK (2003) The Rho/ROCK
pathway mediates neurite growth-inhibitory activity associated with the chondroitin
sulfate proteoglycans of the CNS glial scar. Mol Cell Neurosci 22:319-330.
Nakao A, Afrakhte M, Morén A, et al. (1997) Identification of Smad7, a TGFbetainducible antagonist of TGF-beta signalling. Nature 389:631-635.
Nandi S, Cioce M, Yeung YG, et al. (2013) Receptor-type protein-tyrosine phosphatase ζ
is a functional receptor for interleukin-34. J Biol Chem 288:21972-21986.
Nih LR, Gojgini S, Carmichael ST, Segura T. (2018) Dual-function injectable angiogenic
biomaterial for the repair of brain tissue following stroke. Nat Mater 17:642-651.
Nolte C, Matyash M, Pivneva T, et al. (2001) GFAP promoter-controlled EGFPexpressing transgenic mice: a tool to visualize astrocytes and astrogliosis in living brain
tissue. Glia 33:72-86.
Oberheim NA, Takano T, Han X, et al. (2009) Uniquely hominid features of adult human
astrocytes. J Neurosci 29:3276-3287.
O'Rourke KE, Walsh CD, Kelly PJ. (2009) Safety and efficacy of IV-TPA for ischaemic
stroke in clinical practice--a Bayesian analysis. Cerebrovasc Dis 28:572-581.
Ozaka T, Doi Y, Kayashima K, Fujimoto S (1997) Weibel-Palade bodies as a storage site
of calcitonin gene-related peptide and endothelin-1 in blood vessels of the rat carotid
body. Anat Rec 247:388-394.

56

Pang L, Ye W, Che XM, Roessler BJ, Betz AL, Yang GY (2001) Reduction of
inflammatory response in the mouse brain with adenoviral-mediated transforming growth
factor-ss1 expression. Stroke 32:544-552.
Patel AS, Smith A, Nucera S, et al. (2013) TIE2-expressing monocytes/macrophages
regulate revascularization of the ischemic limb. EMBO Mol Med 5:858-869.
Pauly D, Agarwal D, Dana N, et al. (2019) Cell-Type-Specific Complement Expression
in the Healthy and Diseased Retina. Cell Rep 29:2835-2848.e4.
Perry JJ, Sharma M, Sivilotti ML, et al. (2011) Prospective validation of the ABCD2
score for patients in the emergency department with transient ischemic attack. CMAJ
183:1137-1145.
Pinsky DJ, Naka Y, Liao H, et al. (1996) Hypoxia-induced exocytosis of endothelial cell
Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac
preservation. J Clin Invest 97:493-500.
Qin Y, Garrison BS, Ma W, et al. (2018) A Milieu Molecule for TGF-β Required for
Microglia Function in the Nervous System. Cell 174:156-171.e16.
Raff MC, Lillien LE, Richardson WD, Burne JF, Noble MD (1988) Platelet-derived
growth factor from astrocytes drives the clock that times oligodendrocyte development in
culture. Nature 333:562-565.
Regard JB, Sato IT, Coughlin SR (2008) Anatomical profiling of G protein-coupled
receptor expression. Cell 135:561-571.

57

Reichenbach N, Delekate A, Plescher M, et al. (2019) Inhibition of Stat3-mediated
astrogliosis ameliorates pathology in an Alzheimer's disease model. EMBO Mol Med
11:e9665.
Reijerkerk A, Lakeman KA, Drexhage JA, et al. (2012) Brain endothelial barrier passage
by monocytes is controlled by the endothelin system. J Neurochem 121:730-737.
Reynolds BA, Weiss S (1992) Generation of neurons and astrocytes from isolated cells of
the adult mammalian central nervous system. Science 255:1707-1710.
Rhodes KE, Raivich G, Fawcett JW (2006) The injury response of oligodendrocyte
precursor cells is induced by platelets, macrophages and inflammation-associated
cytokines. Neuroscience 140:87-100.
Richardson MR, Robbins EP, Vemula S, et al. (2014) Angiopoietin-like protein 2
regulates endothelial colony forming cell vasculogenesis. Angiogenesis 17:675-683.
Richardson PM, McGuinness UM, Aguayo AJ (1980) Axons from CNS neurons
regenerate into PNS grafts. Nature 284:264-265.
Rocha SM, Cristovão AC, Campos FL, Fonseca CP, Baltazar G (2012) Astrocyte-derived
GDNF is a potent inhibitor of microglial activation. Neurobiol Dis 47:407-415.
Rogers SD, Demaster E, Catton M, et al. (1997) Expression of endothelin-B receptors by
glia in vivo is increased after CNS injury in rats, rabbits, and humans. Exp Neurol
145:180-195.

58

Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J (2006) Dynamics and
plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol
26:1002-1007.
Rosenzweig ES, Salegio EA, Liang JJ, et al. (2019) Chondroitinase improves anatomical
and functional outcomes after primate spinal cord injury. Nat Neurosci 22:1269-1275.
Roubert P, Gillard V, Plas P, Auguet M, Chabrier PE, Braquet P. (1991) Multiplicité des
récepteurs de l'endothéline sur les cellules musculaires lisses d'aorte de rat en culture.
Arch Mal Coeur Vaiss 84:1057-1059.
Russell FD, Skepper JN, Davenport AP (1998) Evidence using immunoelectron
microscopy for regulated and constitutive pathways in the transport and release of
endothelin. J Cardiovasc Pharmacol 31:424-430.
Rust R, Weber RZ, Grönnert L, et al. (2019) Anti-Nogo-A antibodies prevent vascular
leakage and act as pro-angiogenic factors following stroke. Sci Rep 9:20040.
Salzer JL (2015) Schwann cell myelination. Cold Spring Harb Perspect Biol 7:a020529.
Santos MS, Moreno AJ, Carvalho AP (1996) Relationships between ATP depletion,
membrane potential, and the release of neurotransmitters in rat nerve terminals. An in
vitro study under conditions that mimic anoxia, hypoglycemia, and ischemia. Stroke
27:941-950.
Savant S, La Porta S, Budnik A, et al. (2015) The Orphan Receptor TIE1 Controls
Angiogenesis and Vascular Remodeling by Differentially Regulating TIE2 in Tip and
Stalk Cells. Cell Rep 12:1761-1773.

59

Schachtrup C, Ryu JK, Helmrick MJ, et al. (2010) Fibrinogen triggers astrocyte scar
formation by promoting the availability of active TGF-beta after vascular damage. J
Neurosci 30:5843-5854.
Seegar TC, Eller B, Tzvetkova-Robev D, et al. (2010) Tie1-Tie2 interactions mediate
functional differences between angiopoietin ligands. Mol Cell 37:643-655.
Shalaby F, Rossant J, Yamaguchi TP, et al. (1995) Failure of blood-island formation and
vasculogenesis in Flk-1-deficient mice. Nature 376:62-66.
Shiraki Y, Mii S, Enomoto A, et al. (2017) Significance of perivascular tumour cells
defined by CD109 expression in progression of glioma. J Pathol 243:468-480.
Shen Q, Zhong W, Jan YN, Temple S (2002) Asymmetric Numb distribution is critical
for asymmetric cell division of mouse cerebral cortical stem cells and neuroblasts.
Development 129:4843-4853.
Schneider MP, Boesen EI, Pollock DM (2007) Contrasting actions of endothelin ET(A)
and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 47:731-759.
Shimada IS, LeComte MD, Granger JC, Quinlan NJ, Spees JL (2012) Self-renewal and
differentiation of reactive astrocyte-derived neural stem/progenitor cells isolated from the
cortical peri-infarct area after stroke. J Neurosci 32:7926-7940.
Shi Q, Chowdhury S, Ma R, et al. (2017) Complement C3 deficiency protects against
neurodegeneration in aged plaque-rich APP/PS1 mice. Sci Transl Med 9:eaaf6295.
Simard M, Arcuino G, Takano T, Liu QS, Nedergaard M (2003) Signaling at the
gliovascular interface. J Neurosci 23:9254-9262.
60

Simons M, Trajkovic K (2006) Neuron-glia communication in the control of
oligodendrocyte function and myelin biogenesis. J Cell Sci 119:4381-4389.
Sirko S, Behrendt G, Johansson PA, et al. (2013) Reactive glia in the injured brain
acquire stem cell properties in response to sonic hedgehog. Cell Stem Cell 12:426-439.
Snow DM, Smith JD, Gurwell JA (2002) Binding characteristics of chondroitin sulfate
proteoglycans and laminin-1, and correlative neurite outgrowth behaviors in a standard
tissue culture choice assay. J Neurobiol 51:285-301.
Song G, Feng T, Zhao R, et al. (2019) CD109 regulates the inflammatory response and is
required for the pathogenesis of rheumatoid arthritis. Ann Rheum Dis 78:1632-1641.
Soriano SG, Coxon A, Wang YF, et al. (1999) Mice deficient in Mac-1 (CD11b/CD18)
are less susceptible to cerebral ischemia/reperfusion injury. Stroke 30:134-139.
Spalding KL, Bergmann O, Alkass K, et al. (2013) Dynamics of hippocampal
neurogenesis in adult humans. Cell 153:1219-1227.
Stephany CÉ, Chan LL, Parivash SN, et al. (2014) Plasticity of binocularity and visual
acuity are differentially limited by nogo receptor. J Neurosci 34:11631-11640.
Stoll G, Schroeter M, Jander S, et al. (2004) Lesion-associated expression of
transforming growth factor-beta-2 in the rat nervous system: evidence for downregulating the phagocytic activity of microglia and macrophages. Brain Pathol 14:51-58.
Suzuki Y, Nagai N, Yamakawa K, Muranaka Y, Hokamura K, Umemura K (2015)
Recombinant tissue-type plasminogen activator transiently enhances blood-brain barrier

61

permeability during cerebral ischemia through vascular endothelial growth factormediated endothelial endocytosis in mice. J Cereb Blood Flow Metab 35:2021-2031.
Suzuki Y, Yasui H, Brzoska T, Mogami H, Urano T (2011) Surface-retained tPA is
essential for effective fibrinolysis on vascular endothelial cells. Blood 118:3182-3185.
Takatsuru Y, Eto K, Kaneko R, et al. (2013) Critical role of the astrocyte for functional
remodeling in contralateral hemisphere of somatosensory cortex after stroke. J Neurosci
33:4683-4692.
Toyomoto M, Inoue S, Ohta K, et al. (2005) Production of NGF, BDNF and GDNF in
mouse astrocyte cultures is strongly enhanced by a cerebral vasodilator, ifenprodil.
Neurosci Lett 379:185-189.
Tsang MC, Lo AC, Cheung PT, Chung SS, Chung SK. (2001) Perinatal hypoxia/ischemia-induced endothelin-1 mRNA in astrocyte-like and endothelial cells.
Neuroreport 12:2265-2270.
Turner DL, Cepko CL (1987) A common progenitor for neurons and glia persists in rat
retina late in development. Nature 328:131-136.
Vecino E, Rodriguez FD, Ruzafa N, Pereiro X, Sharma SC (2016) Glia-neuron
interactions in the mammalian retina. Prog Retin Eye Res 51:1-40.
Veldhoen M, Hirota K, Christensen J, O'Garra A, Stockinger B. (2009) Natural agonists
for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation
of Th17 T cells. J Exp Med 206:43-49.

62

Ventura R, Harris KM (1999) Three-dimensional relationships between hippocampal
synapses and astrocytes. J Neurosci 19:6897-6906.
Verhaar MC, Strachan FE, Newby DE, et al. (1998) Endothelin-A receptor antagonistmediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by
endothelin-B receptor blockade. Circulation 97:752-756.
Virchow R (1858) Cellular pathology. As based upon physiological and pathological
histology. Lecture XVI--Atheromatous affection of arteries. Nutr Rev 47:23-25.
Vorstenbosch J, Nguyen CM, Zhou S, et al. (2017) Overexpression of CD109 in the
Epidermis Differentially Regulates ALK1 Versus ALK5 Signaling and Modulates
Extracellular Matrix Synthesis in the Skin. J Invest Dermatol 137:641-649.
Vue TY, Kim EJ, Parras CM, Guillemot F, Johnson JE (2014) Ascl1 controls the number
and distribution of astrocytes and oligodendrocytes in the gray matter and white matter of
the spinal cord. Development 141:3721-3731.
Wanner IB, Anderson MA, Song B, et al. (2013) Glial scar borders are formed by newly
proliferated, elongated astrocytes that interact to corral inflammatory and fibrotic cells
via STAT3-dependent mechanisms after spinal cord injury. J Neurosci 33:12870-12886.
Wang CC, Ying L, Barnes EA, et al. (2018) Pulmonary artery smooth muscle cell HIF-1α
regulates endothelin expression via microRNA-543. Am J Physiol Lung Cell Mol Physiol
315:L422-L431.
Wang DD, Bordey A (2008) The astrocyte odyssey. Prog Neurobiol 86:342-367.

63

Wang H, Song G, Chuang H, et al. (2018) Portrait of glial scar in neurological diseases.
Int J Immunopathol Pharmacol 31:2058738418801406.
Wilhelmsson U, Bushong EA, Price DL, et al. (2006) Redefining the concept of reactive
astrocytes as cells that remain within their unique domains upon reaction to injury. Proc
Natl Acad Sci U S A 103:17513-17518.
Wilhelmsson U, Faiz M, de Pablo Y, et al. (2012) Astrocytes negatively regulate
neurogenesis through the Jagged1-mediated Notch pathway. Stem Cells 30:2320-2329.
Wilhelmsson U, Li L, Pekna M, et al. (2004) Absence of glial fibrillary acidic protein and
vimentin prevents hypertrophy of astrocytic processes and improves post-traumatic
regeneration. J Neurosci 24:5016-5021.
Wilkins A, Majed H, Layfield R, Compston A, Chandran S (2003) Oligodendrocytes
promote neuronal survival and axonal length by distinct intracellular mechanisms: a
novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor. J
Neurosci 23:4967-4974.
Wimmer I, Tietz S, Nishihara H, et al. (2019) PECAM-1 Stabilizes Blood-Brain Barrier
Integrity and Favors Paracellular T-Cell Diapedesis Across the Blood-Brain Barrier
During Neuroinflammation. Front Immunol 10:711.
Witt KA, Mark KS, Hom S, Davis TP (2003) Effects of hypoxia-reoxygenation on rat
blood-brain barrier permeability and tight junctional protein expression. Am J Physiol
Heart Circ Physiol 285:H2820-H2831.

64

Wu CY, Kaur C, Lu J, et al. (2006) Transient expression of endothelins in the amoeboid
microglial cells in the developing rat brain. Glia 54:513-525.
Yaghi S, Willey JZ, Cucchiara B, et al. (2017) Treatment and Outcome of Hemorrhagic
Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific
Statement for Healthcare Professionals From the American Heart Association/American
Stroke Association. Stroke 48:e343-e361.
Yang GY, Chen SF, Kinouchi H, Chan PH, Weinstein PR (1992) Edema, cation content,
and ATPase activity after middle cerebral artery occlusion in rats. Stroke 23:1331-1336.
Yiu G, He Z (2006) Glial inhibition of CNS axon regeneration. Nat Rev Neurosci. 7:617627.
Yuan HT, Venkatesha S, Chan B, et al. (2007) Activation of the orphan endothelial
receptor TIE1 modifies TIE2-mediated intracellular signaling and cell survival. FASEB J
21:3171-3183.
Yun SP, Kam TI, Panicker N, et al. (2018) Block of A1 astrocyte conversion by
microglia is neuroprotective in models of Parkinson's disease. Nat Med 24:931-938.
Zamanian JL, Xu L, Foo LC, et al. (2012) Genomic analysis of reactive astrogliosis. J
Neurosci 32:6391-6410.
Zhang JM, Murakumo Y, Hagiwara S, et al. (2015) CD109 attenuates TGF-β1 signaling
and enhances EGF signaling in SK-MG-1 human glioblastoma cells. Biochem Biophys
Res Commun 459:252-258.

65

Zhang R, Wu Y, Xie F, et al. (2018) RGMa mediates reactive astrogliosis and glial scar
formation through TGFβ1/Smad2/3 signaling after stroke. Cell Death Differ 25:15031516.
Zhang WW, Badonic T, Höög A, et al. (1994) Astrocytes in Alzheimer's disease express
immunoreactivity to the vaso-constrictor endothelin-1. J Neurol Sci 122:90-96.
Zhang YE (2009) Non-Smad pathways in TGF-beta signaling. Cell Res 19:128-139.
Zhuo JM, Tseng HA, Desai M, et al. (2016) Young adult born neurons enhance
hippocampal dependent performance via influences on bilateral networks. Elife 5:e22429.
Zhu Y, Lee C, Shen F, Du R, Young WL, Yang GY (2005) Angiopoietin-2 facilitates
vascular endothelial growth factor-induced angiogenesis in the mature mouse brain.
Stroke 36:1533-1537.
Zöller T, Schneider A, Kleimeyer C, et al. (2018) Silencing of TGFβ signalling in
microglia results in impaired homeostasis. Nat Commun 9:4011.

66

CHAPTER 2: ETBR signaling promotes angiopoetin-2 production by reactive
astrocytes and regulates neuroinflammation after ischemic stroke.
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ABSTRACT
Reciprocal communication between reactive astrocytes and microglial cells provides
local, coordinated control over critical processes such as neuroinflammation,
neuroprotection, and scar formation after CNS injury, but is poorly understood. The
vasoactive peptide hormone endothelin (ET) is released and/or secreted by endothelial
cells, microglial cells and astrocytes early after ischemic stroke and other forms of brain
injury. Using a genetic loss-of-function screen to identify paracrine effectors regulated by
astroglial endothelin receptor B (ETBR) signaling, we identified angiopoetin-2 (Ang-2) as
a factor produced by reactive astrocytes in response to ET. In experiments with primary
adult astrocytes stimulated by IRL1620, a specific ETBR agonist, we found ERK1/2 and
NFB mediated the effects of ET on Ang-2 production. To determine astroglial Ang-2
levels in vivo, reactive astrocytes expressing the high affinity glutamate transporter
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(GLAST, EEAT1) were isolated by magnetic-activated cell sorting 3 days after stroke.
Astrocytes obtained from the ipsilateral hemisphere expressed significantly more Ang-2
compared with astrocytes isolated from the contralateral hemisphere, or from cortices of
sham-operated (control) mice. Notably, analysis of microglia sorted from CX3CR1-eGFP
mice demonstrated increased cell surface expression of Tie-2, the Ang-2 receptor, on
microglial cells from ipsilateral tissue. Targeted loss of ETBR in reactive astrocytes from
GFAP-CreERTM-EDNRB-fl/fl mice significantly decreased the number of proliferating
microglial cells in the peri-infarct area. By contrast, Notch1-cKO in reactive astrocytes
did not decrease microglial proliferation after stroke. Our data indicate paracrine
effectors, such as Ang-2, acting downstream of astroglial ETBR signaling, regulate
microglial cell dynamics and neuroinflammation after stroke and perhaps other forms of
CNS injury.
INTRODUCTION
To regulate blood brain barrier (BBB) integrity, neuroinflammation, and neuroprotection
during CNS injury, microglial cells and reactive astrocytes engage in a complex array of
autocrine, juxtacrine, and paracrine signaling (reviewed by Sofroniew, 2015). Resting
microglia are highly dynamic cells, constantly sampling the extracellular space with their
processes and responding within minutes to BBB disruption (Nimmerjahn et al., 2005).
In ischemic stroke, sentinel microglial cells sense damage signals produced by occluded
blood vessels (e.g. reactive oxygen species, thrombin, complement, ECM components)
(Chamak and Mallat, 1991; Milner and Campbell, 2003; Moller et al., 2000; Roy et al.,
2008; Schafer et al., 2012; Suo et al., 2002; Wang et al., 2006; Webster et al., 2000) and
released from necrotic neurons (e.g. ATP, HMGB1, peroxiredoxins) (Davalos et al.,
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2005; Gulke et al., 2018; Kim et al., 2006; Kim et al., 2007; Lu et al., 2012; Lu et al.,
2018; Monif et al., 2009; Muhammad et al., 2008). These Damage Associated Molecular
Patterns (DAMPS) alter microglial cell phenotype and initiate reciprocal signaling
between nearby microglia and astrocytes. Delineating glial signaling mechanisms during
different phases of injury progression and resolution has exciting potential to help
identify new treatment targets for CNS injuries such as stroke. Notably, however, glial
cell communication and its functional effects in most forms of CNS injury remain poorly
understood.
During cerebral ischemia, vascular endothelial cells as well as astrocytes and
microglia release and secrete endothelins (ET1-3), which are potent vasoactive peptides
that constrict blood vessels by signaling through two G-protein-coupled endothelin
receptors: type A and B (ETAR and ETBR) (reviewed by Davenport et al, 2016). ET
signaling in the developing CNS affects the survival, proliferation and migration of a
variety of cell types that include neural crest derivatives, neuroblasts, and melanocyte
precursors (Lee et al., 2003; Nataf et al., 1996; Shin et al., 1999). In adults, in addition to
controlling vascular tone, ETs regulate critical processes during tissue remodeling and
repair such as inflammation, fibrosis, and angiogenesis (Bagnato and Spinella, 2003;
Clozel and Salloukh, 2005; Leask, 2010; Li et al., 2010; MacCumber et al., 1990; Siren et
al., 2000; Salani et al., 2000). Astroglial proliferation is significantly greater after stroke,
penetrating traumatic brain injury, and spinal cord injury than in
neuroinflammatory/neurodegenerative diseases such as Multiple Sclerosis, Alzheimer’s
Disease, or Parkinson’s Disease (Gadea et al, 2009; Herrmann et al., 2008; Kamphuis et
al., 2012; LeComte et al., 2015; Lepore et al., 2008; Shimada et al., 2011 Simon et al.,
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2011; Sirko et al., 2013; Wanner et al., 2013). Results from our laboratory and others
have shown that astroglial ETBR signaling is an important regulator of reactive astrocyte
proliferation (Gadea et al., 2008; Lecomte et al., 2015).
Of interest, glial cell phenotype(s) and function(s) differ between types of injury
and appear to correlate with changes in astroglial proliferation. For example, in a
lipopolysaccharide (LPS)-based model of neuroinflammation where little astrocyte
proliferation is observed, microglia secrete TNF, IL1, and C1q that induce an
astroglial state that is toxic to neurons (Liddelow et al., 2017). Although the production
of many inflammatory factors such as lipocalin-2 is shared between several injury
systems, it appears that reactive glia assume a more protective phenotype after stroke.
The neuroprotective phenotype is associated with secretion of factors such as BDNF,
GDNF, and IGF-1, that increase the survival of jeopardized neurons (Chen et al., 2019;
Cunningham and Su, 2002; Koyama et al., 2003; Madathil et al., 2013; Rocha et al.,
2012; Saha et al., 2006). Given that proliferating reactive astrocytes require ETBR, we
sought to better understand ETBR function(s) in terms of regulation of paracrine activity
after brain injury.
To identify astroglial paracrine activity controlled by ETBR signaling, we
performed microarray assays to determine changes in gene expression for adult astrocyte
paracrine factors following EDNRB-cKO. Our screen identified multiple genes for
secreted factors involved in neuroinflammation, neuroprotection, blood brain barrier
regulation, and angiogenesis, including angiopoietin-2 (Ang-2). We show that ischemic
stroke causes astrocytes to release Ang-2 and microglia to increase expression of the
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Ang-2 receptor Tie-2. Importantly, we show that Tie-2 signaling alters the microglial
inflammatory state and may serve as a marker of microglial activation.
RESULTS
Loss of ETBR signaling in adult astrocytes impacts gene expression linked to cell-cell
communication and paracrine response(s) to injury.
To identify paracrine activity downstream of ETBR signaling in reactive astrocytes, we
performed a loss-of-function gene expression screen using clonal lines of Reactive
astrocyte-derived Neural Stem Cells (Rad-NSCs). To obtain cell lines capable of
inducible, conditional EDNRB KO (LeComte et al., 2015; Rattner et al., 2013), RadNSCs were isolated from hGFAP-CreERTM:EDNRBflox/flox mice at 3 d after distal Middle
Cerebral Artery Occlusion (dMCAO) surgery to induce stroke. For Affymetrix cDNA
microarray assays, two Rad-NSC clones from different mice were expanded in culture
and differentiated into astrocytes by incubation in serum-containing medium for 7 days.
For EDNRB-cKO, cultured astrocytes were exposed to 4-hydroxytamoxifen (4-OH-TM)
for 10 days. Successful gene knockout in hGFAP-CreERTM-EDNRB-cKO astrocytes was
confirmed by a 103.18-fold decrease in EDNRB expression in cells treated with 4-OHTM compared with vehicle-treated (control) cells (Figure 2.1). Furthermore, by western
blot assays, we demonstrated reduced ETBR levels in both clones after 4-OH-TM
treatment relative to vehicle-treated controls (Data not shown). In agreement with our
prior work on astroglial ETBR signaling, Go-enrichment analysis revealed significant
changes in genes related to cellular proliferation after EDNRB knockout (P = 1.92x10-5)
(Figure 2.1).
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The top 15 cell-cell signaling related genes that increased or decreased after
astroglial EDNRB-cKO are listed in the heatmap in Figure 2.1D. Notably, many genes we
identified were reported to regulate immune cells (Glycam1, Lipocalin-2, Sucnr1),
inflammation (Ptger3, Tgfbr3, CD109, C1s1, Pla2g4a, Metrnl), angiogenesis and BBB
integrity (Anpt2, Renbp, Alcam). In addition, several cell signaling-related genes with
expression changes outside the top 15 have functions in inflammatory and/or angiogenic
cell signaling pathways (C1ra, CD59a, Tgfb3, Vegfa) (CD59a: Inafuku et al., 2018;
Harhausen et al., 2017; Meri et al., 1990; C1ra: Bialas and Stevens, 2013; Gaboriaud et
al., 2014; TGF3: Bialas and Stevens, 2013; Vegfa: Nih et al., 2018; Hiratsuka et al.,
2005; Kaya et al., 2006). For example, Angpt2 is an important regulator of vascular
permeability and angiogenesis (Benest et al., 2013; Gurnik et al., 2016; Parikh et al.,
2006), but was also shown to promote the migration of peripheral macrophages (i.e.
outside the CNS) (Chen et al., 2016; Forget et al., 2014). Among paracrine effectors,
angiopoietin-2 mRNA levels decreased the most in adult astrocytes after EDNRB loss (11.53-fold, P = 0.01) (Figure 2.1), prompting us to investigate the expression and
function(s) of astroglial-derived Ang-2 in vivo after cerebral ischemia.
Astrocyte Ang-2 expression increases in vivo after stroke.
To determine astrocyte-specific Ang-2 levels in vivo, we isolated GLAST+ cells from the
cerebral cortex by Magnetic Activated Cell Sorting (MACS). Astrocytes obtained by
GLAST-MACS were counted by hemocytometer and cell lysate Ang-2 levels were
determined by ELISA. Adult astrocytes sorted from the cortices of uninjured animals had
low to undetectable levels of Ang-2 (Figure 2.2C). In contrast, in mice with stroke we
observed a significant increase in astroglial Ang-2 expression 3 days after dMCAO
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surgery (Uninjured mice, 1.89 ± 0.68 pg/ml, n = 3; Stroke mice, 10.36 ± 1.91 pg/ml, n =
5; P < 0.05; Figure 2.2C). In addition, reactive astrocytes sorted from the ipsilateral
hemisphere after stroke had significantly more Ang-2 relative to astrocytes isolated from
the contralateral hemisphere (Contra, 5.61 ± 1.88 pg/ml, n = 5; Ipsilateral, 15.10 ± 2.98
pg/ml, n = 5; P ≤ 0.05; Figure 2.2D).
Endothelin signaling through ETBR promotes secretion of Ang-2 by astrocytes.
Adult cortical astrocytes predominantly express ETBR compared to ETAR but are capable
of ETAR-mediated signaling (Guo et al., 2014; Hammond et al., 2015; John Lin et al.,
2017; Zhang et al., 2014). To determine the relative contribution(s) of ETAR and ETBR
over control of astroglial Ang-2 secretion, cultures of Rad-NSC derived astrocytes were
treated with endothelin (ET-1, 100 nM) in the presence or absence of selective inhibitors
for ETAR (BQ123) and ETBR (BQ788). Under serum-free conditions, ET-1 treatment
alone significantly increased Ang-2 secretion (Vehicle, 59.14 ± 6.74 pg/ml; ET-1 78.51 ±
5.73 pg/ml; n = 3; P ≤ 0.05; Figure 2.3A; ANOVA). Selective inhibition of ETAR during
ET-1 stimulation had no significant impact on Ang-2 secretion relative to ET-1 treatment
(P = 0.43), but inhibition of ETBR reduced Ang-2 levels to baseline (Vehicle vs ET-1 +
ETBR inhibition, P = 0.81; ET-1 vs ET-1 + ETBR inhibition, P < 0.05; Fig. 2.3A). This
result was consistent with reported low levels of ETAR in astrocytes and the differing
roles of ETAR and ETBR signaling (Hammond et al., 2015; Lange et al., 2007; Zhang et
al., 2014; Zhang et al., 2016; John Lin et al., 2017). ETBR is a G-protein coupled receptor
known to signal through Gq coupling, but also is promiscuous in its G-coupling and
downstream signaling (Takagi et al., 1995; Urtatiz et al., 2016). In various cell types,
ETBR has been reported to signal through various downstream transcriptional effectors
74

including HIF, ERK, and NFB (Cramer et al., 2001; Hung et al., 2014; Spinella et al.,
2014; Heimlich et al., 2015; Grimshaw et al., 2002). We therefore pretreated astrocytes
with inhibitors to these pathways for 1 hour prior to ET-1 treatment. Pretreatment with
inhibitors to NFB and MEK/ERK each significantly decreased angiopoietin-2 secretion
relative to ET-1 treatment alone (ET-1 + NFB inhibitor at 0.33-fold of ET-1, P < 0.05;
ET-1 + MEK/ERK inhibition at 0.18-fold of ET-1, P < 0.01; n = 3; Fig. 2.3C). TGF1
signaling is known to block aspects of astrocyte reactivity and reset astrocytes to a
“resting” state (Liddelow et al., 2017; Diniz et al., 2017). As expected, treatment with
TGF1 (1 ng/ml) also significantly decreased Ang-2 secretion (Vehicle 57.84 ± 2.73
pg/ml, TGF1 19.78 ± 7.22 pg/ml; P < 0.01, Fig. 2.3D).
Astrocyte-specific ETBR knockout does not alter microglial CD68 expression.
Changes in microglial proliferation suggested that other aspects of microglial cell
reactivity might be altered by astroglial loss of EDNRB. CD68 expression positively
correlates with phagocytic and pro-inflammatory microglial functions (Nicoll et al., 2003
and 2005; Song et al., 2011; Barois et al., 2002; Yeo et al., 2019). Therefore, we
performed immunohistochemistry for GFAP, Iba1, and CD68. We assessed CD68
staining outside and inside the infarct area as demarcated by the presence of GFAP+
astrocytes. Iba1+ cell expression of CD68 increased markedly inside of the infarct area,
whereas CD68 expression was lower in tissue outside the infarct zone; this tissue
contained GFAP+ astrocytes. We found that CD68 expression decreased with increasing
distance from the infarct, however, microglial CD68 expression did not differ between
control and EDNRB-cKO mice (Supplemental Fig. 2.3).
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Adult microglia upregulate the Tie-2 receptor after stroke.
Ang-1 and Ang-2 both bind the Tie-2 receptor, and often in an antagonistic fashion (Kim
et al., 2016; Yuan et al., 2009). Whereas Tie-2 expression by microglial cells was
documented early during their development from the fetal yolk sac (Ginhoux et al., 2010;
Gomez et al., 2015; Kierdorf et al., 2013), expression by microglia in the adult brain was
unreported. To determine whether adult cortical microglia express Tie-2, and whether or
not its expression changed in the context of stroke injury, we employed a combination of
MACS and FACS. We first enriched for microglia/macrophages by CD11b MACS from
Cx3cr1-GFP mice 3 days post-stroke. We then used FACS to determine the Tie-2
expression profile of microglia after stroke. Also, cells were incubated with an antibody
to TMEM-119 to specifically mark microglial cells and then Tie-2 antibody to detect the
level of cell surface Tie-2. Of interest, we detected two separate cell populations, which
expressed differing levels of GFP (i.e. Cx3cr1) (Fig. 2.4A). Notably, the Cx3cr1Hi
population corresponded to the TMEM-119+ microglial cells (Fig. 2.4B). After stroke,
cell surface Tie-2 expression was increased on TMEM-119+ cells ipsilateral to the infarct
zone relative to TMEM-119+ cells from the contralateral hemisphere (Figures 2.4C and
2.4D); this indicated that Tie-2 might be a marker of microglial activation after CNS
injury. In agreement with this concept, at 3 days after dMCAO surgery, double
immunohistochemical stains for Tie-2 and TMEM-119 demonstrated the strongest
staining for cells residing in close proximity to the stroke infarct (Fig. 2.4E).
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Ang-2 increases alters microglial inflammatory activity.
After stroke and other forms of brain injury, secretion of cytokines, chemokines,
and inflammatory modulators represent a key function for microglial cells (Zhao et al.,
2017). Accordingly, we next determined whether or not Ang-2 treatment affected the
paracrine activity of microglia. By ELISA, treatment of a mouse microglial cell-line
(SIM-A9) with Ang-2 did not alter IL-6 and TNF, both major inflammatory mediators
(Figures 2.5A and 2.5B). To determine if the effects of Ang-2 were dependent on
signaling through the Tie-2 receptor, we used Bay-826, an inhibitor specific to Tie-2. In
the presence of Ang-2 (100 ng/ml), Bay-826 treatment significantly inhibited microglial
secretion of IL-6 (Figure 2.6B; P < 0.05); these data indicated that the pro-inflammatory
microglial cell phenotypes may be mediated by Tie-2 signaling. We therefore measured
Tie-2 expression in microglia treated with astrocyte conditioned medium (ACM) and/or
CSF1 (100 ng/ml), a factor released in response to CNS injuries. CSF1 increased
microglial Tie-2 expression and ACM limited CSF1-induced Tie-2 expression (Figures
2.5C and 2.5D).
Astrocyte-specific loss of ETBR reduces microglial cell proliferation after stroke.
Previously we reported astrocyte-specific knockout of EDNRB significantly decreased
reactive astrocyte proliferation 3 d after stroke (Lecomte et al., 2015). In subsequent
studies of the peri-infarct area, we identified a subset of non-astrocyte (GFAP-negative)
cells with reduced proliferation (Ki67) after astroglial-specific EDNRB knockout (Figure
2.6C). Signaling cross-talk between reactive astrocytes and microglial cells is an
important determinant of CNS injury outcomes (Bohlen et al., 2017; Guan et al., 2016;
Liddelow et al., 2017; Welser-Alves et al., 2013; Yu et al., 2020). To test whether
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decreased reactive astrogliosis following GFAP-EDNRB-cKO affected also microglial
cell dynamics, we performed immunohistochemistry for proliferative Ki67+/CD11b+ cells
3 days after dMCAO. Of interest, we found that astroglial-specific knockout of EDNRB
significantly decreased the proportion of Ki67+ cells that were CD11b+ (Oil vehicle
controls 0.39 ± 0.12, n = 9; Tamoxifen Knockouts 0.24 ± 0.12, n = 10; P < 0.05; Fig.
2.6D). CD11b+ cells include circulating monocytes, neutrophils, NK cells, granulocytes,
and macrophages as well as microglia (Duan et al., 2016; Fu et al., 2011; Hardersen et al.,
2018). Notably, however, previous studies have shown that peripheral blood-derived cells
do not proliferate upon entering the central nervous system after injury; this suggests that
the Ki67+/CD11b+ cells we counted were primarily microglial cells (Li et al., 2018).
To examine whether other stroke injury-related signals to reactive astrocytes also
affected microglial cell dynamics we studied cells in GFAP-Notch1-cKO mice 3 days
after stroke. In contrast to the pattern observed in EDNRB-cKO mice, the number of
Ki67+/CD11b+ cells in GFAP-Notch1-cKO mice did not change after Notch1-cKO (P =
0.24; supplemental Figure 2.6A). Furthermore, we examined the number of proliferating
CD45+ blood lineage cells as well as NG2+ oligodendrocyte progenitor cells in GFAPNotch1-cKO mice 3 d after stroke. Similar to the CD11b+ cells, the number of
Ki67+/CD45+ or the Ki67+/NG2+ cells did not change after Notch1-cKO (CD45+/Ki67+ P
= 0.57; NG2+/Ki67+ P = 0.80; Supplemental Figures 2.6B and 2.6C); this indicated that
microglial cell proliferation was affected by astroglial ETBR signaling, but not by Notch1
signaling in reactive astrocytes.
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Direct cortical injection of recombinant murine Ang-2 did not alter microglial cell
proliferation in a consistent, predictable manner.
To investigate whether or not Ang-2 could directly impact microglial cell proliferation in
vivo, we injected one cortical hemisphere of Cx3cr1-GFP mice with vehicle (n = 5) and
the other with recombinant murine Ang-2 (100 ng/ml in vehicle, n = 5). The hemisphere
that received Ang-2 injection was randomized in a blinded manner to control for any
possible lateralization effects. Injection of Ang-2 increased microglial proliferation in 3
out of 5 mice injected, whereas proliferation was unchanged in the one mouse, and it
actually decreased in the other (Supplemental Figure 2.2). Thus, direct Ang-2 injection
into the cerebral cortex of otherwise healthy mice did not significantly alter the
proliferation of GFP+ cells. Although the brain stab/injection model we employed clearly
differs from a model of cerebral ischemia (i.e. dMCAO), our results do suggest that other
factors may be required for Ang-2 to change the proliferation of microglia after brain
injury.
METHODS
Distal middle cerebral artery occlusion (dMCAO) surgery. Mice were induced with
4% isoflurane and maintained with 1.5-2% isoflurane in oxygen. Body temperature was
maintained with a heated pad. Under sterile conditions, an incision was made vertically,
between the ear and eye. The temporalis muscle was cut from its attachment on the lateral
portion of the skull. The muscle was retracted and a rectangular portion of the skull was
removed. The dMCA was visualized and a 10-0 suture (03171, Fine Science Tools) was
used to permanently tie off and occlude the artery. The artery was cut to confirm
occlusion (i.e. lack of distal blood-flow). The muscle was then returned to its resting
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position, and the skin was closed with Vetbond (3M). GFAP-CreERTM-EDNRB-fl/fl or
C57BL/6J background animals were injected with Buprenorphine and allowed to recover
for the indicated time periods before either cell isolations or 4% paraformaldehyde
(AAJ19943K2, Affymetrix) transcardiac perfusion and preparation of the brain for
immunohistochemistry.
Generation of Reactive astrocyte-derived Neural Stem Cells (Rad-NSC). Mice
underwent dMCAO surgery and recovered for 3 d before brains were removed for
dissection. Brains were cut coronally, cortical tissue ipisilateral to the stroke injury was
separated from the rest of the brain, and meninges were excluded. Brains were digested in
a solution of Papain (20 units/mL, LS003126; Worthington), L-Cysteine (0.2 mg/mL,
C7352; Sigma), DNase (20 g/mL, Worthington), CaCl2 (1.5 mM), and EDTA (1.5 mM)
in DMEM-F12 (Hyclone) for 20 minutes in a 37°C incubator at 5% CO2. The digestion
solution was neutralized by trypsin inhibitor (1.5 mg/mL, 17075-029; Gibco) and BSA
(1.5 mg/mL, BP1605-100; Fisher) in DMEM-F12. Cells were resuspended in NSC
medium: Neurobasal-A base medium (10888022, ThermoFisher) supplemented with
recombinant human basic FGF (20 ng/mL, produced in our lab), EGF (10 ng/mL, Gibco),
B27 supplement (Gibco), 2 mM L-glutamine, 100 U/mL penicillin and 100 g/mL
streptomycin. To obtain cell populations with uniform and predicable Cre-mediated
knockout, individual cells were maintained until initial neural sphere formation.
Subsequently, single spheres were pipetted into separate wells for clonal expansion.
ELISA. Clonal Rad-NSC populations were expanded in NSC medium. Rad-NSCs were
plated onto dishes previously coated with 5 g/ml Laminin (Corning) and 5 g/ml Polyd-lysine (Corning) at a density of 1 million cells per 10 cm2 dish (Nunc, Thermo Fisher
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Scientific). NSCs were differentiated into astrocytes in DMEM-F12 (Hyclone) medium
containing 10% fetal bovine serum (Atlanta Biologics) for 17 days. Astrocytes were then
treated with ET-1 (100 nM, Sigma), IRL1620 (10 nM, ToCris), BQ-788 (8 M, Sigma or
Caymen Chemicals), and/or BQ-123 (1 M, Sigma or Abcam). Additionally, astrocytes
were maintained for 21 days in 10% serum for 1 hr pretreatment with DMSO (vehicle
control) or TCS-7009 (1 M, HIF2a inhibitor; Tocris Bioscience) or U0126 (10 M,
MEK/ERK inhibitor; Cell Signaling Technologies) or Repsox (1 uM, TGFRI/ALK5
inhibitor; Stemcell Technologies) or K02288 (80 nM, BMPR/ALK1/2/6 inhibitor;
Caymen Chemicals) or NFB inhibitor (10 nM, Calbiochem) or PX-478 (25 M, HIF1α
inhibitor; Caymen Chemicals), followed by treatment with ET-1 (100 nM) or PBS
(vehicle control). Before application of treatments, astrocytes were washed PBS and then
for 5 min at 37°C with PBS. Treatments were added in serum-free DMEM-F12 base
medium for 48 hrs to generate conditioned medium; this medium was filtered (0.22m)
and analyzed by ELISA.
Magnetic-Activated Cell Sorting (MACS). Following dMCAO surgery, mice recovered
for 3 d before brains were removed for dissection. Olfactory bulb, hindbrain, and
meninges were excluded and the hemispheres contralateral and ipsilateral to the stroke
were separated for cell isolations. We adapted our cell isolation protocol from Foo et al.
(2011). Cortical hemispheres were digested separately in a 37℃ incubator at 5% CO2 for
1 hr. The enzymatic dissociation solution contained Hanks Buffered Salt Solution
(HBSS) supplemented with 30% D-Glucose, 1 M NaHCO3, 50 mM EDTA, L-Cysteine 1
mg/mL, Sigma; DNase (20 g/mL, Worthington), and Papain (20 U/mL, Worthington).
The enzymatic tissue digest was neutralized by washing 3x with “low” ovomucoid
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inhibitory solution that was diluted from a concentrated stock to a 1x final concentration
in HBSS containing 30% D-Glucose and 1 M NaHCO3. Low ovomucoid stock solution
(10x): 0.2 mg/mL ovomucoid trypsin inhibitor, Worthington; 1.5% BSA, Miltenyi
Biotech; all dissolved into 1 x Dulbucco’s PBS, pH 7.4. Cells were triturated gently in the
low ovomucoid solution and passed through a filter to generated a single cell suspension
(70 µm, Falcon). The low ovomucoid solution was underlaid with a “high” ovomucoid
solution; this 1x high ovomucoid solution was diluted from a concentrated stock solution
in HBSS supplemented with 30% D-Glucose and 1 M NaHCO3. High ovomucoid stock
solution (10x): 3% BSA solution, Miltenyi; 0.0333 g/ml ovomucoid trypsin inhibitor,
Worthington; all dissolved into 1x DPBS (pH 7.4). After high ovomucoid solution was
underlaid, cell suspensions were centrifuged at 300 x g for 7-minutes. Cell pellets were
resuspended in 140 ul MACS buffer (1 x Miltenyi BSA solution in DPBS) containing 20
l FcR blocking solution (Miltenyi Biotech). FcR block was incubated for 10 min at 4℃.
After blocking, 40 l of biotinylated anti-GLAST antibody (Miltenyi Biotech) was added
and incubated for 20 min at 4℃. Cells were washed with 5 ml of MACS buffer, then
centrifuged at 300 x g for 7 min. Cell pellets were re-suspended in 160 ul of MACS
buffer. After resuspension, 40 ul of paramagnetic-bead conjugated streptavidin (Miltenyi
Biotec) was added and incubated for 20 min at 4℃. Labeled cells were washed with 5 ml
of MACS buffer, centrifuged (300 x g, 7 min), and re-suspended in 3 ml of MACS
buffer. A MACS column (L/S column, Miltenyi Biotech) was primed with 3 ml of
MACS buffer prior to loading on the labeled cell suspension. The MACS columns were
washed 3x with MACS buffer (3 ml, each). GLAST+ cells were eluted in 5 ml of MACS
buffer, centrifuged at 300 x g for 7 min, re-suspended in 400 l of DPBS, and counted by
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hemocytometer. After quantification, the cells were centrifuged 1,000 x g for 10 minutes.
The final GLAST+ cell pellet was lysed in hypotonic lysis buffer compatible with ELISA:
20 mM HEPES pH 7.5, 5% Glycerol, 1.5 mM MgCl2, 10 mM KCL, 10 mM NaCl,
supplemented with 1 x protease (Pierce) and phosphatase (Sigma) inhibitors.
Microarray analysis. For microarray assays, Rad-NSCs were plated and differentiated
into astrocytes for 7 d (as above). On day 7, cells were fed with either 4 hydroxy
tamoxifen (4-OH-TM, 1 M; Tocris Bioscience) or ethanol (vehicle control) in DMEMF12 with 10% FBS. This treatment was renewed 3 times, every 3 d. After 10 d of
treatment (17 d total differentiation), cells were washed and switched to DMEM-F12
base medium with no serum. After 48 hrs of incubation in serum-free medium, astrocyteconditioned medium (ACdM) was harvested for analysis, and cells were lysed using
RNA lysis-buffer (Zymo Research).
Probe set statistics and identification of differential expression was performed by
the Molecular Bioinformatics Shared Resource of the University of Vermont College of
Medicine Vermont Integrative Genomics Resource, using Partek Genomics Suite ®
Version 6.6 (Partek Inc., St. Louis, MO). Probe-level intensities were calculated using the
Robust Multichip Average (RMA) algorithm, including background-correction,
normalization (quantile), and summarization (median polish), for each probe set and
sample. Sample quality was assessed based on 3’: 5’ ratio, relative log expression (RLE),
and normalized unscaled standard error (NUSE). Principal Component Analysis (PCA)
was also used to identify outlier samples that would potentially introduce latent variation
into the analysis of differential expression across sample groups. Multivariate Principal
Component Analysis was performed on the normalized data set using the covariance
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matrix. Univariate linear modeling of sample groups was performed by ANOVA. The
magnitude of the response (fold-change calculated using the least square mean) and the
p-value associated with each probe set and binary comparison were calculated, as well as
a “step-up” adjusted p-value for the purpose of controlling false discovery rate
(Benjamini, Y, and Y Hochberg, 1995). Data were analyzed by Gene Set Enrichment
(Partek), which uses a right-tailed Fisher’s Exact test with a null hypothesis that data are
changing together strictly by chance. The alternative is that the data change in concert
because they are part of a biological gene set of pathway. Functional clusters and
pathways were identified using the DAVID bioinformatics resource (Huang et al. 2009).
Stereotaxic injections. Cx3cr1-GFP mice (Jackson Labs) were induced with 4%
isoflurane and maintained with 1.5-2% isoflurane in oxygen. A heated pad was used to
maintain body temperature. For studies of Ang-2 in brain stab injury, vehicle was
injected into one hemisphere, whereas Ang-2 was injected into the other hemisphere.
Under sterile conditions, a midline incision was made over the dorsal surface of the skull
and the skull was drilled bilaterally. A 26 Gauge needle (SGE010RNS, World Precision
Instruments) was inserted bilaterally: AP = +0.62, Depth = -2.00, Lat = +/- 2.5 mm
relative to Bregma (KOPF stereotaxic device). The needle was allowed to sit for 2 min
before beginning of injection. Injection of 1 l rmAng-2 in sterile PBS (100 g/ml; 7186AN-025/CF, R&D Systems) was performed at 0.1 l/min (UMP-2 and Micro4 Pump
Controller) for 10 minutes, for a total of 100 ng Ang-2. After injection, the needle was
left in place for 5 minutes before being slowly retracted. Animals were closed and
allowed to recover for 48 hours before harvesting brains for immunohistochemistry.
Horizontal (perpendicular to needle stab) serial sectioning was performed for 30 um
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sections, with each serial section separated by 60 m. Tissue was stained for Ki67. Four
representative 40x images were taken within 400 m of the needle track per section, with
5 sections represented per mouse. Counts were performed for GFP+, Ki67+, and
GFP+/Ki67+ cells. All injections and counts were performed by a blinded investigator.
Stroke tissue processing and cell-counts: Fixed brain tissue was cryosectioned at 30
m per section, with 270 m between each section. Tissue was stained for CD11b and
Ki67. For counts, 3 representative 40x images were taken per section within the dorsal
portion of the peri-infarct area; this region typically has the highest level of cellular
proliferation after stroke. For 3 sections from each brain, blinded counts were performed
for Ki67+ and CD11b+/Ki67+ cells. Counts of CD11+/Ki67+ cells were normalized to the
total number of Ki67+ cells.
Microglial Cell Culture: Human Microglia (Celprogen 37089-01), and immortalized
microglia (SIM-A9, END001) were cultured in DMEM-F12 medium supplemented with
10% FBS and 5% Horse Serum. Prior to plating ELISA experiments, the serum content
was reduced to 1% FBS (v/v) and 0.5% Horse Serum (v/v) for at least 24 hrs. Microglia
were lifted by trypsinization (GIBCO), passed through a single cell filter (40 m,
Falcon), and plated at 200,000 cells per well in a 6-well dishes (Nunc) in reduced serum
(1% FBS and 0.5% Horse Serum). Cell culture dishes were coated with 5 g/ml Laminin
and 5 g/ml Poly-D-lysine (both from Corning). After 24 hrs, the serum-containing
medium was removed, cells were washed with PBS and switched to serum-free defined
medium (AdM), 50:50 Neurobasal-A/DMEM with heparin sulfate (SIGMA) B25 (made
in house) or B27 (Invitrogen) and L-Glutamine (GIBCO) and Pen/Strep (GIBCO). After
24 hrs in AdM (to remove serum), cells were treated in AdM and put into normoxia or
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hypoxia (1% oxygen). After 48 hour medium was removed and cells were centrifuged at
1000 x g for 10 min. Cell pellets and adherent cells were kept for standard cyquant assay
(Invitrogen) and conditioned medium was analyzed by ELISA.
Statistical analysis
Statistical analyses were performed with GraphPad Prism Software (Version 7.01).
Groups were compared by Student’s T-test and multiple comparisons were made by
ANOVA. P-values of less than 0.05 were considered significant.
DISCUSSION
In our prior studies of the peri-infarct area after stroke, we reported a subpopulation of
proliferating reactive astrocytes that expressed GLAST, the RC2 antigen, and high levels
of Jagged-1 and ETBR. Similar to conditional knockout of the Notch1 receptor, astroglialspecific loss of ETBR demonstrated its requirement for survival of proliferating reactive
astrocytes. As the population of proliferating reactive astrocytes is characteristically antiinflammatory and neuroprotective in the context of stroke (Shimada et al., 2011),
traumatic brain injury (Frik et al., 2018), and spinal cord injury (Anderson et al., 2016),
we hypothesized that astroglial ETBR signaling promotes paracrine activity associated
with a neuroprotective astrocyte phenotype.
Our microarray analysis of adult astrocytes after EDNRB-cKO revealed
significant changes in gene expression related to cell-cell signaling. Notably, we
observed significantly reduced expression for genes associated with neuroprotection (e.g.
CD109) (Liddelow et al., 2017), angiogenesis (e.g. Angpt2) (Zhu et al., 2005), BBB
homeostasis (e.g. Alcam) (Lecuyer et al., 2017), and axon guidance (e.g. Sema3c)
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(Hernandez-Montiel et al., 2008). Due to the potential for increased vascular
permeability, administration of factors such as VEGF early after stroke can be
problematic (Marteau et al., 2012; Zhang et al., 2000). Notably, however, treatment with
Ang-2 prior to stroke was shown to protect the blood brain barrier and reduce stroke
injury (Marteau et al., 2013).
Genes with expression upregulated by EDNRB-cKO were largely proinflammatory in nature. Multiple genes encoded proteins that regulate inflammatory
responses of microglia/monocyte/macrophages (e.g. Lcn2, Glycam1, Sucnr1, Metrnl)
(Bridgewood et al., 2019; Jin et al., 2014; Keiran et al., 2019; Williams et al., 2017) and
prostaglandin signaling (e.g. Ptger3) (Aronoff et al., 2004), and some were antiangiogenic (e.g. Serpinf1) (Wietecha et al., 2015). Particularly notable were increases in
gene expression related to complement and TGFβ signaling (e.g. Tgfb3). In the
developing brain, TGFβ-3 was demonstrated to upregulate synaptic C1q expression
during the process of synaptic pruning (Bialas and Stevens, 2013). Additionally,
astroglial EDNRB-cKO increased expression of C1r and C1s; these proteins complex
with C1q to form complement C1, a key initiator of the complement cascade
(Dunkelberger and Song, 2010). In regard to neurotoxicity, the results suggested EDNRB
loss in reactive astrocytes may promote TGF/complement signaling that tags neuronal
synapses and/or neurons for elimination.
Among paracrine factors, angiopoietin-2 (Ang-2) mRNA levels decreased the
most in response to ETBR knockout. Perhaps best known as a positive regulator of
angiogenesis, Ang-2 was also shown to affect peripheral monocyte/macrophage
migration and angiogenic activity (Chen et al., 2016; Forget et al., 2014; Patel et al.,
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2013). By ELISA, we found that reactive astrocytes isolated by GLAST-MACS
significantly increased Ang-2 levels in cortical tissue ipsilateral to the stroke injury. In
contrast, Ang-2 was barely detectable in astrocytes sorted from the contralateral
(uninjured) hemisphere or from healthy, uninjured mice.
ETBR is highly expressed in reactive astrocytes, whereas ETAR is expressed at
comparably lower levels (Guo et al., 2014; Hammond et al., 2015; John Lin et al., 2017;
Zhang et al., 2014). Our experiments with pharmacological inhibitors specific to ETAR
and ETBR confirmed that ETBR promotes Ang-2 expression and secretion, whereas ETAR
inhibition had no effect on Ang-2 secretion. ET-1 interacts with both ETAR and ETBR,
whereas ET-3 selectively interacts with ETBR. Thus, ET-1 and ET-3 may have different
effects after stroke and/or other brain injuries.
In experiments to determine downstream effectors of ETBR signaling, we found
that ET-1 induced Ang-2 secretion by primary astrocytes in a NFκB and MEK/ERKdependent manner. ELISA of TNF and IL-6 in CdM from SIMA9 cells that were exposed
to Ang-2 suggested that high (>100 ng/ml) levels of Ang-2 could have a modest proinflammatory effect on microglia. In the presence of 100 ng/ml Ang-2, treatment of
microglia with a specific Tie-2 inhibitor (Bay826) decreased TNF and IL-6 secretion. As
Ang-1 is the major agonist ligand for Tie-2, some of this effect, may be due to decreased
autocrine Ang-1 signaling. In peripheral monocytes and macrophages, Ang-1 was
reported to support differentiation of cells toward a pro-inflammatory (i.e. M1)
phenotype and increase secretion of TNF and to a lesser extent IL-6 (Seok et al., 2013).
In endothelial cells, Ang-2 may function as a Tie-2 antagonist at low doses and a Tie-2
agonist at high doses (e.g. >50 ng/ml) (Fiedler and Augustin, 2006). As a receptor ligand,
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there is thus potential for Ang-2 to act as an antagonist (supporting M2, antiinflammatory phenotypes in microglia/monocytes), or as an agonist (promoting M1, proinflammatory phenotypes), depending on its local concentration and the signaling milieu
in a particular injury/disease environment.
In normal, healthy brain recent findings have demonstrated regional differences in
subpopulations of microglia (Stratoulias et al., 2019), and astrocytes in the spinal cord
(Hochstim et al., 2008) and the brain (Lin et al., 2017). We and others have demonstrated
that several subpopulations of reactive astrocytes can be identified based on their
proximity to tissue damage (i.e. stroke infarct core), proliferation status, and
environmental milieu (Lecomte et al., 2015; Liddelow et al., 2017). In regard to Ang-2
and its function(s) in vivo, it will be important to determine which astrocytes secrete it
and where. Based on the regulation of astroglial Ang-2 secretion by ETBR and that the
proliferating reactive astrocytes nearest to the infarct core express the highest levels of
ETBR, it is likely that reactive astrocytes expressing the most Ang-2 may actually be
deleted from the peri-infarct area in our GFAP-CreERTM-ETBR-cKO mouse model after
stroke. Accordingly, experiments in GFAP-CreERTM-Angpt2-cKO mice may provide
further insight into the effects of astrocyte-secreted Ang-2 on microglia, the BBB,
angiogenesis and recovery post-stroke. In addition, single cell analyses of reactive
astrocytes and microglia sorted from injured CNS tissues using cell surface markers such
as ETBR and Tie-2 may provide insight into the specific functions of diverse, interacting
glial subpopulations.
In a rat model of stroke, Leonard and Gulati (2013) demonstrated that systemic
treatment with IRL-1620 reduced stroke size and improved stroke outcomes. They
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posited that agonizing ETBR had direct beneficial effects on neuron survival in the acute
phase of injury and potentially benefit also angiogenesis and/or neurogenesis to enhance
stroke outcome (Leonard and Gulati, 2013). Our data indicate that direct effects on the
paracrine activity of neuroprotective reactive astrocytes and indirect effects on microglial
dynamics may be responsible for some of the benefits observed after IRL-1620 treatment
of stroke.
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Figure 2. 1.
Microarray analysis of cultured EDNRB-knockout reactive astrocytes revealed cell-cell
signaling related changes in gene expression. A) Schematic illustrating workflow for
generating reactive astrocyte derived neural stem cells (Rad-NSCs) from the periinfarct area. Reactive astrocytes were generated by differentiation of Rad-NSCs from
GFAP-CreERTM-EDRNB-fl/fl mice. Differentiated astrocytes were treated with ethanolvehicle or 4-OH-tamoxifen (1 M) to knockout EDNRB. After 2wks astrocytes were
lysed, and RNA was purified for analysis. B) Principal Component Analysis (PCA) of
control and knockout astrocytes derived from two separate Rad-NSC clones. C)
Volcano plot illustrating significance and magnitude of mRNA expression changes
after astoglial EDNRB-knockout. D) Heat-map of the top astroglial cell-cell signalingrelated genes altered by EDNRB-knockout.
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Figure 2. 2.
Astrocytes isolated by Magnetic Activated Cell Sort (MACS) against GLAST express
increased Ang-2 expression 3 d after stroke. A) Schematic of GLAST-MACS
workflow, cell lysis, and Ang-2 ELISA. B) Immunoblot for GFAP showing the
enrichment of astrocytes in the GLAST+ cell fraction after GLAST-MACS. C)
Comparison of uninjured control animals (n = 3) and dMCAO animals (n = 5).
Astroglial Ang-2 expression significantly increased following stroke. D) Astroglial
Ang-2 expression significantly increased in the hemisphere ipsilateral to the stroke (n =
5) compared with that of the contralateral hemisphere (n = 5). *P < 0.05.
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Figure 2. 3.
ET-1 signals through ETBR, and downstream NFB and MEK/ERK, to stimulate Ang2 production by cultured astrocytes. A) Cultured astrocytes were treated with ET-1
(100 nM), and vehicle, ETAR inhibitor (BQ-123, 1 M), or ETBR inhibitor (BQ-788, 8
M). Inhibition of ETBR blocked the ET-1 dependent increase in astroglial Ang-2
secretion (Veh vs. ET-1 + ETB inhibitor: P = 0.81). B) Treatment with IRL1620
significantly increased astroglial Ang-2 expression in normoxia but not hypoxia (n = 3
for all groups). C) Prior to treatment with ET-1 (100 nM), astrocytes were pretreated
for 1 hr with inhibitors to multiple signaling pathways: HIF2 (TCS-7009, 1 M),
NFB (10 nM), TGFRI/ALK5 (Repsox, 1 M), MEK/ERK (U0126, 10 M),
ALK1/2/6 (K02288, 80 nM), HIF1 (PX-478, 25 M). NFB or MEK/ERK inhibition
significantly reduced astroglial Ang-2 expression. D) TGF1 treatment significantly
decreased Ang-2 secretion. n = 3 for both groups. *P < 0.05; **P < 0.01.
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Figure 2. 4.
Cx3cr1-GFPHigh microglia express Tie-2 in both cerebral hemispheres 3 d after dMCAO
surgery. A) Cell population was enriched for microglia by MACS against CD11b. By
FACS, we observed two populations of Cx3cr1-GFP+ cells; Cx3cr1-GFPHigh and Cx3cr1GFPlow. B) The Cx3cr1-GFPhigh cell population expressed the microglial marker
TMEM119, both ipsilateral and contralateral to the ischemic infarct. Cx3cr1low cells
expressed less TMEM119. C, D) The Cx3cr1-GFPhigh population (TMEM119+ microglia)
expressed the Tie-2 receptor in both hemispheres, ipsilateral and contralateral to the
stroke. E) Immunohistochemistry for Tie-2 and TMEM119, demonstrated prominent Tie2 expression in the vasculature (blue circles) contralateral to the stroke injury.
TMEM119+ microglia (green cells) co-expressed Tie-2 (red, white arrows) ipsilateral to
the stroke injury.
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Figure 2. 5.
Microglia alter cytokine secretion in response to Ang-2/Tie-2 signaling and Tie-2
expression in response to CSF1. A) Treatment with Ang-2 or Tie-2 inhibitor did not
significantly change microglial TNF secretion. B) In the presence of Ang-2 (100
ng/ml), Tie-2 inhibition (BAY-826 0.1 M) significantly lowered microglial IL-6
secretion (Ang-2 100 ng/ml treatment: 2,550 ± 34.96 pg/ml IL-6 normalized to
200,000 cells, Ang-2 100 ng/ml + BAY-826 0.1 M: 1,371.15 ± 151.01 pg/ml IL-6
normalized to 200,000 cells, n = 2, Ang-2 100 ng/ml vs. Ang-2 100 ng/ml + BAY-826
0.1 M; *P < 0.01 by 1-way ANOVA). C) Treatment with CSF1 (100 ng/ml, greenline) increased the expression of Tie-2 relative to vehicle treatment (blue line). Isotype
control for PE (red line). D) Astrocyte conditioned medium limits the effects of CSF1
on induction of cell surface Tie-2 (black line). Isotype control (red line) and CSF1
treatment (green line) are as in C.
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Figure 2. 6.
Astroglial-specific EDNRB-knockout reduced the number of proliferating microgliallike cells. A) Immunohistochemistry for microglia/macrophages/monocytes (CD11b,
green) and proliferating cells (Ki67, red) 3 d post-stroke at the infarct edge, in vehicleinjected (Corn oil, control) and tamoxifen(tam)-injected GFAP-CreERTM-EDNRB-fl/fl
mice. Arrows indicate proliferative CD11b+ cells. B) EDNRB loss significantly
decreased the number of proliferating non-astroglial cells (GFAP-neg/Ki67+) (Control: n
= 3; Knockout n = 3) . C) EDNRB loss significantly decreased the proportion of
double-positive (Ki67+/CD11b+) (Controls: n = 9; Knockouts: n = 10). Scale bars = 25
m. *P < 0.05.
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Supplemental Figure 2. 1.
Astroglial-specific Notch1-knockout did not affect proliferation of non-astroglial cell
types. A) Representative immunohistochemistry for microglia/macrophages/monocytes
(CD11b, red) and a nuclear proliferation marker (Ki67, green) in vehicle-treated (Oil,
control) and tamoxifen-treated (TAM, knockout) GFAP-creERTM-Notch1-fl/fl mice. The
number of proliferating microglia-like cells did not differ between control (n = 4) and
knockout mice (n = 5) (P = 0.24). B) Representative immunohistochemistry for
hematopoietic-lineage cells (CD45, red) and a nuclear proliferation marker (Ki67,
green) in control (Oil-treated) and knockout (TAM-treated) GFAP-creERTM-Notch1-fl/fl
mice. Quantification of proliferative hematopoietic-lineage cells shows no significant
difference (P = 0.57) between control (n = 3) and knockout mice (n = 4). C)
Representative immunohistochemistry for Oligodendrocyte Progenitor Cells (OPCs,
i.e. polydendrocytes) and pericytes (NG2, red) and a nuclear proliferation marker
(Ki67, green) in control (Oil-treated) and knockout (TAM-treated) GFAP-creERTMNotch1-fl/fl mice. The number of proliferative OPCs and/or pericytes did not differ
between control (n = 3) and knockout mice (n = 5) (P = 0.80). N.S. = not significant.
Scale bars = 25 m.

117

118

Supplemental Figure 2. 2.
Stereotaxic injection of Ang-2 did not affect microglial proliferation. A) Schematic for
stereotaxic injection paradigm. The hemisphere that received Ang-2 injection was
randomized in a blinded manner to control for any possible lateralization effects. B)
Representative images of immunohistochemistry of vehicle-treated Cx3cr1-GFP mice
stained for a proliferative marker (Ki67, red) and nuclei (DAPI, blue). Arrows
indicated proliferative GFP+ cells. C) Representative images of immunohistochemistry
of Ang-2 treated (100 ng injection) Cx3cr1-GFP mice stained for a proliferative marker
(Ki67, red) and nuclei (DAPI, blue). Arrows indicated proliferative GFP+ cells. Circle
indicates GFP+ cells that just divided. D) The number of proliferating Cx3cr1-GFP+
cells did not differ (n = 5 both groups) (P = 0.12). N.S. = not significant. Scale bars =
25 m.
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Supplemental Figure 2. 3.
Astroglial-specific EDNRB-knockout did not alter expression of CD68 in Iba1+ cells at
the peri-infarct edge. A) Representative images of the infarct edge 3 d post-stroke in
vehicle treated (corn oil, control) GFAP-CreER-EDNRB-fl/fl (left panel, 10x; scale bar
= 100 m) (right panels, 40x; scale bars = 25 m) B) Representative images of the
infarct edge 3 d post-stroke in tamoxifen-treated (TAM, knockout) GFAP-CreEREDNRB-fl/fl (left panel, 10x; scale bar = 100 m) (right panels, 40x; scale bars = 25
m) A, B) Immunohistochemical assays for astrocytes (GFAP, gray), microglia (Iba1,
green), and a marker of inflammatory/phagocytic cells (CD68, red). C, D)
Quantification of CD68 reactivity in Iba1-expressing cells showed no difference in the
number of cells expressing high levels of CD68 either inside the infarct (n = 3 Oilcontrols, n = 4 TAM-knockout mice; P = 0.38) or outside the infarct (n = 3 Oilcontrols, n = TAM-knockout mice; P = 0.95), as demarcated by the edge of GFAP
reactivity.
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ABSTRACT
Following ischemic stroke, reactive astrocytes proliferate and form a glial scar that limits
progressive damage to the central nervous system (CNS). Recently, a paradigm was
proposed in which discrete subpopulations of reactive astrocytes found in different
inflammatory/neurodegenerative diseases were characterized as neurotoxic, whereas
those observed after stroke or spinal cord injury were deemed neuroprotective (stroke).
Accordingly, the new model has inspired research directed at identifying markers that
effectively parse the subpopulations and also to determine their paracrine activity. Of
special interest, the neuroprotective subpopulation was shown to express high levels of
CD109 mRNA. In several different forms of CNS injury, our group and others have
demonstrated that proliferating reactive astrocytes possess neuroprotective function(s).
After ischemic stroke, reactive astrocyte proliferation and survival are regulated, in part,
by Endothelin receptor type-B (ETBR) signaling. Here we show that astroglial ETBR
signaling promotes the expression of CD109 after stroke. For reactive glia, CD109 was
primarily expressed on aquaporin-4+ endfeet of astrocytes that were associated with the
microvasculature. In studies of primary adult astrocytes with shRNA-mediated
knockdown of CD109, reduction of CD109 significantly impacted astroglial expression
of the neurotoxic marker complement C3 (C3) in response to TNF and ETBR signaling.
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Treatment with recombinant CD109 after stroke tended to increase infarct sizes as well as
neuroinflammatory activity in areas of the brain distal to the infarct. Our results suggest
that soluble (free) CD109 may serve as a modulator of neuroinflammation after stroke.
Further research is needed to better understand the cell-autonomous effects of membranebound CD109 on reactive astrocyte phenotypes and the non-cell-autonomous effects of
cleaved/released CD109 during neuroinflammation and injury progression after stroke.
INTRODUCTION
Reactive astrocytes display heterogeneous phenotypes that vary between CNS injuries
and diseases and also across an individual injury environment, such as ischemic stroke.
Recently, complement C3+ astrocytes were described as “neurotoxic astrocytes” based on
their secretion of a paracrine protein factor(s) that trigger neuronal cell death in
neuroinflammatory diseases (Alzheimer’s, multiple sclerosis, Parkinson’s) (Liddelow et
al. 2017; Yun et al., 2018). C3+ neurotoxic astrocytes are induced by inflammatory
factors such as IL-1, TNF, and C1q that are released by microglial cells in response to
bacterial antigens (e.g. lipopolysaccharide, LPS) or central nervous system (CNS)
degeneration. To treat neuroinflammatory/neurodegenerative diseases, therapies are
being pursued to block the neurotoxic inducing factors or neutralize complement factors
associated with neurotoxicity (Alawieh et al., 2020; Guttenplan et al., 2020; Qian et al.,
2019; Yun et al., 2018).
Neurotoxic astrocytes have been contrasted with astrocytes bearing a
“neuroprotective” phenotype. Primarily observed after stroke and spinal cord injury
(Anderson et al., 2016; LeComte et al., 2015; Tyzack et al., 2017), the neuroprotective
phenotype is characterized by a relatively high rate of proliferation as compared with
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reactive astrocytes described in neuroinflammatory disease (Kamphuis et al., 2012;
LeComte et al., 2015; Lepore et al., 2008; Liddelow and Barres, 2017; Liddelow et al.,
2017; Shimada et al., 2011; Simon et al., 2011; Sirko et al., 2013). Although further
definition is clearly needed, putative markers for neuroprotective astrocytes include the
RC2 antigen (phosphorylated form of Nestin, an intermediate filament protein), high
expression of Jagged-1 (Notch-ligand), phosphorylated Signal Transducer and Activator
of Transcription-3 (STAT3), high levels of endothelin receptor type B (ETBR), and
proteins associated with cell proliferation, such as Ki67 (Herrmann et al., 2008; Shimada
et al., 2010; Shimada et al., 2011; Wanner et al., 2013; LeComte et al., 2015). After CNS
injury, proliferative/neuroprotective astrocytes are linked to tissue preservation, reduction
of inflammation and injury progression, glial scar formation, and injury resolution
(Anderson et al., 2016; Bush et al., 1999; Shimada et al., 2011). Numerous signals found
within the injury environment have been shown to induce reactive astrogliosis
(Sofroniew, 2009; Pekny and Pekna, 2016) and promote reactive astrocyte proliferation
(e.g. EGF, HB-EGF, Jagged1, Shh, and endothelin) and scar formation (e.g.
TGF) (Schachtrup et al., 2010; Shimada et al., 2011, 2012; Sirko et al., 2013; LeComte
et al., 2015; Zhang et al., 2018) Importantly, a wide variety of signals are similarly found
under injury conditions of sterile inflammation (e.g. stroke and spinal cord injury),
trauma (e.g. brain stab injury), and neuroinflammatory/neurodegenerative diseases such
as Alzheimer’s and Parkinson’s. The specific signals that drive reactive astrocytes to
become neuroprotective or neurotoxic remain poorly understood.
Previously, CD109 gene expression in reactive astrocytes was reported to
correlate with the neuroprotective phenotype (Liddelow et al., 2017; Zamanian et al.,
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2012). CD109 is a TGF co-receptor and a member of the alpha (2)
macroglobulin/complement C3, C4, C5 family (Li et al., 2016; Lin et al., 2002). CD109
interacts with both TGF ligands and receptors and was demonstrated to shunt signaling
from SMAD2/3 to alternative SMAD1/5 signaling (Vorstenboschet al., 2017). CD109 is
cleaved by membrane-bound proteases such as furin and retains many of its biological
functions as a free, soluble protein (Li et al., 2017). Research suggests that CD109
modulates TGF1 and EGFR signaling in its membrane tethered form and that released
CD109 retains TGF1 modifying abilities but loses EGFR modulation (Zhang et al.,
2015). Consistent with its function altering EGFR signaling, CD109 can also alter
STAT3 activity and possibly interacts with Gp130 signaling (Chuang et al., 2017).
Notably, whereas CD109 expression levels may identify astrocytes with different
molecular phenotypes, the function(s) of CD109 in the brain and during reactive
astrogliosis have not been determined.
Here we demonstrate that ETBR signaling in reactive astrocytes promotes CD109
expression. In loss-of-function experiments with reactive astrocytes from GFAP-CreERTEDNRB-fl/fl mice, tamoxifen treatment decreased multiple forms of CD109. By contrast,
IRL1620, a specific ETBR agonist, increased the membrane-localized form of CD109 as
well as its cleaved, soluble form. We found that astrocyte CD109 knockdown by shRNA
decreased the secretion of Angiopoietin-2, a mitogen/survival factor for microglia. Of
special interest, we found that CD109 and IRL1620 mediated TNF-induced expression
of complement C3 and C3d. Delivery of soluble CD109 to mice 24-hours post-stroke
tended to exacerbate primary cortical stroke-injury as well as secondary thalamic
inflammation.
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RESULTS
We first identified CD109 as a putative downstream effector of ETBR signaling in
reactive astrocytes using a loss-of-function screen for EDNRB (the gene encoding ETBR).
Astroglial EDNRB-knockout in cultured cells isolated from GFAP-CreERTM-EDNRB-fl/fl
mice decreased CD109 gene expression by ~4.0-fold (Chapter 2, Figure 2.1). To confirm
that EDNRB-knockout also affected CD109 protein, we immunoblotted cell lysates from
two separate, clonal transgenic reactive astrocyte populations following treatment with 4hydroxy tamoxifen (4-OH-TM). Although baseline CD109 expression levels varied
between clones, EDNRB-knockout similarly decreased both cleaved and un-cleaved
forms of CD109 (Figure 3.1A). To further investigate the potential relationship between
ETBR and CD109, we treated adult astrocytes with IRL1620, a truncated form of
endothelin that binds ETBR, but not ETAR. Treatment of cultured astrocytes with 100 nM
IRL1620 increased expression of cell-associated CD109 as well as the released form of
CD109, detected in serum-free astrocyte-conditioned medium (Figure 3.1B).
To investigate the effects of CD109 loss-of-function in reactive astrocytes, we redifferentiated astrocytes from Reactive astrocyte-derived NSC that were isolated from
peri-infarct cortical tissue 3 d after stroke (as reported previously, Shimada et al., 2012).
To generate CD109 knockdown cell lines, Rad-NSC from the same clone were split into
separate culture wells and then transduced with control lentiviral shRNA vector
(shScrambled) or shRNA specific to CD109 (shCD109). By immunoblot assays,
astrocytes with CD109 knockdown had decreased expression for multiple CD109
isoforms (i.e. cleavage products). Notably, several CD109 isoforms of similar size
decreased after EDNRB-knockout in astrocytes from GFAP-CreERTM-EDNRB-fl/fl mice
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(Figure 3.1A, 3.1B); these results confirmed that the antibody we used detected multiple
full-length, cleaved, and released forms of CD109 (Figure 3.1B).
To detect CD109 during reactive astrogliosis at 3 d after stroke, we performed
double immunohistochemical stains for CD109 and Glial Fibrillary Acidic Protein
(GFAP, an intermediate filament protein,) or the aquaporin-4 water channel (AQP4). At
the blood brain barrier (BBB), astrocytes and endothelial cells form a gliovascular unit
that is critical to maintain the appropriate balance of fluid and ions in the brain.
Accordingly, AQP4 is typically highly-expressed at astrocyte endfeet, which wrap the
cerebral microvasculature (Simard et al., 2003). After stroke, we observed co-localization
of CD109 with AQP4 at blood vessels both ipsilateral and contralateral to the ischemic
injury (Figure 3.2A). Notably, our observations were consistent with a prior ribotagging
study that reported CD109 mRNA was actively translated at gliovascular endfeet. To
determine if CD109 was limited only to glial endfeet and/or expressed elsewhere in the
cell body, we examined reactive astrocytes at the infarct edge, within the peri-infarct
area, and within the outlying brain parenchyma. At 3 d after stroke, we observed that the
majority of GFAP+ astrocytes that stained for CD109 were located proximal to the infarct
and in close contact with the vasculature (Figure 3.2B). Of interest, we also observed rare
GFAP+CD109+astrocytes that expressed CD109 throughout the entire cell body, but did
not appear to contact blood vessels (Figure 3.2C).
To further characterize astroglial expression of CD109 and its cleavage products,
we performed dMCAO surgeries on control (corn oil-injected) and tamoxifen-treated
GFAP-CreERTM-EDNRB-fl/fl mice (EDNRB-cKO). We isolated astrocytes from the stroke
and non-stroke hemispheres of control and knockout mice by magnetic-activated cell
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sorting with antibodies directed against the Glutamate Aspartate Transporter (GLAST
MACS) (Figure 3.3A). By immunoblot for vehicle controls, CD109 (~60 kDa cleavage)
was significantly higher in astrocytes from the stroke vs. the non-stroke hemisphere
(Vehicle-treated uninjured-hemisphere: 16,488.52 ± 2,950.03; Vehicle-treated strokehemisphere: 28,551.66 ± 4,703.08, n = 4 per group; P < 0.05) (Figures 3.3E, 3.3F).
Although CD109 is reported as a marker of reactive astrocytes, it was also detected in
astrocytes isolated from cortical tissue contralateral to the stroke (Figure 3.3E). In
EDNRB-knockout animals, astroglial CD109 levels appeared to be elevated in cells from
the uninjured hemisphere relative to those of vehicle controls (Figure 3.3E). Notably, in
EDNRB-knockout animals, CD109 expression levels were not significantly different
between cells isolated from stroke and non-stroke hemispheres (TM-treated uninjuredhemisphere: 24,837.52 ± 7,554.83; TM-treated stroke-hemisphere: 18,312.55 ± 5,343.51;
n = 4 per group; P = 0.54) (Figure 3.3E, 3.3G). We detected multiple bands
corresponding to different cleavage products of CD109, consistent with our previous
immunoblots of lysates from cultured EDNRB-knockout and shCD109 astrocytes. The
pattern of CD109 expression paralleled that of GFAP expression, which also tended to
increase in response to stroke and presented higher baseline levels in EDNRB-knockout
mice relative to levels observed in vehicle-treated control mice (Figure 3.3B).
CD109 mRNA is a reported marker of a neuroprotective astrocyte phenotype; we
therefore utilized shCD109 Rad-NSC derived astrocytes to assess the expression of
inflammatory factors. Western blots for the neurotoxic marker complement C3 (C3) and
its cleavage products containing the C3d domain (C3d), showed that clones expressed
variable baseline levels of C3d (Figure 3.4A). This is consistent with the differences we
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observed in the expression of CD109 between astrocytes derived from different Rad-NSC
clones (Figure 3.1A). Astroglial stimulation with tumor necrosis factor- (TNF), an
inducer of neurotoxicity, increased several forms of C3 (shCT TNF-treatment 185 kDa
C3: Up 5.38-fold ± 3.67; shCD109 TNF-treatment 185kDa C3: Up 6.95-fold ± 2.57)
(Figure 3.4). Treatment with IRL1620 simultaneous with TNF consistently decreased
C3 expression relative to TNF treatment alone, particularly cleavage products at 26-28
kDa (shCT TNF-treatment: 0.81-fold ± 0.05 of vehicle-treatment; shCT TNF +
IRL1620-treatment: 0.60-fold ± 0.05 of vehicle treatment; n = 2; P < 0.05) (Figures
3.4A; Figure 3.4D). Importantly, in astroglial CD109 knockdown cells stimulated with
TNF, IRL1620 treatment was unable to decrease expression of C3 (shCD109 TNFtreatment: 0.71-fold ± 0.08 of vehicle-treatment; shCD109 TNF + IRL1620-treatment:
0.77-fold ± 0.06 of vehicle treatment; n = 2; P = 0.95) (Figure 3.4C, P = 0.989; Figure
3.4E, P = 0.952).
In order to assess the impact of CD109 signaling on astroglial paracrine and
neuroinflammatory responses, we utilized shRNA CD109 knockdown astrocytes to
measure angiopoietin-2 (Ang-2) secretion. We previously characterized a novel function
of Ang-2 in regulating microglial inflammatory activity. ELISA of conditioned medium
demonstrated that CD109 knockdown may decrease astroglial Ang-2 secretion (shCT
IRL1620-treated: 1.20-fold ± 0.16 of shCT-vehicle; shCD109 IRL1620-treated: 0.43-fold
± 0.23 of shCT-vehicle; n = 2; P = 0.09) (Figure 3.5A). TGF1 interacts with CD109 and
we previously showed that TGF1 treatment significantly decreases astroglial Ang-2
secretion. We found that CD109 knockdown altered the ability of TGF1 treatment to
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repress Ang-2 secretion (shCT TGF1-treated: 0.15-fold ± 0.07 of shCT Vehicle-treated;
shCD109 TGF1-treated: 1.57-fold ± 1.05 of shCD109 Vehicle-treated; n = 2; P = 0.31)
(Figure 3.5A).
Astrocytes express soluble CD109 in vitro in response to ETBR signaling,
suggesting that soluble CD109 is being released in response to stroke and could impact
stroke progression. To study the impact of secreted CD109 on stroke, we injected soluble
recombinant human CD109 (rhCD109) 24-hours post-stroke and analyzed the effect
stroke outcomes after 7 d of stroke recovery. CD109 treatment tended to increase stroke
sizes at 7 d post-stroke as measured by the necrotic GFAP-negative portion of the cortex
(Vehicle-treated Stroke size: 4.94 ± 1.45 mm2; CD109-treated stroke size: 12.23 ± 5.21
mm2; n = 6 vehicle-treated, n = 7 CD109-treated; P = 0.24) or by Cresyl violet staining
for viable neural tissue (Vehicle-treated Stroke size: 4.81 ± 1.87 mm2; CD109-treated
stroke size: 11.91 ± 5.65 mm2; n = 5 both groups; P = 0.27) (Figures 3.6A, 3.6B, and
3.6C). After stroke, neuroinflammation is often observed in secondary areas such as the
thalamus; this is due to reciprocal connections between the thalamus and cortical tissue
with infarction. We noted GFAP, IBA1, and CD68 reactivity in the thalamus ipsilateral to
stroke and minimal reactivity in the contralateral thalamus (Figure 3.7). When the
reactive GFAP area in the thalamus ipsilateral to the infarct was measured, there was a
trend towards increased GFAP reactive area in CD109 treated animals as compared to
controls (Vehicle-treated: 1,212,520 ± 359,227 m2; CD109-treated: 2,276,554 ±
917,740 m2; n = 5 both groups; P = 0.31) (Figure 3.7A, 3.7B, and 3.7D).
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METHODS
Mice
All mice were bred, maintained, and treated in accordance with NIH and AAALAC
guidelines and a protocol approved by an Institutional Animal Care and Use Committee
(IACUC, University of Vermont, Burlington, VT). GFAP-CreERTM:EDNRBfl/fl mice
were bred and genotyped using a commercial kit (RED-Extract-N-Amp kit, Sigma), as
described previously (LeComte et al., 2015). GFAP-CreERTM mice express Cre
recombinase under control of the human GFAP promoter; these mice undergo conditional
knockout of EDNRB (gene sequence encoding ETBR) upon intraperitoneal injection with
tamoxifen (0.1 mg/g animal weight, dissolved in ethanol and corn-oil).
Distal middle cerebral artery occlusion (dMCAO) surgery.
Mice were anesthetized with an isoflurane/oxygen mixture (1-4%, to effect) and body
temperature was maintained at 37℃ using a water-circulated, heated pad (T/pump and
pads, Gaymar). Incisions were made to uncover the lateral portion of the skull between
the eye and ear. Using a drill, a rectangular portion of skull was then removed to reveal
the distal middle cerebral artery. Nylon Suture (10-0, 12051-10, Fine Science Tools) was
used to ligate and occlude the artery. To confirm a lack of blood flow, the artery was cut
distal to the ligature. The wound was closed using Vetbond (3M) and pain was managed
after surgery by Buprenorphine injections. Mice were monitored daily for any signs of
pair or distress and normal patterns of feeding, drinking, nesting, and ambulation until
euthanization.
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CD109 treatment
At 8-12 weeks of age, dMCAO surgeries were performed as above on male C57BL/6J
mice (Cat# 000664, Jackson Labs). At 24 hrs after stroke, mice were re-anesthetized with
isoflurane. The chest of the mouse was shaved and sterilized to visualize the apex of the
heart. For injection into the arterial circulation, 100 l of vehicle (normal saline) or saline
containing CD109 (10 g) was slowly infused over 1 min into the heart (left ventricle
lumen). Needle entry into the heart was confirmed by flash of blood before injection.
After treatment, all mice were returned to the vivarium in individual cages and recovered
for 6 d. At 7 days after stroke, mice were euthanized and transcardiac-perfused with 4%
paraformaldehyde in phosphate-buffered saline (PBS), and brains dissected for
immunohistochemistry. Stroke size was determined by cresyl violet staining as described
previously (Bakondi et al., 2009). The area of GFAP-reactivity in the thalamus was
traced by a blinded observer and measured with software (ImageJ).
Generation of Reactive astrocyte-derived neural stem cells (Rad-NSC).
Whole brains were dissected 3 d after dMCAO and meninges were removed. Brains were
cut coronally to visualize the stroke area and cortical material with infarction was
separated from the rest of the brain. Cells were dissociated with a solution of Papain (20
U/mL, LS003126; Worthington), L-Cysteine (0.2 mg/mL, C7352; Sigma), DNase (20
g/mL, Worthington), CaCl2 (1.5 mM), and EDTA (1.5 mM) in DMEM-F12 base
medium (Hyclone) for 20 minutes in a 37℃ incubator at 5% CO2. The papain digest was
neutralized with soybean trypsin inhibitor (1.5 mg/mL, 17075-029; Gibco), and bovine
serum albumin (BSA, 1.5 mg/mL, BP1605-100; Fisher) in DMEM-F12. The final cell
solution was resuspended in neural stem cell medium (NSC medium): Neurobasal-A
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(Gibco); human basic FGF (20 g/mL, produced in-house); EGF (Gibco); 1 x B27
supplement (Gibco); 2 mM L-glutamine (Gibco); and 100 U/mL penicillin and 100
g/mL streptomycin (Gibco). The cells were grown in NSC medium until initial neural
sphere formation. After sphere formation, single spheres were pipetted into separate wells
for clonal expansion and identification of clones with predictable Cre-mediated gene
knockout. Clonal populations were maintained in NSC medium prior to differentiation
and other assays.
Rad-NSC differentiation into reactive astrocytes
For studies in GFAP-CreERTM-EDNRB-cKO astrocytes, cultured Rad-NSC were plated
onto dishes previously coated with Laminin/Poly-d-Lysine (5 g/ml each, Corning
354232 and 354210). Rad-NSC were differentiated astrocytes by 7 d incubation in
DMEM-F12 base medium supplemented with 10% fetal bovine serum and 2 mM Lglutamine, 100 U/mL penicillin, and 100 g/mL streptomycin (Gibco). For gene
knockout, differentiated astrocytes were maintained in differentiation medium containing
vehicle (EtOH) or 4-OH-Tamoxifen (1 M, Tocris) for an additional 10 d. To generate
conditioned medium, astrocytes were washed twice with PBS and then incubated in
serum-free DMEM-F12 for 2 d.
Lentiviral shRNA knockdown
Lentiviral shRNA knockdown experiments were performed with a scrambled-sequence
shRNA (control) or shRNA specific to CD109 (Mission Lentiviral particles, Sigma).
Cultured Rad-NSC were infected over 3 d. Transduced cells were selected in NSC
medium containing puromycin (2 g/ml, MP Biomedicals). To generate knockdown
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stem-cell lines, selection was performed for a minimum of 1 wk. Puromycin was
withdrawn from the medium for at least 3 d prior to astrocyte differentiation.
Magnetic-Activated Cell Sorting (MACS)
At 3 d after dMCAO surgery, brains were dissected. Olfactory bulb, hindbrain, and
meninges were removed and the hemispheres contralateral and ipsilateral to the stroke
injury were reserved for separate cell isolations. Based on a protocol adapted from Foo et
al. (2011), ipsilateral and contralateral cortices were digested separately in a 37℃
incubator at 5% CO2 for 1 hr. The digestion solution contained Hanks Buffered Salt
Solution (HBSS) supplemented with 30% D-Glucose, 1 M NaHCO3, 50 mM EDTA, LCysteine 1 mg/mL, Sigma; DNase (20 g/mL, Worthington), and Papain (20 U/mL,
Worthington). Enzymatic activity of the resulting tissue digest was neutralized by 3
washes with an inhibitory “low” ovomucoid solution that was diluted to a 1:10 final
concentration in HBSS containing 30% D-Glucose and 1 M NaHCO3.
Low ovomucoid solution (10x stock): 0.2 mg/mL ovomucoid trypsin inhibitor,
Worthington; 1.5% BSA, Miltenyi Biotech; all dissolved into 1 x Dulbucco’s PBS, pH
7.4. Cells were triturated gently in the low ovomucoid solution and filtered to a single
cell suspension (70 µm, Falcon). The low ovomucoid solution was underlaid with a
“high” ovomucoid solution; this solution was similarly diluted at 1:10 in HBSS
supplemented with 30% D-Glucose and 1 M NaHCO3. High ovomucoid solution (10x
stock): 3% BSA solution, Miltenyi; 0.0333 g/ml ovomucoid trypsin inhibitor,
Worthington; all dissolved into 1x DPBS (pH 7.4). Once underlaid, cells were
centrifuged at 300 x g for 7-minutes. Cell pellets were resuspended in 140 ul MACS
buffer (1 x Miltenyi BSA solution in DPBS) containing 20 l FcR blocking solution
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(Miltenyi Biotech). Cells were incubated in FcR block for 10 min at 4℃. After the
blocking step, 40 ul of biotinylated anti-GLAST antibody (Miltenyi Biotech) was added,
and the solution was incubated for an additional 20 min at 4℃. Cells were washed with 5
ml of MACS buffer and then centrifuged at 300 x g for 7 min. The resulting cell pellet
was re-suspended in 160 ul of MACS buffer. After the addition of 40 ul of paramagneticbead conjugated streptavidin (Miltenyi Biotec), the cells were incubated for 20 min at
4℃. Labeled cells were washed with 5 ml of MACS buffer, centrifuged (300 x g, 7 min),
and re-suspended in 3 ml of MACS buffer. A MACS column (L/S column, Miltenyi
Biotech) was primed with 3 ml of MACS buffer prior to loading on the labeled cell
suspension. After applying the cell solution, the MACS column was thrice washed with
MACS buffer (3 ml, each). GLAST+ cells were eluted in 5 ml of MACS buffer,
centrifuged at 300 x g for 7 min, re-suspended in 400 ul of DPBS and counted by
hemocytometer. After quantification, the cells were collected by centrifugation (1,000 x
g, 10 min). The final GLAST+ cell pellet was lysed in RIPA buffer: 25 mM Tris-HCl, 150
mM NaCl, 1% Triton X-100 (w/vol), 0.5% Sodium Deoxycholate (w/vol), 0.1% SDS
(w/vol), pH 7.4, supplemented with 1 x protease (Pierce) and phosphatase (Sigma)
inhibitors.
Immunohistochemistry
Paraformaldehyde (PFA)-perfused brains were post-fixed (4% PFA in PBS) for 24 hrs
and then incubated in PBS with 30% sucrose at 4℃ until equilibration (sinking). The
fixed brains were embedded in O.C.T. compound and frozen using an ethanol slurry on
dry-ice. Sections were cut at 30 m thickness, with 270 m between each section. Tissue
sections were stored at -80℃ until staining procedures. For immunohistochemistry,
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individual sections were thawed on a slide warmer for 20 min, washed with PBS, and
blocked/permeabilized for 1 hr (PBS with 5% Goat Serum [vol/vol] and 0.5% Trition-X
[vol/vol]). Fresh blocking buffer was used for primary antibody incubations (either
overnight at 4℃ or for 2 hr at room temperature) and secondary antibody incubations
(1:1000 dilutions of cross-adsorbed goat polyclonal antibodies, 1 hr at room
temperature). The following primary antibodies were used: GFAP (Rabbit anti-GFAP,
Z0334, DAKO; Mouse anti-GFAP, G3893, Sigma; Rat anti-GFAP, 13-0300,
ThermoFisher), AQP4 (PA5-85767, ThermoFisher), CD109 (sc-271085, Santa Cruz),
Iba1 (019-19741, WAKO), and CD68 (MCA1957GA, BioRad). Tissue sections were
washed 3-times with PBS after primary antibody incubations. Secondary Alexa-Fluor
polyclonal goat antibodies against mouse (A-11032 and A-11029, Thermofisher), rat (A11007 and A-11006, ThermoFisher), and Rabbit (A-11037 and A-11034, ThermoFisher)
were incubated at room temperature for 1-hour. Sections were then washed again 3-times
with PBS, then mounted with DAPI-mount (Southern Biotech 010020). Mouse CD109
staining was performed using Vector Labs Mouse on Mouse kit (BMK-2202), according
to manufacturer instructions.
Immunoblotting
The protein concentration of cell lysates in RIPA buffer was determined by BioRad-DC
protein assay according to the manufacturer’s instructions. Novex Bis-Tris gels
(Invitrogen) were loaded for equal protein, or equal cell number in the case of GLAST
MACS samples. Following electrophoresis, proteins were transferred to PVDF
membranes (Millipore) and blocked for 1 hr in TBS-T buffer (20 mM Tris,150 mM
NaCl, and 0.1%TWEEN 20) containing 5% BSA (w/vol). Primary antibodies were
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diluted in the same blocking buffer and incubated overnight at 4℃. Washes were done
with TBS-T and secondary antibodies conjugated to horse radish peroxidase were
incubated in blocking buffer for 1 hr at room temperature. Primary antibodies were used
against: CD109 (Rabbit Polyclonal BS-6067r, Bioss; Mouse Monoclonal, SC-281085,
Santa Cruz), GFAP (Rabbit Polyclonal anti-GFAP Z0334, DAKO), -actin (A5441,
Sigma), and Complement C3d (Goat anti-C3d AF2655, R&D Systems).
Statistical analysis
Statistical analyses were performed with GraphPad Prism Software (Version 7.01).
Groups were compared by Student’s T-test and multiple comparisons were made by
ANOVA. P-values of less than 0.05 were considered significant.
DISCUSSION
Among other markers, neurotoxic astrocytes (termed A1) were reported to express
complement C3 and neuroprotective astrocytes (termed A2) were reported to express
mRNA for CD109 (Liddelow et al., 2017; Clarke et al., 2018; Smith et al., 2020).
Whereas several inflammatory factors and LPS were shown to induce a neurotoxic
astroglial phenotype, the signaling environment or factors necessary to induce a
neuroprotective astroglial state are less understood. Here we demonstrated that primary
adult astrocytes express several forms of CD109 protein, both cleaved and uncleaved, and
reactive astrocytes significantly increased CD109 in response to stroke.
Previously, we found that ETBR signaling regulates a population of proliferative,
RC2+ reactive astrocytes in the peri-infarct area after stroke (LeComte et al., 2015). The
RC2+ astrocytes reduced immune cell invasion into the peri-infarct area, consistent with a
neuroprotective phenotype (Shimada et al., 2011). Importantly, the results shown here
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demonstrate astroglial ETBR signaling regulates CD109 in vivo and, potentially, reactive
astrocyte phenotype(s) after CNS injury. In the absence of stroke injury, astrocytes
isolated from tamoxifen-treated GFAP-CreERTM-EDNRB-cKO mice exhibited a “prereactive” or inflammatory state with increased GFAP and CD109 compared with cells
from vehicle-treated mice. Notably, in contrast with cells from vehicle-treated control
mice, GLAST+ reactive astrocytes isolated from the cortices of GFAP-CreERTM-EDNRBcKO mice did not increase CD109 levels after stroke.
In agreement Liddelow et al. (2017), we observed that treatment of astrocytes
with TNFα, an inducer of neurotoxic astrocytes, increased the level of full length
complement C3. Notably, in the presence of TNFα, ETBR-specific agonist (IRL1620)
reduced complement C3 expression. Also, IRL1620 treatment significantly reduced the
cleaved C3d form of complement; this form is critical in the progression of complement
cascades and microglial cell activation. However, in TNFα-treated astrocytes with
shRNA knockdown of CD109, IRL1620 did not affect C3d levels. These data indicate
that CD109 may influence protease activity associated with the complement cascade
during neuroinflammation, or complement itself. It is worth noting that CD109 and
complement C3 share homology in several domains and are both cleaved by furin and
related proteases (Hagiwara et al., 2010; Misumi et al., 1991).
In light of possible neuroprotective functions for CD109, we experimented with
the soluble (free) form of CD109 as a potential therapeutic for ischemic stroke. Although
not significant, at 7 d after stroke onset, our data trended toward an increase in stroke
volume after treatment, rather than a decrease. This observation agrees with a recent
paper from Song et al. (2019) demonstrating pro-inflammatory effects of CD109 in
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rheumatoid arthritis. In their model, treatment with neutralizing antisera to CD109 was
shown to improve both histological and behavioral measures of injury. It is important to
note that astroglial membrane-bound forms of CD109, acting as co-receptors, may
function differently compared with various cleaved forms that are released into the injury
environment by protease activity. In this regard, the membrane-bound form of CD109
could promote neuroprotective outcomes, whereas the soluble (free) form could promote
neuroinflammation with negative consequences.
Further characterization of the astroglial CD109 co-receptor, its interaction
partners, and the function(s) of its membrane-bound and cleaved forms will help better
define its role(s) in glial cell phenotype and neuroinflammation in the context of different
CNS injuries and diseases. Direct sorting of CD109high- and CD109low-expressing
astrocytes from different injury/disease systems could reveal if the cellular mRNA
signature for CD109 truly correlates with neuroprotective function(s). Further studies of
CD109 cleavage by furin, thrombin, mesotrypsin and other proteases will be essential to
determining if CD109 cleavages occur in parallel to those for complement and/or alter
the generation of neuroprotective and neurotoxic astrocytes.
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Figure 3. 2.
Immunoblotting of EDNRB-knockout and IRL1620 treated astrocytes demonstrates
that ETBR signaling controls multiple isoforms of CD109. A) Immunoblots of two
Rad-NSC clones derived from GFAP-creERTM-EDNRB-fl/fl mice, differentiated into
astrocytes, and treated with ethanol-vehicle (CT) or 4-OH-tamoxifen (KO) to induce
EDNRB-knockout. EDNRB-knockout reduced multiple cellular isoforms of CD109. B)
Clonal Rad-NSC populations were split and transduced with lentiviral particles
containing non-targeting, scrambled shRNA (shCT) and particles containing shRNA
specific to CD109 (shCD109). Control and knockdown Rad-NSCs were differentiated
into astrocytes, treated with an ETBR-specific agonist (IRL1620), and astrocyteconditioned medium (ACdM) and cell lysates were immunoblotted for CD109.
IRL1620 treatment increased cellular and released CD109. shCD109 knockdown
confirmed antisera specificity for multiple CD109 isoforms detected by immunoblot.
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Figure 3. 3.
CD109 is predominantly expressed by astrocytes that contact the vasculature. A)
Images of immunohistochemistry for astrocyte vascular contacts and endfeet by
aquaporin-4 (AQP4) and CD109 in proximity to the ischemic infarct 3 d after dMCAO
(Inset: 1.8x). B) Immunohistochemistry for GFAP and CD109, showing rare instance
of a GFAP+/CD109+ astrocyte cell body with no visible vascular contacts (Inset 2.3x).
C) Immunohistochemistry for GFAP and CD109 showing astrocytes contacting the
vasculature in proximity to the infarct 3-days post-stroke (Inset: 1.55x). Scale bars = 25
m.
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Figure 3. 4.
Astrocytes increase CD109 expression during stroke and markers of inflammation in
EDNRB-knockout mice. A) Schematic illustrating the GLAST-MACS protocol to
isolate and immunoblot astrocytes from stroke (ipsilateral, IPS) and non-stroke
(contralateral, CON) hemispheres of oil-control (Ctrl) and Tam-knockout (cKO) mice.
B) Immunoblot showing GFAP expression by astrocytes isolated by GLAST-MACS.
Cells were counted by hemocytometer C) Quantification of GFAP immunoblots from
control mouse hemispheres contralateral and ipsilateral to stroke (n =2 for both
groups). D) Quantification of GFAP immunoblots from astrocyte-specific EDNRBknockout mouse hemispheres contralateral and ipsilateral to stroke (n =2 for both
groups). E) Representative immunoblot of CD109 from GLAST-MACS astrocytes. F)
Quantification of astrocyte CD109 (60 kDa band) in hemispheres contralateral and
ipsilateral to stroke in control mice (Control contralateral mean: 16,488.52 ± 2,950.03;
Control ipsilateral mean: 28,551.66 ± 4,703.08; Contralateral vs. Ipsilateral P = 0.03, n
= 4 for both groups). G) Quantification of astrocyte CD109 (60 kDa band) in
hemispheres contralateral and ipsilateral to stroke in astrocyte-specific EDNRBknockout mice (Knockout contralateral mean: 24,837.52 ± 7,554.84; Knockout
ipsilateral mean: 18,312.55 ± 5,343.51; Contralateral vs. Ipsilateral P = 0.54; n = 4 for
both groups).
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Figure 3. 5.
ETBR signaling interacts with TNF and CD109 to alter expression of the neurotoxic
marker, complement C3. A) Immunoblots from two different clones for complement
C3 and cleavages containing the complement C3d sequence. Cells were plated at equal
density, and blots represent equally loaded volumes of conditioned medium. B)
Quantification of fold-change relative to vehicle for the 185 kDa isoform of C3 in
treated shControl (shScrambled) cells. C) Quantification of fold-change relative to
vehicle of the 185 kDa isoform of C3 in treated shCD109 cells. D) Quantification of
fold-change relative to vehicle of the 26 kDa isoform of C3 in treated shControl cells,
demonstrates that IRL1620 lowers C3 in the presence of TNF (shCT cells TNFtreatment: 0.81-fold ± 0.05 of vehicle treatment; shCT cells TNF + IRL1620treatment: 0.60-fold ± 0.05 of vehicle treatment; n = 2; P < 0.05). E) Quantification of
fold-change relative to vehicle of the 26 kDa isoform of C3 in treated shCD109 cells,
finds that IRL1620 did not lower C3d in the context of TNF and CD109-knockdown
(shCD109 cells TNF-treatment: 0.71-fold ± 0.08 of vehicle-treatment; shCD109 cells
TNF + IRL1620 treatment: 0.77-fold ± 0.06 of vehicle treatment; n = 2; P = 0.95).
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Figure 3. 6.
Knockdown of CD109 alters astroglial Ang-2 expression in response to IRL1620 and
TGF1. A) ELISA quantification of Ang-2 in condition medium of control and
CD109-knockdown astrocytes in response to IRL1620. B) ELISA quantification of
Ang-2 in condition medium of control and CD109-knockdown astrocytes in response
to TGF1. C and D) ELISA quantification of Ang-2 in condition medium of control
and CD109-knockdown astrocytes in response to TNF, TGF1, and CD109.
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Figure 3. 7.
At 7 d after stroke, infarct size increases in response to CD109 treatment as measured
by GFAP-negative necrotic area and Cresyl violet staining for viable neural tissue. A)
Immunohistochemistry for GFAP (green) and nuclear DAPI (blue), in mice treated
with transcardiac injections of vehicle and CD109 24-hours after dMCAO surgery.
Brains were harvested 7 d after dMCAO (scale bar = 250 m). B) Measures of GFAPnegative necrotic stroke areas 7 d post-stroke in mice treated with vehicle and CD109
(Vehicle mean: 4.94 ± 1.46 mm2; CD109 mean: 12.23 ± 5.21; n = 6 vehicle, n = 7
CD109; vehicle vs. CD109 P = 0.24). C) Measures of unstained Cresyl violet brain
necrotic stroke areas 7 d post-stroke in mice treated with vehicle and CD109 (Vehicle
mean: 4.81 ± 1.87 mm2; CD109 mean: 11.91 ± 5.65; n = 6 vehicle, n = 7 CD109;
vehicle vs. CD109 P = 0.27).
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Figure 3. 8.
Secondary GFAP+ inflammation in the thalamus ipsilateral to stroke after CD109
treatment. A) Immunohistochemistry for GFAP (green) in the thalamus ipsilateral to
stroke, in mice treated with transcardiac injections of vehicle and 24-hours after
dMCAO surgery (scale bar = 250 m). B) Representative 10x image of
immunohistochemistry for GFAP (green) in the thalamus ipsilateral to stroke, in mice
treated with transcardiac injections of CD109 (10 g) and 24-hours after dMCAO
surgery (scale bar = 250 m). C) GFAP staining in the thalamus contralateral to the
stroke. D) Measures of GFAP-reactive area 7-days post-stroke in mice treated with
vehicle and CD109 (Vehicle mean: 1,212,520 ± 359,227 m2; CD109 mean: 2,276,554
± 917,740; n = 5 for both groups; vehicle vs. CD109 P = 0.31).
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CHAPTER 4: Conclusions and further directions
Rad-NSCs as a cell culture model
In multiple pathologies of the central nervous system, damage to neurons drives
functional decline. Importantly, however, there is not significant neuronal regeneration in
the adult CNS. Neuronal replacement is viewed as a promising therapeutic avenue and
achieving significant survival and distribution of immature neural stem cells in the adult
CNS is notoriously difficult. As such, transplantation of immature stem cells has had
limited success in addressing neuronal loss in adult diseases and injuries. Furthermore,
many diseases involve diffuse neuronal loss and stem cell replacement is better suited to
localized transplantation. These hurdles have led the field to pursue adult stem cell-like
sources that might improve transplantation or that could be targeted for direct in vivo
conversion into neurons (Heinrich et al., 2014; Mattugini et al., 2019; Wu et al., 2020). In
traumatic injuries to the CNS, multiple labs found that reactive astrocytes take on a stem
cell-like phenotype and can be cultured as neural spheres (i.e. Rad-NSCs). Although they
are multipotent for neurons, oligodendrocytes, and astrocytes in culture, Rad-NSCs are
restricted to a glial fate when cultured and transplanted back into the brain. These cells
have been transduced with pro-neural transcription factors in vivo and converted into
neurons (Brulet et al., 2017; Mattugini et al., 2019). A drawback to this approach is that
pro-neural transcription factors may only be able to reprogram in the presence of injury,
even if the injury simply results from the needle injecting the pro-neural constructs. This
indicates that neural conversion therapies could be restricted to localized traumatic
injuries and might be minimally effective in diffuse neuroinflammatory diseases.
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Difficulty in accessing injured brain areas for viral transduction will further challenge
application of this therapy in humans.
With increased focus on the role(s) of glial cells in CNS injury and disease, the
glial-restricted nature of Rad-NSCs may provide a valuable tool for disease modeling and
treatment. For the experimental work of this dissertation, we harnessed the glial-restricted
nature of Rad-NSCs to generate large numbers of astrocytes ex vivo and to model
astroglial paracrine signaling post-stroke. This was advantageous over other models that
are derived from immature animals, prone to contaminating non-astroglial cell types, are
prohibitively expensive, and/or that generate too few viable cells. Recently developed
embryonic and iPSC methods for generating differentiated neural cell types produce cells
with immature phenotypes that don’t recapitulate cellular phenotypes in adult disease
(Miller et al., 2013). By contrast, our Rad-NSC system allowed us to generate large
numbers of adult astocytes from transgenic animals and investigate critical glial signaling
mechanisms in stroke.
It is worth noting some potential drawbacks to our approach. For example, our
current differentiation protocol to generate astrocytes from Rad-NSCs involves exposure
of the stem cells to fetal bovine serum. Exposure to serum alters the inflammatory profile
of reactive astrocytes. In fact, serum exposure represents a significant drawback to many
standard astrocyte culture methods. An important future direction for our laboratory and
others will be to develop a Rad-NSC astrocyte differentiation protocol that uses defined
factors without serum.
Having outlined these drawbacks, our culture model has proven reliable
repeatedly. Our in vitro results match in vivo results out of our lab and multiple other
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labs. Rad-NSC derived astrocytes do not proliferate significantly in culture after
differentiation, whereas immature astrocytes do proliferate in culture after isolation.
Therefore, Rad-NSC astrocytes more closely match the non-proliferative phenotype of
resting adult astrocytes in vivo. Importantly, we found a significant increase in Lcn2 gene
expression (4.92-fold) in response to EDNRB knockout. In amyotrophic lateral sclerosis
(ALS) models, LCN2 is an adult specific reactive astrocyte marker that was not
expressed by immature reactive astrocytes in vitro or in vivo (Tripathi et al., 2017).
Finding differences in Lcn2 expression in our astrocytes indicates that our model may
recapitulate adult reactive astrogliosis. Furthermore, results presented here showing in
vivo Ang-2 expression changes and also changes in Lcn2 gene expression demonstrate
the value of the Rad-NSC platform in modeling reactive astrogliosis.
Astroglial gene expression changes in response to EDNRB-knockout
Assessing the essential paracrine factors released by adult reactive astrocytes after an
injury is difficult due to problems associate with producing adult astrocytes in large
numbers. Our Rad-NSC derived astrocytes enabled us to knockout EDNRB, a critical
regulator of the reactive astroglial response to stroke, and to perform a microarray-based
screen of control and EDNRB-KO astroctyes. Our goal was to identify reactive astroglial
genes regulated by this pro-proliferative signaling pathway. It is worth noting that the
reactive glial response likely results from an ensemble of damage-associated molecular
signals. Our approach targeted ETBR, elucidating a paracrine profile downstream of this
particular endothelin signaling pathway. Future studies knocking out ETBR in conjunction
with other signaling receptors commonly activated after stroke (TNFR, Notch1, TGFR,
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Ptch), will be important for determining how the array of injury signals generated after
stroke interact and promote specific reactive astrocyte phenotypes.
Our microarray data confirmed the efficacy of the GFAPcreERT-EDNRB-cKO
Rad-NSC model with ~103-fold decrease in EDNRB mRNA in knockout cells (reduced
~103-fold; Figure 2.1). Consistent with our prior research, genes associated with
proliferation and growth were also impacted. However, as we expected, there was not a
simple relationship between the single signaling pathway we studied and single cellular
function. ETBR signaling regulates a reactive astroglial mRNA profile that includes, but
is not limited to, cellular proliferation. Of the significant gene expression changes
associated with cell-cell signaling, we found 3 broad gene categories that were
disproportionately impacted: 1. Cell-cell adherence and guidance signals (Cdh19,
Sema3c, Spon1, Pcdhb2, Plxdc2, Glycam1, Cdon); 2. Inflammatory signals, with
members of a TGF-complement signaling axis particularly represented (Ptger3, Tgfb3,
Tgfbr3, C1s1, C1ra, Pla2g4a, Eda2r, CD109); 3. Vascular signals that regulate
endothelial growth and BBB permeability (Angpt2, Renbp, Alcam, Serpinf1). These
signals are notable because several gene knockout mouse models that decrease reactive
astrocyte proliferation also increase BBB permeability. Many of the genes that changed
after EDNRB-knockout regulate BBB permeability and/or blood-cell extravasation. It is
worth noting that a number of these genes have functions that significantly overlap in all
three categories listed above. For example, genes associated with inflammation and
injury such as those involved in TGF and TNF signaling (e.g. Eda2r, Tgfbr3, CD109,
Tgfb3) also regulate angiogenesis and the BBB. Furthermore, genes that regulate axon
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guidance signaling such as plexin-semaphorin signaling (Sema3c, Plxdc2) may also
control angiogenesis.
It is notable that proliferative astrocytes with a high level of ETBR signaling,
mirror many aspects of putative “neuroprotective” astrocytes that appear in traumatic
injuries to the CNS. Stroke results in significant endothelin release, and our gene array
data suggest that ETBR-regulated genes are driving these some of these “neuroprotective”
features. This paradigm is further illustrated by the number of changes relating to a
TGF-complement-neurotoxicity signaling axis (Tgfbr3, C1s1, C1ra, CD109, Eda2r,
Tgfb3) that has been described, in large part, by the labs of Beth Stevens and Ben Barres.
The function of this axis is demonstrated in developing retinal ganglion cells that express
complement C1 at their excess synapses in response to TGF3. Microglia detect the C1
expression and phagocytose the synapses (Bialas and Stevens, 2013). Like many other
developmental signals, this paradigm is recapitulated during injuries to the adult nervous
system and diseases such as complement-driven microglial synapse removal in
Alzheimer’s disease. Of interest, we found that ETBR knockout significantly altered
expression for a variety of genes linked to the TGF-complement signaling axis and
increased the expression of many putative “neurotoxic” complement-related signals
(C1ra, C1s1, Tgfb3). One explanation is that ETBR signaling represses features of this
neurotoxic axis and that removal of ETBR signaling unleashes a neurotoxic astrocyte
phenotype. Alternatively, there are multiple instances of ETBR and ETAR signaling
having antagonistic effects. Removal of ETBR may increase signaling of endothelins
through ETAR, thereby inducing neurotoxicity. The possibility that ETAR signaling drives
features of neurotoxic phenotypes in reactive astrocytes warrants further investigation.
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One hypothesis is that mechanisms driving astroglial proliferation also promote
neuroprotective glial phenotype. Our lab previously showed that Notch1 is necessary for
astroglial proliferation and is upstream of ETBR signaling. In many tissues, Notch1 acts a
stem-cell regulator by maintaining self-renewal and multipotency. Endothelins direct
neural crest cell migration and differentiation in development. While Notch is upstream
of ETBR and possibly neuroprotection, some research indicates instead that Notch is
upstream of neurotoxic phenotypes (Qian et al., 2019). It is possible that Notch1
potentiates multiple reactive astrocyte phenotypes, and that ETBR/ETAR are amongst the
receptors directing the type of astrocyte reactivity. Shh is another signal known to
potentiate reactive astrocyte proliferation and a stem-cell like phenotype, but how Shh
interacts with the better characterized Notch1-STAT3-ETBR reactive astrocyte signaling
pathway has not been elucidated (Sirko et al., 2013). For treatment of CNS injury, it will
be important to characterize mechanisms that promote reactive astroglial proliferation
and the specific factors that control neuroprotective or neurotoxic astroglial phenotypes.
Astroglial Ang-2 Expression
Infiltration of serum components and/or blood-cells after stroke are associated with
neuronal cell death and increased infarct size. Reducing BBB permeability and inducing
angiogenesis are essential to recovery after a stroke. With a portion of vascular
distribution to the brain occluded and subsequent death of downstream vasculature, it is
essential that collateralization and angiogenesis re-establish vascular supply to the infarct
and peri-infarct areas. Ang-2 is critical to promoting post-stroke angiogenesis and
restricting vascular permeability. Importantly, Ang-2 can act as an agonist or antagonist
for Tie-2 depending on the context, including alterations in inflammatory status and
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expression levels of Tie-1. There is some evidence that juvenile brains regenerate better
after traumatic CNS injury, in part because of higher levels of Ang/Tie-2 signaling
(Brickler et al., 2018). Ang-2 may act as a vaso-protectant in the acute phase after stroke,
whereas VEGF promotes vascular permeability (Marteu et al., 2013). Unfortunately, part
of the process of angiogenesis promoted by Ang-2 is the downregulation of tight
junctions between endothelial cells and increased vascular permeability. These different
facets of angiogenesis and Ang-2 signaling after stroke may account for conflicting
studies regarding the beneficial nature of Ang-2 signaling after stroke (Gurnik et al.,
2016). Also, there may be distinctions between the acute functions of Ang-2 after stroke
versus stroke recovery.
Our work adds a layer of complexity and consideration to these observations. We
show that astrocytes express Ang-2 acutely in response to endothelins and in response to
stroke. Astrocytes, which are intimate participants in BBB regulation, may secrete Ang-2
as a part of acute stroke vascular protection. In stroke, the primary infarct area is devoid
of astrocytes, has vascular disfunction, and blood cell infiltration (Shimada et al., 2011).
It is possible that acute therapeutic delivery of Ang-2 into the primary infarct area is
acting as a replacement for absent astroglial Ang-2 vaso-protection. It is also possible that
astrocyte and endothelial cell-derived Ang-2 have different functions post-stroke that will
require further research. Our data show microglial expression of the Ang-2 receptor Tie2. Thus, any therapeutic interventions altering Ang-2 or Tie-2 signaling will need to
account for possible changes in microglial activity. As therapies promoting angiogenesis
and protection of the vasculature progress, it will be important to account for potentially
different effects of Ang-2 signaling through microglial or endothelial Tie-2 receptors.
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We have established the control of astroglial Ang-2 expression by ETBR, but an
important next step is to determine the function of Ang-2/Tie-2 signaling in microglia in
vivo after stroke. Two specific mouse genetic models that would allow us to begin
characterizing this mechanism. The first would be a GFAP-creERT-Angpt2-cKO mouse,
where Ang-2 secretion by astrocytes could be specifically removed prior to performing
the dMCAO surgery. The second genetic approach would be to use TMEM119-creERTTie2-cKO mice to specifically remove the Tie-2 receptor from microglial cells prior to
dMCAO surgery. The necessary mice for these crosses recently became commercially
available (TMEMcreERT) or have been generated by academic labs (Tie2-flox).
Tamoxifen induction of the gene knockouts can be performed in adult mice prior to
stroke, thus avoiding developmental compensatory effects.
Immunohistochemistry and FACS for microglia, using TMEM119 as a
microglial-specific marker, could be used to assess microglial numbers, phenotype, and
distribution after stroke in the presence or absence of astroglial Ang-2 or microglial Tie2. These two genetic models may help to determine the mechanistic effects of Ang-2/Tie2 signaling on microglial survival in vivo and confirm some of our in vitro data. Any
differences in microglial survival and inflammation between the astroglial Ang-2
knockout and microglial Tie-2 knockout could indicate the presence of other sources of
Ang-2 that alter microglial activity. These differences could also help to clarify Ang-2
specific effects on microglia, as opposed to the effects of other Tie-2 ligands such as
Ang-1. Apart from characterizing post-stroke inflammation, both mouse models could
address questions regarding astroglial Ang-2 and microglial Tie-2 signaling in vascular
and microglial development.
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Astroglial CD109
Increased CD109 mRNA in reactive astrocytes is observed in several CNS
disorders and CD109 is reported as a marker of neuroprotective reactive astrocytes.
Complement C3, which often used as a marker of neurotoxic astrocytes, is under study in
many neurological disorders. The function of CD109 is poorly understood. In fact, to our
knowledge there are no mechanistic studies of CD109 in the brain. If CD109 is truly a
reactive gliosis marker and a marker of certain cancers, more work is needed to
determine its exact function within the brain.
Two functions for CD109 described outside of the nervous system make it
essential to study it the CNS. Epidermal CD109 was shown to alter TGF signaling
through downstream SMADs. Latent TGF activation is an important signaling event
that triggers astrocytes to form a glial scar (Schachtrup et al., 2010; Zhang et al., 2018).
This functions to protect CNS tissue from injury, and modulation of TGF signaling may
affect the progression of CNS disease. TGF-induced astroglial scar formation occurs in
the presence of high astroglial CD109 expression, but the function of CD109 in glial scar
formation remains unknown. The second potential function of CD109 relates to its
complement system activity. CD109 has homology with other complement proteins that
include complement C3. Complement proteins tend to interact with one another,
promoting or inhibiting the complement cleavage cascade. Complements have essential
functions in synapse elimination and neurotoxicity, so understanding if CD109 modulates
complement activity will be important for ascertaining its potential neuroprotective
functions.
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We show that ETBR signaling promotes increased astroglial CD109 expression.
Thus, if CD109 is a marker of neuroprotective astroglia, ETBR signaling acts as a potent
activator of neuroprotection. This is consistent with our microarray data showing that
ETBR knockout lowers CD109 and that there is a corresponding rise in the highly
neurotoxic factor Lcn2 (Tripathi et al., 2017). Also, if astrocyte-derived Ang-2 is an
ETBR-induced vascular-stability signal after stroke, this adds evidence suggesting ETBR
induces a vasoprotective astrocyte phenotype. ETBR is part of a STAT3 signaling axis
which is protective in spinal cord injury and amyotrophic lateral sclerosis (Anderson et
al., 2016; Tyzack et al., 2017). Future studies to determine if CD109 is linked to STAT3
signaling will be important to define functions of CD109 in neuroprotection.
Paracrine signals are essential to neurotoxic/neuroprotective phenotypes, and
CD109 knockdown by shRNA significantly decreased astroglial Ang-2 secretion. This is
consistent with studies of rheumatoid arthritis, where blocking CD109 alters
inflammation and improves histological outcomes. This indicates that CD109 alters
inflammatory activity in multiple tissues.
To specifically address questions regarding CD109-mediated neuroprotection,
more specific tools and methods will be necessary. Unfortunately, there is currently no
mouse model with a floxed CD109 gene. A GFAP-creERT-CD109-cKO mouse would
allow for astroglial-specific knockout of CD109. Astrocyte CD109-cKO in uninjured,
stroked, and lipopolysaccharide injected mouse models could help to clarify the
function(s) of CD109 in reactive gliosis. The specific CD109 cleavage patterns that we
identified are of great interest. Mutagenic studies using CRISPR or similar methods could
be used to generate Rad-NSCs or iPSC-derived astrocytes with uncleavable CD109.
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Alteration of astroglial phenotype and paracrine secretion in uncleavable CD109
astrocytes may reveal the functional consequences of this cleavage. It’s particularly
important to assess the neuronal toxicity of secreted factors from astrocytes with CD109
knockdown or uncleavable CD109.
Overview
There has been significant progression in our understanding of glial cells, glial
scarring, and CNS injury. The historic view of the glial scar was that it inhibits axonal
growth and is therefore inhibitory to CNS generation. However, the glial scar is now
widely recognized as a mix of pro and anti-axonal growth factors, with functions
essential to protecting CNS tissue from further damage. Astrocytes take on a stem celllike phenotype in response to CNS injuries as they contribute to the formation of the glial
scar. There have been many attempts to harness this stem cell-like nature to regenerate
neurons or to transplant neuronally-fated stem cells, but with limited positive outcomes.
In our approach, we take lessons from other stem cell transplantation attempts,
particularly those utilizing mesenchymal stem cells. The factors secreted from these cells
and their derivatives are often the source of their therapeutic benefits, rather than
engraftment and cellular replacement. Secreted factors provide a more controllable
therapeutic, in part, because they can be produced consistently in recombinant form.
Additionally, stem cell therapies suffer from significant variability, host anti-graft
reactions, and often high costs.
Reactive astrocytes secrete beneficial (neuroprotective) and/or harmful
(neurotoxic) paracrine factors, but the features of the injury environment that influence
the choice between neuroprotective and neurotoxic secreting astrocytes have not been
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determined. Data from spinal cord injury and neurotoxic inflammatory models indicate
that multiple secreted factors act as an ensemble to produce particular astroglial
phenotypes. Determining the ensemble of factors and cell-autonomous regulators
involved in promoting neuroprotection or neurotoxic astroglial phenotypes has significant
implications for treating disease. Therapeutics altering the activity of singular signaling
molecules have provided significant benefit to patients with diseases such as arthritis and
Crohn’s disease, but have shown less benefit in stroke. Inducing a neuroprotective
astrocyte phenotype would alter an entire paracrine profile, rather than a singular
paracrine factor, and could provide significant benefit to a variety of diseases of the
central nervous system.
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